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Protein glycosylation is essential for cell survival and proliferation. Comprehensive 
analysis of protein glycosylation can aid in a better understanding of protein functions, cellular 
activities, and the molecular mechanisms of diseases. Emerging mass spectrometry (MS)-based 
proteomics enables comprehensive analysis of protein glycosylation and many other types of 
modifications. However, due to the heterogeneity of glycans and the low abundance of many 
glycoproteins in complex biological samples, it is extraordinarily challenging to globally and 
site-specifically analyze glycoproteins. This thesis focuses on the development of new methods 
for global analysis of glycoproteins, and the applications of the newly developed methods for 
biomedical research.  
 This thesis is constituted of six chapters. Chapter 1 is an overview of MS-based 
glycoproteomics analysis, with an emphasis on the endeavors in the literature to solve the two 
major problems for global analysis of glycoproteins mentioned above. This chapter retraces the 
developments of important chemical and enzymatic methods in this field, and includes the 
discussion regarding how these methods have enabled qualitative and quantitative analyses of 
glycoproteins in a variety of biological systems. Chapter 2 focuses on the development of a 
strategy that utilizes the universal recognition between boronic acid and sugars, in order to 
enrich glycopeptides for LC-MS/MS analysis. Chapter 3 shows the approach of achieving 
quantitative analysis of protein glycosylation through the combination of boronic acid 
enrichment and quantitative proteomics. Chapter 4 describes a strategy for cell-surface N-
glycoproteome analysis. Metabolic labeling, click chemistry, and MS-based proteomics were 
combined to specifically map the glycoproteins located only on cell surface. The labeling 
efficiencies of different sugar analogs were compared, and this method was combined with 
either stable isotope labeling in cell culture (SILAC) or tandem mass tag (TMT)-labeling to 
quantitatively study the surface N-glycoproteins. Chapter 5 explains how protein S-
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GlcNAcylation was unexpectedly found in human cells. Starting with an attempt to profile 
protein O-GlcNAc, hundreds of S-GlcNAcylation sites were surprisingly identified on cysteine 
residues. This modification was demonstrated not to be caused by chemical reactions with the 
cleavable linker during sample preparation nor due to false site assignment. Furthermore, 
protein S-GlcNAcylation events were investigated with different sugar analog labeling in three 
cell lines. Chapter 6 features an application of MS-based proteomics in biomedical research. 
In this chapter, the cellular responses and pleiotropic effects in statin-treated cells on the 
proteome, glycoproteome, and phosphoproteome levels were analyzed. 
In addition to the independent projects discussed above, the collaborative projects about 
that investigation of the cellular mechanisms of gold-nanorod assisted cancer photothermal 
therapy, and the discordance between mRNA and proteome in ovarian cancer tissues were also 
conducted. The abstracts of the publications resulted from the collaborations are shown in the 
appendix.  
In conclusion, the work presented in this thesis majorly combines chemical biology and 
modern MS-based proteomics to study protein modifications, especially glycosylation. This 
thesis strives to advance the techniques of glycoproteomics and apply the state-of-the-art 









CHAPTER 1. INTRODUCTION TO MASS SPECTROMETRIC 
ANALYSIS OF GLYCOPROTEINS IN COMPLEX BIOLOGICAL 
SYSTEMS 
 
1.1 Background Introduction 
Mass spectrometry (MS)-based proteomics has become an increasingly powerful tool 
to study diverse topics in complex biological systems. Protein post-translational modifications 
(PTMs) are extremely important in biological systems and regulate nearly every cellular 
activity including gene expression, signal transduction and cellular response to environmental 
cue. Comprehensive and site-specific analysis of protein modifications is beyond reach of 
conventional biochemistry methods. Modern MS technology provides a unique opportunity to 
globally and site-specifically characterize protein PTMs. However, it is extraordinarily 
challenging because of the low abundance of many modified proteins, sub-stoichiometry of 
protein modification, and the complexity of biological samples.  In addition, the modified 
groups are different, and therefore no common method can be used for all types of protein 
modifications. Innovative and effective methods are crucial to achieve the global analysis of 
protein modification. 
Among hundreds of known PTMs, protein glycosylation is one of the most important 
modifications and is essential for cell survival because it determines protein folding, trafficking, 
and stability and regulates many cellular activities, especially extracellular activities. Many 
glycoproteins are of extremely low abundance compared to non-modified proteins; meanwhile, 
glycosylation is very complex due to the heterogeneous glycan structures and a variety of 
amino acid residues being modified with glycans. To overcome the challenges brought by the 
complexity of glycosylation and the low abundance of glycosylated proteins, many elegant 
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methods were developed to qualitatively and quantitatively study protein glycosylation events 
in various kinds of samples.  
Here some major MS-based methods for global analysis of protein glycosylation are 
discussed. In the first part, we summarize the chemical and enzymatic methods for MS-based 
glycoproteomics, including different enrichment methods and the methods to generate a 
common tag for global analysis of protein N- and O-glycosylation with MS. Second, because 
reversible protein glycosylation makes glycoproteins highly dynamic, MS-based methods for 
glycoprotein dynamics study are included. The last part includes selected applications of MS-
based glycoproteomics in a variety of biology systems.  
 
1.2 Global Analysis of Glycoproteins 
1.2.1 Glycopeptide enrichment 
In order to globally analyze protein glycosylation, glycoprotein enrichment is 
imperative prior to MS analysis due to the low abundance of many glycoproteins, the dynamic 
nature of protein modifications and the complexity of biological samples 1-4. Enrichment can 
allow us to minimize the interference from highly abundant non-glycoproteins on the analysis 
of protein glycosylation, and to reach low-abundance glycoproteins. In the literature, a variety 
of enrichment methods were reported, and each method has its own advantages and limitations. 
 
1.2.1.1 Lectin 
Commercially available lectins were mostly originated from plants, with some also 
from bacteria and animal species. Each lectin can bind one or several types of glycans, and 
therefore lectins were extensively used to perform glycoprotein/peptide enrichment, although 
to an extent the specific binding also limits lectins from enriching all types of glycans for more 
comprehensive analysis of glycoproteins in complex biological samples. Several lectins, such 
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as concanavalin A (Con A, mainly specific for internal and nonreducing terminal α-D-
mannosyl and α-D-glucosyl groups), wheat germ agglutinin (WGA, specific for N-acetyl-D-
glucosamine and sialic acids), and ricinus communis agglutinin I (RCA I/ RCA 120, binds 
galactose or N-acetylgalactosamine residues) were widely used for glycoprotein/peptide 
enrichment 5. Typically, lectins were immobilized onto solid support and served for solid-phase 
extraction of glycopeptides. The lectin-functionalized beads can also be packed into separation 
columns, allowing for enrichment and elution of glycopeptides coupling with liquid 
chromatography (LC). Zielinska et al. combined lectin enrichment with filter-aided sample 
preparation (FASP) to map the N-glycosylation sites in four mouse tissues and blood plasma 6. 
They identified 6,367 sites on 2,352 proteins from extracellular space, organelle lumens, and 
other cellular locations. In addition to the widely known NX[S/T] (X stands for any amino acid 
residue other than proline) motif for protein N-glycosylation, they also found other rare motifs, 
such as the NXC motif. The same group further employed the FASP method coupled with 
lectins to profile the N-glycosylation sites across seven evolutionarily distant species, and 
found the distant species have common characteristics including sequence recognition patterns, 
structural constraints, and subcellular localization although the N-glycoproteome from those 
species are largely divergent 7. 
Besides protein N-glycosylation, lectin-based enrichment methods were also applied 
for O-glycosylation analysis although the strategies are not as mature as those for N-
glycosylation analysis. For instance, Darula and Medzihradszky used the jacalin lectin (specific 
for recognizing GalNAcα1-O- extension of the core 1 structure) to enrich O-glycopeptides and 
identified O-glycosylation sites from bovine serum through mass spectrometric analysis 8. The 
same lectin was also employed by Durham and Regnier, and they immobilized jacalin onto 
silica beads and further packed an LC column for serial lectin affinity chromatography analysis 
of O-glycopeptides after removing N-glycopeptides with Con A 9. Steentoft et al. performed 
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O-glycosylation analysis combining vicia villosa agglutinin (VVA) lectin chromatography 
with the SimpleCell technology 10, which will be discussed in more details in a section below.  
As an important and special type of O-glycosylation, O-GlcNAcylation has been well-
studied in the past three decades, and lectin-based methods have also been developed for 
comprehensive mapping of protein O-GlcNAcylation. In this context, WGA was exploited for 
the enrichment of O-GlcNAcylated proteins or peptides due to its substrate specificity. For 
example, Vosseller et al. developed lectin weak-affinity chromatography (LWAC), and by 
combining it with b-elimination/Michael addition with DTT (BEMAD) and ECD mass 
spectrometry, they analyzed 145 unique O-GlcNAcylated peptides from a postsynaptic density 
preparation 11. Overall, lectin-based strategies have greatly expanded the pool of N- and O-
glycosylation sites identified. 
 
1.2.1.2 Hydrazide chemistry 
In 2003, Zhang et al. developed an elegant strategy based on hydrazine chemistry for 
glycopeptide enrichment, followed by protein N-glycosylation analysis with MS 12. They 
oxidized the glycans to generate aldehyde groups, and then conjugated the glycoproteins to a 
solid support using hydrazide chemistry. After on-beads digestion, the non-glycopeptides were 
removed and the enriched glycopeptides were recovered by using Peptide-N-Glycosidase F 
(PNGase F) to cleave off the glycans. The peptides were then identified and quantified by LC-
MS/MS. This method was further modified by many groups for better performance and has 
been extensively used to study protein N-glycosylation in a variety of samples and species, 
from cells to clinical samples 13-15. During the oxidation, the glycans are damaged, and thus 




Although initially this method was designed for protein N-glycosylation analysis as 
PNGase F can only recognize the N-glycans, researchers developed variants and used them for 
O-glycosylation analysis. Nilsson et al. combined hydrazide chemistry with acid cleavage to 
analyze sialylated glycoproteins, and identified 36 N-linked and 44 O-linked glycosylation 
sites from human cerebrospinal fluid with site and glycan structural information 16. Later they 
applied a similar strategy to study human urinary glycoproteins containing glycan information, 
and 58 N- and 63 O-linked “intact” glycopeptides were identified from 53 glycoproteins 17. 
This method was further improved by pretreating the samples with PNGase F to remove N-
glycans, and used CID-MS2/MS3 and ECD/ETD to comprehensively analyze the samples 18. 
Taga et al. combined hydrazide chemistry with galactose oxidase oxidation and formic acid-
induced cleaving of the hydrazone bond to study the O-glycosylations unique to collagen 19. 
Klement et al. also applied hydrazide chemistry to O-GlcNAcylation studies where they 
elevated the concentration of sodium periodate and reaction temperatures, and enriched the 
modified proteins through hydrazide chemistry 20. The O-GlcNAcylated peptides were released 
by hydroxylamine treatment and analyzed by tandem MS. A total of 12 O-GlcNAcylated 
peptides from 5 proteins were identified in that study.  
 
1.2.1.3 HILIC 
Hydrophilic interaction liquid chromatography (HILIC) is a separation technique that 
has been widely used in glycoproteomics to separate/enrich glycopeptides from non-
glycopeptides. Contrary to reverse-phase chromatography, the stationary phase of HILIC is 
very hydrophilic, allowing binding of hydrophilic analytes. Silica particles, amino or hydroxyl 
groups, zwitter ions are common materials for the HILIC stationary phase 21. The gradient of 
the mobile phase usually starts with high percentage of relatively nonpolar organic solvent, 
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then the percentage of polar component (usually aqueous solutions) is increased through the 
gradient timeline, resulting in higher hydrophilicity of the solution and stronger elution power.  
Because glycans are extremely hydrophilic molecules, the retention time of 
glycopeptides are generally longer than non-glycopeptides. In the literature, Hägglund et al. 
combined zwitter-ionic hydrophilic interaction chromatography (ZIC-HILIC) enrichment and 
partial deglycosylation to study protein N-glycosylation in human plasma, and identified 62 
glycosylation sites from 37 glycoproteins 22. The same group later employed a similar strategy 
to establish an enzymatic deglycosylation scheme to study core fucosylated N- and O-
glycosylation among human plasma proteins 23. HILIC enrichment was extensively applied for 
glycosylation analysis, including site mapping, intact glycopeptide analysis, and also 
contributed in O-GlcNAcylation studies 24.  However, if a non-glycopeptide contains multiple 
hydrophilic amino acid residues, its retention time may be comparable to glycopeptides, 
rendering the specificity of HILIC lower than many other enrichment methods. Nevertheless, 
HILIC can be coupled with other enrichment methods to perform two-dimensional separation 
and fractionation. There are some reports in the literature to improve the performance of HILIC, 
such as introducing ion-pairing reagents in the mobile phase and further functionalizing the 
stationary phase 25, 26, and have considerably advanced the use of HILIC in glycoproteomics. 
 
1.2.1.4 IsoTag 
Recently Woo et al. developed a highly innovative isotope-targeted glycoproteomics 
(IsoTaG)  method 27, which combined metabolic labeling, isotopic recording, and MS-based 
proteomics to analyze intact N- and O-glycopeptides. They synthesized an isotopic affinity 
probe, which has four critical parts: the aizde for tagging the glycans through copper-catalyzed 
azide-alkyne [3+2] cycloaddition (CuAAC), the biotin group for enriching the tagged 
glycopeptides through strong biotin-avidine interactions, the silane scaffold being readily 
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cleaved to release the glycopeptides after enrichment, the dibromide motif for MS detection of 
glycopeptides.  Due to the natural abundance of the stable isotopes of Br (Br79:Br80=1:1), 
glycopeptides tagged with the probe display a special pattern in MS analysis (termed IsoStamp) 
28. 
Four major steps are involved in the IsoTaG strategy: (1) metabolically label the 
glycans with a functional sugar analog (i.e. N-azidoacetylgalactosamine (Ac4GalNAz)); (2) 
tag the labeled glycoproteins with the probe, and then capture the glycoproteins on a solid phase 
through biotin-avidin interactions. The enriched glycoproteins were digested using trypsin and 
the glycopeptides were released by cleaving the silane scaffold; (3) analyze the glycopeptides 
by tandem MS. Here they used a pattern-searching algorithm, which recognizes the 2:5:1 
distribution of the dibromide motif to selectively sequence the glycopeptides; (4) assign 
glycosylation sites and glycan structures using Byonic software.  
IsoTaG increases the selection and detection speed of glycopeptides owning to the 
pattern-searching algorithm, and greatly aids in the analysis of intact glycopeptides. This 
strategy can be widely used for not only glycoproteomics, but also a variety of PTMs and 
targeted protein analyses. The metabolic labelling may limit its application for glycoprotein 
analysis of clinical samples. In addition, it requires many steps to perform the analysis (from 
probe synthesis to data-independent MS analysis), which may hinder its wide usage. 
 
1.2.1.5 NGAG 
Zhang and co-workers recently reported an innovative chemoenzymatic method, named 
solid phase extraction of N-linked glycans and glycosite-containing peptides (NGAG), to 
comprehensively analyze N-glycoproteins and glycans in complex samples 29. This method 
utilizes enzymatic and chemical reactions to analyze the N-glycans and their parent 
deglycosylated peptides. Briefly, proteins were firstly digested, and the resulting peptides were 
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guanidinized to block the ε-amino groups on the lysine side chain. Peptides were then 
conjugated to the solid phase via their N-termini, and the carboxyl groups of aspartic acid (D), 
glutamic acid (E), peptide C termini, and sialic acids were reacted with aniline to facilitate the 
mass spectrometric detections. N-glycans were released from the solid support by PNGase F 
treatment and subjected to MS analysis while their corresponding asparagine residues were 
converted to aspartic acids. This provides the opportunity for Asp-N-induced cleavage of the 
peptides, and thus releasing them from the solid phase while the aspartic acids that are not 
generated from PNGase F cleavage of N-glycans will not be affected because they were 
modified by aniline in the prior step. The released deglycosylated peptides were also identified 
by MS.  
This strategy led to the identification of 2,044 unique N-glycopeptides, and in an 
experiment comparing NGAG and hydrazide chemistry methods, they analyzed a total of 3,083 
unique N-glycosite-containing peptides from 1,473 glycoproteins in OVCAR-3 cells. 
Quantitative analysis of glycopeptides based on NGAG was also performed, and proved 
treating cells with tunicamycin mainly caused glycan occupancy reduction on the glycosylation 
sites. Further glycan dynamic experiments also showed differential alteration of glycans by the 
tunicamycin treatment. Overall, NGAG is an excellent example of rationale usage of chemical 
and enzymatic reactions to advance MS-based glycoproteomics, although the complex steps 
could potentially put limitations to its applications.  
 
1.2.1.6 Boronic acid-based enrichment methods 
Boronic acids have great potential for enriching glycopeptides/glycoproteins because 
one common feature of all glycans is that they all contain multiple hydroxyl groups. The 
covalent interactions between boronic acids and cis-diols on glycans have been extensively 
studied in the literature, and has been applied for glycoprotein analysis. Yang and co-workers 
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designed a boronic acid-functionalized core-satellite-structured composite material to capture 
glycopeptides/proteins, and analyzed 194 unique glycosylation sites from 155 different 
glycoproteins 30. Later the same group synthesized a boronic acid-functionalized detonation 
nanodiamond to enrich glycopeptides and analyze glycoproteins, which has led to the 
identification of 40 unique N-glycospeptides from 34 unique glycoproteins in mouse liver 31. 
Zeng et al. designed a surface patterned sample support with a hydrophobic outer layer and an 
internal boronic acid-modified gold microspot, to selectively enrich glycopeptides. The 
enriched glycopeptides were then directly subjected to MALDI MS analysis 32. Metz and co-
workers combined boronate affinity chromatography with ETD MS to analyze non-
enzymatically glycated peptides 33.  
Wu and co-workers have conjugated boronic acids onto magnetic beads, and then used 
the functionalized beads to enrich glycopeptides from protein digestions for MS-based 
proteomic analysis 34. Due to the nature of the pH-dependent reversible interactions between 
boronic acids and hydroxyl groups, the enrichment was performed under basic condition 
(pH=10) to capture glycopeptides on the beads. After several washes to remove non-
glycopeptides, the elution was performed under acidic condition to release glycopeptides. The 
enriched glycopeptides were then treated with PNGase F in heavy oxygen water (H218O) for 
only three hours to generate a common tag for N-glycosylation site identifications, which 
distinguishes the bona fide glycosylation sites from spontaneous asparagine deamidation sites. 
They applied this strategy to study the yeast glycoproteome, and identified 816 N-glycosylation 
sites on 332 proteins.  
The reactions between boronic acid and hydroxyl groups make boronic acid-based 
chemical enrichment universal for nearly all types of glycopeptides/glycoproteins. The 
reversible nature of this interaction and the mild reaction conditions ensures the glycans 
undamaged after enrichment, therefore this method is able to be used for intact glycopeptide 
 
10 
analysis with glycan structural information. This method can be further improved by 
strengthening the binding between boronic acids and glycans, allowing the capturing of more 
glycopeptides and minimizing glycopeptide loss. Overall, the combination of boronic acid-
based enrichment methods and MS-based proteomics has the potential to universally analyze 
protein glycosylation with structural information on a large scale. 
 
1.2.1.7 Click chemistry-based methods 
Metabolic labeling of glycans with unnatural sugar analogs has been proven to be 
powerful to study glycoproteins35. In the recent two decades, the Bertozzi group has been a 
pioneer in using unnatural sugar analogs to label glycoproteins. They firstly developed a cell 
surface engineering strategy by combining metabolic labeling with a modified Staudinger 
ligation reaction 36. They found that acetylated azide-containing sugar analogs have much 
greater labeling efficiency than the non-acetylated versions. Azide-containing sugar analogs 
are commonly used in these methods because the azide group is small, which does not create 
an unacceptable steric hindrance that renders the analog unable to be recognized by the 
enzymes, and it is relatively stable and biologically inert.  
To date, a variety of sugar analogs have been used for metabolic labeling, such as 
GalNAc, GlcNAc, fucose, and ManNAc analogs  37. After incorporation of the azido sugar 
analogs, a click reaction is performed to introduce another chemical handle for affinity 
enrichment. The glycoproteins/ glycopeptides can be analyzed by a variety of methods 
including proteomics techniques. 
 
1.2.1.8 Other chemical and enzymatic enrichment methods 
Chemical and/or enzymatic methods facilitated the identification and quantification of 
not only protein N-glycosylation, but also O-glycosylation, especially O-GlcNAcylation. For 
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instance, Khidekel et al. established a method, termed quantitative isotopic and 
chemoenzymatic tagging (QUIC-Tag), which enzymatically incorporates the ketone group 
onto O-GlcNAcylated proteins, and then tags it with biotin for affinity enrichment of O-
GlcNAcylated peptides/proteins for rapid and sensitive identification and quantification 38. 
Through combining this strategy with quantitative isotopic dimethyl labeling, they studied O-
GlcNAcylation dynamics in cultured neurons and rat brain samples. 
Wang et al. developed a click chemistry-based strategy by combining 
chemical/enzymatic tagging, photochemical cleavage, and electron-transfer dissociation (ETD) 
mass spectrometry to enrich O-GlcNAc modified peptides and map O-GlcNAcylation sites 39. 
They used enzyme GalT1 to transfer an azide-containing sugar analog (UDP-GalNAz) onto 
the O-GlcNAc moieties on the modified peptides, and then incorporated a biotin group on it 
through CuAAC for the enrichment. The enriched O-GlcNAcylated peptides were then 
released by photochemical cleavage, followed by LC-MS analysis. The same group has also 
made significant contributions to study the biological importance of protein O-GlcNAcylation 
and investigate the cross-talk between O-GlcNAcylation and phosphorylation through 
proteomics-based strategies 40-45. 
Chemical and enzymatic strategies significantly broaden the toolbox of MS-based 
proteomics, and have facilitated various qualitative and quantitative studies of protein PTMs. 
We envision that further development of chemoenzymatic methods will tremendously advance 
our understanding of protein glycosylation. 
 
1.2.2 Generating a common tag for MS analysis 
Glycans are highly heterogeneous, and the diverse structures contain a wealtj of 
biological information. At the same time, diversity of glycans results in difficulty for global 
analysis of protein glycosylation with MS. Unlike other modified groups with a fixed structure, 
 
12 
such as protein phosphorylation or methylation with a universal mass shift for all modified 
peptides and proteins 46, protein glycosylation does not have a common mass tag for MS 
analysis. In order to globally identify glycosylation sites, methods that generate a tag for 
glycosylation sites will provide convenience for spectra matching. This section covers the 
methods generating a common mass tag for MS-based glycoproteomics analysis. 
 
1.2.2.1 A common tag for protein N-glycosylation 
The simplest strategy is to remove the glycans while the residual mass can serve as a 
tag to localize the glycosylation site. To achieve this goal, enzymatic methods have been widely 
used to deglycosylate N-glycans. The enzyme peptide-N4-(N-acetyl-β-
glucosaminyl)asparagine amidase F (PNGase F) is the most commonly used to remove protein 
N-glycans. PNGase F was initially isolated from Flavobacterium meningoseptic in 1984 47, 
and has been used for N-glycan removal since then. It was reported to recognize a broad 
spectrum of substrates and can hydrolyze the glycosylamine linkage between the glycan and 
the amino acid, which generates a deglycosylated peptide and an intact oligosaccharide with 
the di-N-acetylchitobiose unit at the reducing end 48.  In the process, the asparagine residue will 
be converted to aspartic acid, introducing a mass shift which can serve as a universal mass tag 
for glycosylation site localization. The reaction is shown in Figure 1.1. 
 
Figure 1.1 Deglycosylation using PNGase F. After glycoprotein/glycopeptide enrichment, the 



























Although PNGase F has been widely used, there are still a few drawbacks of using this 
method. First, spontaneous deamidation of asparagine residues occurs at all time in vitro and 
in vivo which generates the same mass shift as PNGase F cleaving reaction, rendering it hard 
to control the false positive glycosylation site identification. To solve this problem, heavy 
oxygen water (H218O) has been employed as the solvent to carry out the enzymatic removal of 
N-glycans by PNGase F 49, 50. In this case, the mass tag of accumulated spontaneous 
deamidation is different from the one from authentic deglycosylation with PNGase F. The 
reaction can be performed for a shorter period of time to limit the impact of deamidation during 
PNGase F treatment. In our previous experiment, under the PNGase F treatment at neutral 
conditions, the spontaneous deamination effect can be negligible. The other limit of this method 
is that PNGase F is not able to remove glycans with fucose attached α1 → 3 to the asparagine-
linked N-acetylglucosamine residue 51. This problem has not been solved yet, although 
combining several deglycosylation enzymes may help release the glycans more efficiently. 
Aside from PNGase F, the endoglycosidases are a family of important deglycosylation 
enzymes that have also been reported in the literature. Endoglycosidase H (Endo H) is the most 
widely used one among the endoglycosidases. It cleaves within the chitobiose core of high 
mannose and some hybrid oligosaccharides from N-linked glycoproteins, although it does not 
work efficiently against complex glycans. Endo H was firstly isolated from Streptomyces 
plicatus and its structure was described by Robbins et al. in 1984 52. The residual mass of Endo 
H cleavage is different from that of PNGase F removal because the innermost GlcNAc residue 






Figure 1.2 Deglycosylation using Endo H. After cleaving the glycan, the peptide is left with 
one residual GlcNAc. 
 
The remaining GlcNAc can serve as the mass tag for glycosylation site localization. 
However, this tag is considerably larger than the one from PNGase F treatment, which may 
have a negative effect on the quality of tandem MS, especially when collision-induced 
dissociation (CID) is used to fragment glycopeptides. In addition, Endo H has higher substrate 
specificity comparing to PNGase F, rendering the enzymatic glycan release not as complete. 
To improve the glycoproteome coverage, researchers have combined several endoglycosidases 
to remove glycans. For instance, Hägglund et al. combined Endo H and Endo D to 
deglycosylate glycopeptides enriched by hydrophilic interaction liquid chromatography, which 
led to the identification of 62 glycosylation sites on 37 glycoproteins from human plasma 
samples (Hägglund et al., 2004). 
 
Although enzymatic methods have their advantages, each enzyme has its own 
specificity besides that they are not cost-effective. Therefore, it is very difficult to universally 
remove all glycans using a single enzyme or a combination of several enzymes. Chemical 
methods were also developed to remove glycans for glycosylation mapping. More than three 
decades ago, Edge et al. developed a method using trifluoromethanesulfonic acid (TFMS) to 
remove glycans from fetuin, and found that this treatment at 0 or 25°C results in rapid cleavage 
of peripheral sugars, slow loss of serine- and threonine-linked GalNAc, and retention of N-

























deglycosylation were also reported in the literature 54. Recently, Chen et al. developed a method 
combining removal of glycans using TFMS and MS-based proteomics to perform large-scale 
analysis of protein N-glycosylation from complex biological samples 55. This method takes the 
advantage of the difference between the amide bond of the innermost N-linked GlcNAc and 
the glycosidic bond among the rest of the sugars, where TFMS can cleave the glycosidic bonds 
but not the amide bond. Therefore, after cleavage, the innermost GlcNAc remains on the 
peptide to serve as a tag for N-glycosylation site mapping. Although the tag is the same as that 
from Endo H treatment, this chemical method has the advantage of not being affected by the 
compositional and structural variation of the glycans, which can lead to a much broader 
glycoproteome coverage.  
Combining this method with lectin enrichment of glycopeptides, the authors identified 
555 N-glycosylation sites from 219 glycoproteins without further glycopeptide fractionation. 
The authors also compared this method to the Endo H method, and demonstrated that this 
chemical method outperformed the other by a large margin. Following this study, Ma et al. 
developed a strategy used TFA to deglycosylate glycopeptides with the assistance of 
microwave heating, which shortened the treatment time to merely ten minutes 56. Combining 
the new strategy with ZIC-HILIC enrichment and higher-energy collisional dissociation (HCD) 
fragmentation, they identified a total of 257 N-glycosylation sites and 144 N-glycoproteins 
from healthy human serum. Although chemical deglycosylation methods are generally more 
universal than enzymatic methods, the harsh deglycosylation conditions sometimes would 
damage the peptide backbone and thus sabotage the glycosylation site identification. 
 
1.2.2.2 A common tag for protein O-glycosylation 
 Although it is well known that protein O-glycosylation plays crucial roles in biological 
systems 57-59, the tools to study protein O-glycosylation is relatively under-represented 
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compared to N-glycosylation. As one of the methods that can deglycosylate O-glycans and 
leave a mass tag on the peptides, β-elimination has been well studied in the literature. The 
general principle of this method is to perform alkaline-induced release of glycans and leaves 
an alkene group on the deglycosylated site. The carbon-carbon double bond is reactive and 
susceptible to nucleophilic attack, and therefore, reduction was then performed on the alkene 
to stabilize the structure and create a mass tag for proteomic studies.  
 More than two decades ago, Greis et al. designed a β-elimination-based strategy to 
analyze O-GlcNAc-modified glycopeptides using MS. They demonstrated that β-elimination 
can create a mass shift for O-GlcNAcylated peptides, converting the previously glycosylated 
serine and threonine residues to alanine and 2-aminobutyric acid, respectively, and thus can be 
used for detection and site mapping of glycopeptides in complex samples 60. The same research 
group further developed this method by coupling β-elimination with Michael addition of 
dithiothreitol, termed BEMAD 45. This method creates a 136.2 Dalton mass shift through the 
loss of the glycans and addition of the DTT molecule, which can serve as a common mass tag 
for O-glycosylation (especially O-GlcNAcylation) site analysis. In the literature, there are also 
many other reports on β-elimination-based methods for maping protein O-glycosylation 9, 44, 61-
69. For instance, Rademaker et al. used NH4OH to initiate β-elimination, and after completion, 
NH3 was incorporated onto the amino acid residue from which the glycan was released. This 
method yielded a unique mass tag for database searching and was proved to be effective for as 
low as 1 pmol of starting material 70. Despite β-elimination-based methods hold the potential 
to generate common mass tags for O-glycosylation sites, the major drawback is that the reaction 
conditions are relatively harsh, which induces significant degradation of peptides. 
 Unlike N-glycans that can usually be removed by Endo H or PNGase F prior to LC-
MS/MS analysis, O-glycans are more daunting to be released by enzymatic methods. Despite 
this fact, attempts were still made on using enzymes to deglycosylate O-glycans. Hägglund et 
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al. combined two enzymatic deglycosylation strategies to identify both core fucosylated N-
glycans and O-glycosylation sites from human plasma proteins. They carried out PNGase F 
removal of N-glycans in H218O first, then Endo D and Endo H, along with several 
exoglycosidases (β-galactosidase, neuraminidase and N-acetyl- -glucosaminidase), were used 
to cleave the glycosidic bond between the two GlcNAc residues in N-glycans, leaving only one 
GlcNAc residue with potential fucosyl side chain on the peptide. Although initially this strategy 
was devised for N-glycosylation analysis, several O-glycosylated peptides were also found 
with a single GalNAc attached to the modification site, which was attributed to partial de-O-
glycosylation by the combination of endo- and exoglycosidases 23.  
In addition to the enzymatic and chemical methods mentioned above, another very 
elegant method was developed by Steentoft et al., which employs zinc-finger nuclease (ZFN) 
to genetically engineer cells, simplifying the O-glycan structures to create a common mass tag 
10. The modified cell lines are named SimpleCell lines. They applied ZFN targeting to modify 
the O-glycan elongation pathway in human cells, and thus truncate the human glycans. 
SimpleCell lines with homogenous O-glycosylation were generated. These cell lines solely 
express GalNAcα (Tn) or NeuAcα2-6GAlNAcα (STn) O-glycans, allowing O-glycopeptides 
to be easily enriched by lectins. The glycopeptide sequencing process is also greatly simplified 
due to the common tags. A total of >100 O-glycoproteins with >350 O-glycosylation sites were 
identified by combining this method with nano-flow liquid chromatography-mass spectrometry 
(nLC-MS/MS) with electron transfer dissociation (ETD) fragmentation. This method has 
opened up a new avenue to analyze the O-glycoproteome. With the development in gene 
editing techniques in recently years, similar strategies should have broader applications in 
protein modification studies. 
Following their first publication, Steentoft et al. further optimized the experimental 
conditions and mapped nearly 3,000 glycosylation sites in over 600 O-glycoproteins from 12 
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human cell lines 71. These cells were from different organ origins and the glycoproteomes are 
considerably different across these cell lines. Meanwhile, they also improved NetOGlyc4.0 as 
a tool for O-glycosylation prediction. In summary, this study contains very comprehensive O-
glycosylation information. 
 
1.3 Glycoprotein Dynamics 
Glycosylation is a reversible protein modification and glycoproteins are dynamic in and 
outside of cells. However, investigating glycoprotein dynamics can be quite challenging. The 
rapid advancement in glycoproteomics and multiplexed proteomics has provided the exciting 
possibility. The following subsection review several studies on MS-based proteomic 
investigation of glycoprotein dynamics. 
 
1.3.1 O-GlcNAcylated protein dynamics 
There are several methods reported in the literature to study glycoprotein dynamics and 
most of these studies were conducted in recent years. For instance, Wang et al. metabolically 
labeled O-GlcNAc by feeding cells with 13C6-glucose. The isotopically labeled glucose 
metabolized into 13C-labeled UDP-GlcNAc through the hexosamine biosynthetic pathway, and 
eventually labeled O-GlcNAcylated proteins. They then employed the boronic acid-based 
glycoprotein enrichment method to enrichment O-GlcNAcylated peptides for quantitative 
proteomics analysis. Through this strategy, protein O-GlcNAcylation turnover rates were 
determined. They identified 105 O-GlcNAcylated peptides from 42 proteins, and determined 






1.3.2 N-glycoprotein dynamics 
Recently Xiao et al. developed a method that integrated isotopic labeling, chemical 
enrichment, and multiplexed proteomics to perform glycoprotein degradation and synthesis 
rates simultaneous 73. In this study, cells were cultured in media containing heavy lysine and 
arginine, then chased in media with all light amino acids for different duration before being 
harvested. Then the proteins were extracted, digested, and the resulting peptides were subjected 
to boronic acid-based glycopeptide enrichment. The enriched glycopeptides from cells 
harvested at different time points were labeled by tandem mass tags (TMT) reagents, and then 
analyzed by LC-MS/MS. Due to the fact that after chasing cells with light media, the abundance 
of existing heavy amino acid-labeled proteins decrease and the light proteins increase, heavy 
glycoproteins were used for the determination of degradation rates and light glycoproteins for 
synthesis rate investigations. The synthesis rates of 847 N-glycoproteins and degradation rates 
of 704 N-glycoproteins were calculated in this study. 
 
1.4 Applications of MS-Based Glycoproteomics 
Protein glycosylation is one of the most complex modifications in all types of organisms. 
Characterizing glycosylation events in various samples will certainly lead to a deeper 
understanding of many cellular processes and better solutions of biomedical problems. The 
strategies developed in the field of glycoproteomics have been widely applied to investigate a 
great variety of experimental subjects, from prokaryotic cells to eukaryotic cells, from plants 
to animals, and from cultured cells to clinical samples. In this section, we review the 







Yeast (Saccharomyces cerevisiae) is most commonly used in biology laboratories. 
Although it serves as an excellent model system for eukaryotic cells, the global analysis of 
glycoproteins in yeast is still challenging. Unlike human glycan structures, the yeast glycans 
are mostly the high-mannose type 74, and the molecular weight of these N-glycans can 
sometimes be very large. In addition, yeast also has cell walls, and many cell wall proteins are 
heavily mannosylated. Investigating protein glycosylation in yeast has long been intriguing to 
researchers. 
In 2009, Schulz and Aebi designed a novel strategy to quantify glycosylation site 
occupancy in yeast. They enriched glycoproteins bound to the yeast polysaccharide cell wall, 
and released the glycans using Endo H, which also creates a mass tag at the same time. The 
peptides and glycopeptides were analyzed by LC-MS/MS. Their experimental results also 
revealed that the paralogues Ost3p and Ost6p have crucial roles in efficient glycosylation of 
distinct defined glycosylation sites 75.  
Bailey and Schulz demonstrated that adding a protein deglycosylation step prior to 
enzymatic protein digestion can systematically improve N-glycoprotein identification in yeast 
lacking Alg3p. By treating the proteins with PNGase F before AspN or trypsin digestion, the 
quality of yeast cell wall proteome identification was improved 76. 
As discussed above, Chen et al. developed a chemical deglycosylation method to study 
lectin-enriched yeast glycoproteome, and 555 protein N-glycosylation sites were identified on 
250 glycoproteins in yeast cells. They later devised a boronic acid-based enrichment strategy 
to universally analyze glycoproteins in yeast, and identified 816 N-glycosylation sites from 
332 glycoproteins. 
Xiao et al. performed quantification of the proteome and glycoproteome changes in 
yeast cells with or without the tunicamycin treatment. A total of 4,259 proteins and 135 
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glycoprorteins were quantified. More than 5% of the proteins were found to be decreased by at 
least 2-fold and 168 out of 465 glycopeptides were down-regulated due to the protein N-
glycosylation inhibition effect of tunicamycin 77. Smeekens et al. identified and quantified 
secreted yeast proteins (including glycoproteins) from tunicamycin-treated cells. The secreted 
yeast glycoproteins were separated from cells through mild washing and centrifugation that 
avoided cell death, limiting the impact of the intracellular proteins on the secretome analysis. 
A total of 27 glycoproteins were quantified and 26 of them were down-regulated, testifying 
that the secretion of some proteins is regulated by glycosylation 78. 
 
1.4.2 Plant 
Since glycosylation is an essential protein modification in all eukaryotic cells that 
regulates a variety of cellular processes, plant glycosylation is also of importance to investigate. 
Similar to mammalian cells, most proteins of the extracellular and endomembrane systems are 
glycosylated by N-linked oligosaccharides in plants. Protein N-glycosylation impacts not only 
their physicochemical properties, but also their biological functions 79. Despite the fact that 
protein glycosylation is relatively conserved across all eukaryotic species,  glycosylation in 
plant cells does have its uniqueness compared to mammalian cells. However, compared to lots 
of endeavors been put into glycosylation studies in mammalian cells, plant glycosylation is still 
relatively not as well-studied. While there is no universal protocol or procedure for plant 
proteomics, in general, a plant proteomics experiment typically involves the following steps: 
cell/tissue preparation, protein extraction and digestion, peptide separation, and MS-based 
identification 80. For modification studies, there usually is an additional enrichment step. The 
protein extraction procedure for plant can be very different from mammalian protein extraction 
because (1) plants have a great variety of tissues and the extraction procedure can be different 
for different tissues; (2) protein concentrations in plant samples are usually low and yet plant 
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tissues have high amount of proteases; (3) many plant-originated chemicals, such as the 
polysaccharides in cell wall, lipids, pigments, and metabolites, can greatly interfere with 
several steps of the typical proteomics workflow. 
Proteomic studies of plant glycoproteins have emerged since early 2000s. In 2003, 
Andon et al. performed a proteomic study on the mannose-binding proteins in rice (Oryza 
sativa). Instead of directly analyzing glycoproteins, they studied the proteins that are involved 
rice sugar metabolism, including several rice lectins 81. The method they used to enrich these 
proteins is column affinity chromatography, and α-D-mannose was used as the ligand to pack 
the column and bind the desired glycoproteins. Saravanan and Rose evaluated several 
extraction techniques to analyze proteins in recalcitrant plant tissues, and found that compared 
to acetone-based protein precipitation methods, phenol-based methods gave higher numbers of 
protein and glycoprotein identifications as shown in their results 82.  
Wimmer et al. designed an method to isolate “membrane-associated, boron-interacting 
proteins”, such as glycoproteins, glycosylphosphatidylinositol (GPI)-anchored proteins, using 
boronate affinity chromatography. Resin-immobilized phenylboronic acid was employed to 
capture glycoproteins from root microsomal preparations of arabidopsis (Arabidopsis thaliana) 
and maize (Zea mays). These proteins were then analyzed by 2D-gel electrophroresis and 
matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) MS 83.  
Albenne et al. systematically studied plant cell wall proteins including glycoproteins. 
They established a workflow to prepare cell wall peptides for MS analysis, and developed a 
bioinformatics tool to interpret the data. In that study, N-glycosylation was found on 
peroxidases, such as PER32. Their MS data also provided insights into N-glycan structures and 
facilitated protein glycosylation prediction 84. 
In later studies, especially those published in recent years, lectin-based enrichment 
strategies were the most widely used to enrich plant glycoproteins. Typically, one or several 
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lectins are immobilized on the resin to pack a column, and then lectin affinity chromatography 
is performed to separate and purify plant glycoproteins. Through this enrichment, researchers 
were able to analyze both N- and O-glycosylation. For instance, Rose and co-workers carried 
out a comparative study to analyze N-glycoproteins in tomato fruit. In one experiment, by 
combining three lectins, namely Con A, snowdrop lectin, and lentil lectin to enrich 
glycoproteins, they identified 448 putative N-glycoproteins. In the other parallel experiment 
using lectin affinity chromatography plus hydrophilic interaction chromatography as the 
enrichment method, 318 putative N-glycosylation sites on 230 N-glycoproteins were identified. 
Of note, 17 N-glycan structures were also studied 85. In another study on tomato fruit 
glycoproteins, Thannhauser and co-workers combined  ConA lectin affinity chromatography 
and LC-MALDI-MS/MS, and analyzed glycoproteins that involved in biological processes 
such as carbohydrate metabolism, proteolytic activity, oxidative catabolism, phosphatase 
activity, nucleic acid catabolism/transcriptional regulation 86. 
 
1.4.3 Mouse 
Mouse has been an excellent model for researchers to study biology in complex and 
dynamic physiological systems. It is frequently used in biomedical research as a substitute for 
human subjects. To overcome its several limitations in modeling human disease, many 
clinically-relevant mouse models were generated to mimic the cellular processes of human 
diseases 87. Through these models, molecular mechanisms and clinical responses of diseases 
were investigated. The data collected in these studies contribute immensely to developing new 
therapies to cure diseases. Due to the biomedical importance of mouse models, analyzing 
mouse glycoproteins have been the focus of many reports in the literature. 
Besides the large-scale mouse N-glycoproteome study performed by Mann and co-
workers that is described in the first section of this review, there are also many other impactful 
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glycosylation studies on mouse samples. Cima et al. used a glycoproteomics approach to aid 
in the discovery of serum biomarkers for prostate cancer. Hydrazide chemistry coupling with 
solid phase extraction was employed for the enrichment, and through this, they identified 775 
N-glycoproteins from sera and prostate tissue of wild-type and Pten-null mice 88. Label-free 
quantification was then performed, and the results demonstrated that Pten deletion led to 
changes in prostate and serum glycoproteomes. Based on these results, further targeted-
proteomics and bioinformatics studies were carried out to screen out potential biomarkers. This 
study is an excellent example of how rational design of proteomic analysis in mouse models 
can lead to the discovery of biomarkers. 
Goldberg et al. developed a program named Peptoonist that enabled automated N-
glycopeptide identification, which can identify glycopeptides and also annotate glycan 
composition. To validate this strategy, they prepared mouse models and then isolated proteins 
from these mouse ovaries and tested the program 89. Zhang et al. optimized a protocol for the 
enrichment of both glycopeptides and phosphopeptides through electrostatic repulsion 
hydrophilic interaction chromatography (ERLIC), and then analyzed 922 glycosylation sites 
on 544 unique glycoproteins, and 915 phosphorylation sites on 383 phosphoproteins from 
mouse brain membrane 90.  
Many mouse O-glycosylation studies were also reported in the literature. Alfaro et al. 
devised a strategy combining metabolic labeling and chemical/enzymatic photochemical 
cleavage to study mouse brain O-GlcNAcylated proteins as discussed above 41. From 100 µg 
tryptic peptides, they were able to identify 458 O-GlcNAc sites and 195 glycoproteins. 
Palmisano et al. combined titanium dioxide enrichment with HILIC to investigate protein 
modifications during mouse brain development, and were able to identify 3246 unique formerly 
sialoglycopeptides. More than 10% of these peptides were found to be differentially regulated 
in the development process 91. Although O-glycosylation studies in mouse are still quite 
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challenging now, with the development in enrichment strategies and MS fragmentation 
methods, we expect more applications of O-glycosylation analyses in mouse models will come 
up and greatly expand our knowledge of the functions of O-glycoprotein in cells with healthy 
or diseased states. 
 
1.4.4 Human cell lines and intact glycopeptide analyses 
The commonly used human cell lines along with stem cells 92 are the most widely used 
models in the glycoproteomics field. Using human cell lines, glycoproteome analysis has 
advanced from glycoprotein identification-centric studies to glycosylation site localization and 
site-specific structural characterization of glycan-containing peptides and proteins. Although 
bottom-up and top-down glycoproteomics are both developing rapidly, glycopeptide-based 
glycoproteomics is more commonly used to study the glycosylation sites and glycan structures 
on glycopeptide. In addition, stoichiometry and glycan occupancy information can also be 
obtained from this working route. To study glycan-containing glycopeptides in human cells, 
different fragmentation methods have their advantages and disadvantages. CID can generate 
abundant B- and Y- ions that are useful to identify the glycan composition and structure. 
However, CID, especially resonance-type CID technique cannot produce adequate and reliable 
fragments for glycosylation site and peptide sequence determination. Beam-type higher-energy 
collisional dissociation (HCD) usually can generate enough b- and y- ions for peptide 
identification, but the frequent detachment of glycans renders the site localization hardly 
reliable. ECD (electron-capture dissociation) and ETD (electron-transfer dissociation) type 
fragmentation methods yield c- and z- ions to determine the peptide backbone sequence and 
glycosylation site, but not enough information can be gathered to study the actual glycan side 
chain substructure.  
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Due to the drawbacks of each technology, attempts were made to perform MS3 or 
combine different fragmentation methods to analyze intact glycopeptides 93, 94. These attempts 
can improve peptide backbone fragmentation efficiency or allow pre-selection of glycopeptides, 
thus filtering out non-glycopeptides and allocating more analysis time for glycopeptides. 
Parker et al. combined glycomics and glycoproteomics to study the N-glycoproteome 95. They 
analyzed the glycosylation sites and glycan structures separately. The glycopeptides were 
deglycosylated with PNGase F and identified by LC-MS/MS first to accurately localize the N-
glycosylation site, then glycan-containing form of the same peptide and glycans were analyzed 
to find out the glycan composition. Eventually the data collected from both analyses were 
combined to reconstruct the intact-glycopeptides. With both glycome and glycoproteome 
information, a total of 863 unique N-glycopeptides from 161 glycoproteins were studied. Other 
attempts were focused on developing computational algorithms for site-specific assignments 
of intact glycopeptides. Zhang and co-workers developed software named GPQuest to analyze 
intact glycopeptides using the data collected from HCD-LC-MS/MS. This software firstly 
generates a spectral library of glycosite-containing peptides from MS analysis using HCD as 
the fragmentation method. Intact glycopeptides are then selected based on the oxonium ions, 
and the spectra are compared with the library generated from glycosite-containing peptides. 
This step assigns MS/MS spectra of intact glycopeptides to specific glycosite-containing 
peptides. The glycans were then determined by calculating the mass shift between the precursor 
ion of intact glycopeptide and the glycosite-containing peptide, and match the mass difference 
to a glycan database 96, 97.  
In 2012, Frese et al. developed a novel method that combined HCD with ETD (termed 
EThcD) to improve peptide backbone fragmentation. After the initial electron-transfer 
dissociation, all ions were fragmented by collision induced dissociation. Therefore, in the end, 
b-, y-, c-, and z-ions can be observed in the same spectrum 98. They later applied it for 
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phosphorylation analysis 99. This strategy was recently adopted and optimized by Yu et al. to 
analyze intact glycopeptides. After lectin and HILIC enrichment, the glycopeptides were 
analyzed by EThcD MS 100. Since both glycosidic and amide bonds were cleaved, rich 
information on glycan structure and peptide sequence were obtained. The authors also 
compared the number of glycoforms identified from EThcD or HCD alone, and demonstrated 
that a greater number of glycoforms were observed using EThcD. 
 
1.4.5 Clinical samples 
Glycosylation can changes chemical and physical properties of proteins, and regulate 
their binding and interactions with ligands or extracellular matrix, which is important in many 
biological processes. Aberrant glycosylation patterns reflect abnormal cellular processes and 
can be used to monitor disease status 101. Glycoproteomics has been applied in the research of 
a great variety of diseases, such as hepatitis, cancer, and infectious diseases. For instance, an 
increase on sialylation is a common feature of cancer cells 102. With the increased levels of 
sialic acid residues in cells, abnormal glycosylation patterns such as STn antigens start to 
present on cells 103. Also, as described by the Warburg effect, cancer cells predominantly 
produce energy through glycolysis instead of mitochondrial oxidative phosphorylation. This 
leads to a great increase in glucose uptake, which elevates the level of UDP-GlcNAc, the end 
product of hexosamine biosynthetic pathway. Correspondingly protein O-GlcNAcylation may 
increase dramatically. Due to this reason, hyper O-GlcNAcylation is also one of the hallmarks 
of cancer progression in cells 104.  
Currently, one of the most important glycoproteomic applications in clinical samples is 
to find new disease biomarkers 105. Unlike traditional strategies that screen a single or a small 
number of potential biomarker(s), monitoring a larger group of candidates using 
glycoproteomic approaches can often result in higher sensitivity and specificity. For example, 
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Ahn et al. attempted to screen biomarkers for small cell lung cancer through a glycoproteomic 
approach. They enriched glycoproteins using a lectin column, and then analyzed the 
glycoproteome changes through both label-free quantification and multiplex proteomics. The 
results demonstrated that the expression and glycosylation changes in fucosylated proteins, 
such as paraxonase 1, might serve as serological markers for small cell lung cancer 106. Qiu et 
al. profiled plasma glycoproteins in order to find biomarkers for colorectal cancer. They 
combined lectin glycoarray with LC-MS to determine the glycan patterns from the plasma 
samples from 9 normal, 5 adenoma, and 6 colorectal cancer patients, and found several proteins 
with elevated sialylation and fucosylation as potential biomarkers of colorectal cancer. These 
markers were then validated by lectin blotting of plasma samples from thirty patients 107.  
Halim et al. devised several applicable strategies to analyze glycoproteins with glycan 
structural information in clinical samples. In 2012, they performed a study to analyze N- and 
O-linked glycoproteins in urine samples. After eliminating the interferences by dialysis, they 
performed the enrichment with hydrazide chemistry, and characterized intact glycopeptides by 
CID and ECD. Later they combined PNGase F pretreatment and automated CID-MS2/MS3 
fragmentation for glycopeptide identification, and ECD/ETD for glycosylation site localization, 
to analyze intact O-glycopeptides in glycoproteins from human cerebrospinal fluid samples. 
This study provided guidance for future research of finding O-glycoproteins as potential 
biomarkers. In 2014, by using synthetic glycopeptides, urine samples, and peptides from 
human cerebrospinal fluid samples, they found that oxonium fragmentation patterns can be 
used to differentiate O-GlcNAc from O-GalNAc, which is a important discovery for intact O-
glycopeptide analysis 108. 
The applications of glycoproteomics in clinical samples are far more than what we 
described in this section, there are many comprehensive reviews that discuss the importance of 
glycoproteomic technologies in biomedical research 109-114.  Due to the irreplaceable roles of 
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glycoproteins play in various diseases, high-throughput glycoproteomic technologies will 
continue to be developed to enable large-scale and sensitive analysis of glycopeptides and 




The tremendous development in chemical biology and MS technologies have allowed 
for rapid advancements in the glycoproteomics field. Here, we reviewed the chemical and 
enzymatic methods for glycoprotein analysis. We first included widely used methods for the 
enrichment of glycopeptides/proteins, such as lectin, hydrazide chemistry, HILIC, click 
chemistry-based and boronic acid-based enrichment methods. Following this, we discussed 
several enzymatic and chemical methods for the generation of common mass tags. This section 
focused on how researchers have attempted to solve the two challenging problems in 
glycoproteme analysis (low abundance of many glycoproteins and heterogeneity of glycan 
structures). With the methods described above and multiplexed proteomics, large-scale 
investigation of glycoprotein dynamics has come to realization. Therefore, The methods 
recently reported for studying the dynamics of the whole glycoproteome were also included. 
In the last section, we discussed many applications of MS-based glycoproteomics in different 
species, from yeast, plant, mouse models, to clinical samples, and intact glycopeptide analysis 
in human cells. 
With these methods and many other strategies underway, much valuable information 
about protein glycosylation have been and will be obtained, including glycoprotein 
identification, glycosylation site localization, and glycan structure elucidation, glycosylation 
stoichiometry investigation, and glycoprotein analysis with spatial and temporal information. 
Global analysis of protein glycosylation will undoubtedly provide important data that can have 
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tremendous impact on biochemical and biomedical research.  In addition, as we are entering 
an era where computational power advances immensely, we expect to see further developments 
in mass spectrometry. Next generation mass spectrometers will be able to enable more sensitive 
peptide sequencing, faster analyzing speed, and more suitable fragmentation techniques.  
Higher computational power also will allow for new bioinformatics tools to aid in 
glycoproteomics. New and innovative software will be developed to help us quickly and 
accurately identify glycopeptides, especially intact glycopeptides, and to provide us more 
valuable information regarding protein glycosylation sites and glycan structures. With the 
development of hardware and software, and effective chemical and enzymatic methods, it is 
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CHAPTER 2. A CHEMICAL METHOD BASED ON SYNERGISTIC 
AND REVERSIBLE COVALENT INTERACTIONS FOR LARGE-
SCALE ANALYSIS OF GLYCOPROTEINS 
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2.1 Introduction 
Glycosylation is one of the most common and essential protein modifications in cells. 
It often determines protein folding, trafficking and stability, and regulates many cellular events, 
especially cell-cell communication, cell-matrix interactions, and cellular response to 
environmental cues1-4. Glycoproteins contain a wealth of information related to cellular 
developmental and diseased statuses5, 6, and aberrant protein glycosylation is directly related 
to human disease, including cancer and infectious diseases7-10. Global analysis of protein 
glycosylation is critical in understanding glycoprotein functions and identifying glycoproteins 
as biomarkers and drug targets10-12. However, due to the low abundance of many glycoproteins 
and heterogeneity of glycans, it is extraordinarily challenging to comprehensively analyze 
glycoproteins in complex biological samples.  
Currently mass spectrometry (MS)-based proteomics provides a unique opportunity to 
globally analyze protein modifications13-22, including glycosylation23-31. However, effective 
enrichment prior to MS analysis is imperative for each type of protein modification. For 
example, with the maturity of phosphoprotein enrichment methods, the global analysis of 
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protein phosphorylation has advanced tremendously, from the identification of several hundred 
phosphorylation sites a decade ago to over ten thousand sites in recent studies32-34.  
In order to comprehensively analyze protein glycosylation in complex biological 
samples, several glycoprotein/peptide enrichment methods have been reported, including 
lectin-based35, 36 and hydrazide chemistry-based methods37, 38, and hydrophilic interaction 
liquid chromatography (HILIC)39, 40. Currently lectin-based methods are most commonly used 
to enrich glycopeptides prior to MS analysis. Due to the inherent specificity of lectins, each 
type of lectin can only recognize a specific glycan structure, and thus, no single lectin or a 
combination of several lectins can universally enrich all glycosylated peptides or proteins. 
HILIC has also been extensively used to enrich glycoproteins or glycopeptides based on the 
increased hydrophilicity of glycopeptides. However, this method lacks specificity because it 
cannot distinguish glycopeptides from many hydrophilic non-glycopeptides. Recently, two 
elegant methods, i.e. isotope-targeted glycoproteomics (IsoTaG)41 and solid phase extraction 
of N-linked glycans and glycosite-containing peptides (NGAG)42, have been reported. By using 
IsoTaG, 32 N-glycopeptides and over 500 intact and fully elaborated O-glycopeptides from 
250 proteins across three human cell lines were identified41. NGAG was beautifully designed 
for N-glycopeptide enrichment, and 2,044 unique N-glycopeptides were identified in 
mammalian cells42. According to prediction and computational results, protein glycosylation is 
the most common modification43, 44. Despite the considerable progress that has been made in 
the past decade35, 37, 41, 42, 45-50, there is still a substantial gap between the number of 
glycoproteins reported in the literature and those existing in complex biological samples. 
Effective enrichment of glycopeptides/glycoproteins will profoundly advance the global 
analysis of protein glycosylation through MS-based proteomics.  
Previously, boronic acid (BA) was demonstrated to have great potential in universally 
enriching glycopeptides for the global analysis of protein glycosylation because of its 
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reversible covalent interactions with glycans51, 52. However, the method suffers from relatively 
weak interactions; therefore, low-abundance glycoproteins are not effectively enriched. In this 
work, we develop a new method to more effectively enrich glycopeptides, especially those of 
low-abundance, by greatly enhancing the interactions between boronic acid and glycopeptides. 
First, different boronic acid derivatives are tested, and benzoboroxole is found to be highly 
effective to enrich glycopeptides due to dramatically strengthened interactions. Second, based 
on the common features of a glycan containing multiple monosaccharides and one sugar 
bearing several hydroxyl groups, benzoboroxole conjugated dendrimer beads can 
synergistically interact with glycopeptides. The experimental results demonstrate that 
conjugating benzoboroxole to a dendrimer significantly increases the enrichment efficiency, 
even for glycopeptides only containing O-GlcNAc (N-acetyl glucosamine).  
The novel method is applied for the global analysis of glycoproteins in yeast (S. 
cerevisiae), mouse brain tissue, and human cells (MCF7, HEK 293T and Jurkat). Over 1,000 
N-glycosylation sites in yeast and 4,691 sites on 1,906 glycoproteins in human cells are 
identified, including many proteins with low abundance. The reversible nature of the 
interactions allows us to analyze intact O-glycopeptides with glycan structure information. We 
identify 234 O-mannosylated proteins in yeast and many glycoproteins with O-GlcNAc in 
human cells. These results demonstrate that the new method is universal and highly effective 
in enriching glycopeptides, especially from low-abundance glycoproteins that are normally of 
great biological importance. The current results also provide valuable information regarding 
glycoproteins in yeast and human cells to biological and biomedical research communities. 






2.2 Experimental section 
2.2.1 Materials  
Complete protease inhibitors were purchased from Roche Applied Sciences and 
sequencing grade trypsin was from Promega. Dulbecco’s Modified Eagle‘s Medium (DMEM), 
phosphate buffered saline (PBS), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC), 4-carboxy-2-nitrophenylboronic acid, (2-aminomethyl-5-fluoro) 
phenylboronic acid hydrochloride, 2-aminomethyl-4-fluorophenylboronic acid hydrochloride, 
trifluoroacetic acid (TFA), formic acid (FA), trimethylamine (TEA), piperidine, methanol, 
chloroform, dichloromethane (DCM), acetonitrile (ACN), and dimethylsulfoxide (DMSO) 
were from Sigma-Aldrich. 3-aminomethylphenylboronic acid hydrochloride was from Frontier 
Scientific Inc. 5-carboxybenzoboroxole and 1-hydroxy-7-azabenzotriazole (HOAt) were 
purchased from AK Scientific, Inc. (2,5-dioxopyrrolidin-1-yl) (2S)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino] hexanoate (Fmoc-L-
Lys(Boc)-OSu) and (S)-2,5-dioxopyrrolidin-1-yl 2,6-bis((tert-butoxycarbonyl) amino) 
hexanoate (Boc-Lys(Boc)-OSu) were from Ark Pharm, Inc. and Sigma-Aldrich. MagnaBind™ 
amine derivatized beads, MagnaBind™ carboxyl derivatized beads, and fetal bovine serum 
(FBS) were bought from Thermo Fisher Scientific. 
 
2.2.2 Magnetic beads derivatization 
MagnaBindTM carboxyl (or amine) derivatized beads were washed with DMSO three 
times. EDC was added to the beads slurry and incubated end-over-end for 10 min; HOAt was 
subsequently added, and the reaction mixture was further incubated for one hour. HOAt-
activated beads were washed with DMSO twice and incubated overnight with different amino 
boronic acids in DMSO containing 3.0% triethylamine (TEA). The boronic acid functionalized 
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beads were washed with DMSO twice and 20% ACN three times and stored in 20% ACN for 
further use.  
For dendrimer boronic acid derivatization, the solvent containing the MagnaBindTM 
amine derivatized beads was gradually changed from water to isopropanol to finally DCM 
(Figure 2.1 and 2.2). Then Fmoc-L-Lys(Boc)-OSu was reacted with the amino beads in DCM 
containing 0.3% TEA overnight. On the following day the beads were washed with DCM three 
times, and the Boc protection group was removed by incubation of beads in 50% TFA in DCM 
at room temperature for two hours. The beads were washed with DCM three times and one 
time with 3% TEA in DCM. To continue the derivatization, Boc-Lys(Boc)-OSu was added to 
the bead DCM solution followed by the addition of TEA (final concentration 3.0%). The 
reaction was carried out at room temperature with end-over-end rotation overnight. Then the 
Boc group was deprotected by 50% TFA as mentioned above. The Boc-Lys(Boc)-OSu 
conjugation step was repeated twice. Then the Fmoc groups were removed by mixing the 
functionalized beads in 50% piperidine DCM solution at room temperature for 30 minutes. 
Finally, all free amine groups were coupled with 5-carboxybenzoboroxole through EDC HOAt 














Figure 2.2 Conjugation of the boronic acid derivative, benzoboroxole, to the dendrimer. 
 
2.2.3 Yeast cell culture and protein extraction  
Yeast cells (strain BY4742, MAT alpha, derived from S288c) were grown in yeast 
extract peptone dextrose (YPD) media until they reached log-phase (optical density (OD) was 
about 1.0 at 600 nm). For biological duplicate experiments, cells were grown independently. 
Yeast cells were harvested by centrifugation and resuspended in a buffer containing 50 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 150 mM NaCl, 0.5% 
sodium deoxycholate (SDC) and protease inhibitor cocktail (one tablet (complete mini, Roche) 
per 10 ml lysis buffer) at 4 ºC. Cells were lysed using the MiniBeadbeater (Biospec) at 
maximum speed, three cycles of 30 s each, with 2 min pauses between cycles to avoid 
overheating the lysates. After centrifugation, lysates were transferred to new tubes, and the 






2.2.4 Human cell culture, cell lysis and protein extraction  
MCF7, HEK 293T and Jurkat cells (American Type Culture Collection (ATCC)) were 
cultured following the instructions provided by ATCC. Once MCF7 and HEK 293T cells 
reached 80% confluency, cells were washed with PBS twice and harvested by scraping. Jurkat 
cells were harvested by centrifugation and then washed with PBS. Cell pellets were suspended 
in the ice-cold RIPA buffer (50 mM HEPES, pH=7.4, 150 mM NaCl, 0.5% SDC, benzonase 
(25 U/mL), and protease inhibitor cocktail) and incubated end-over-end for 1 hour at 4 °C. 
After complete solubilization of nuclei and digestion of genomic DNA, the lysate was 
centrifuged at 25,000 g for 10 minutes. The supernatant was collected and the protein 
concentration was measured by BCA protein assay.  
 
2.2.5 Protein extraction from mouse brain tissues  
For mouse brain samples, brain tissues from two C57BL/6 mice (3 and 6 months) were 
frozen in liquid nitrogen and homogenized in the RIPA buffer mentioned above. The mixtures 
were incubated on ice for an hour, and then clarified by centrifugation at 5,000 g for 20 minutes. 
Half of the supernatants (~8 mg proteins per experiment) were used for protein glycosylation 
analysis. 
 
2.2.6 Protein reduction, alkylation and digestion  
Lysates from yeast, human cells, or mouse brain tissue were reduced with 5 mM 
dithiothreitol (DTT) (56 °C, 25 minutes) and alkylated with 15 mM iodoacetamide (RT, 30 
minutes in the dark). Proteins were purified by the methanol-chloroform precipitation method. 
The purified proteins were digested with Lys-C (Wako) at a protein:enzyme ratio of ~100:1 in 
50 mM HEPES, pH=8.2, 1.6 M urea, 5% ACN at 31 °C overnight, and then 10 ng/µL trypsin 
(Promega) for 4 h. Digestion was quenched by the addition of TFA to a final concentration of 
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0.1%, and precipitate was removed by centrifugation at 5,000 g for 10 min. The supernatant 
was collected, and peptides were purified using a Sep-Pak tC18 cartridge (Waters). 
 
2.2.7 Glycopeptide enrichment  
For boronic acid derivative experiments, mammalian peptides were dissolved in 100 
mM ammonium acetate buffer and incubated for one hour with different boronic acid 
derivatized magnetic beads at room temperature. After incubation, the beads were washed with 
the binding buffer, and enriched peptides were eluted first by incubation with a solution 
containing ACN:H2O:TFA (50:49:1) at 37 °C for 30 min. Then the peptides were eluted two 
more times through incubation with 5% formic acid at 56 °C for 5 min each time. For the 
enrichment of peptides from yeast, human cells or mouse brain tissues using DBA, ~10 mg of 
peptides were used in each experiment and incubated with DBA beads in DMSO containing 
0.5% TEA, then washed five times using a buffer containing 50% DMSO and 50% 100 mM 
ammonium acetate (pH=11). Glycopeptides were then eluted as described above.  
For lectin enrichment, ConA and WGA-conjugated agarose beads (Vector Laboratories) 
were washed five times using the enrichment buffer (20mM tris-base pH=7.4, 0.15 M NaCl, 1 
mM MgCl2, 1 mM CaCl2, and 1 mM MnCl2)35. Peptides were dissolved in the enrichment 
buffer, mixed with the lectin beads, and vortexed under 37 oC for an hour. The beads were then 
washed again with the enrichment buffer for five times before glycopeptide elution using the 
elution buffer (0.2 M α-methyl mannoside, 0.2 M α-methyl glucoside, 0.2 M galactose, and 0.5 
M N-Acetyl-D-Glucosamine in PBS). The elution was performed twice with vortex for half an 
hour each, and the eluents were combined.  
 For HILIC enrichment, SeQuant® ZIC-HILIC SPE cartridges (the Nest Group) were 
washed with ten column volumes of 1.0% TFA in water, followed by three washes with the 
loading buffer (1.0% TFA in 80% ACN, 20% H2O)38-40. Peptides were loaded onto the column 
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in the loading buffer using a slow flow rate. The flow-through was re-loaded onto the column 
once. The column was then washed with the loading buffer three times. Glycopeptides were 
eluted using 1.0% TFA in water three times, and the eluents were combined. 
 
2.2.8 Glycopeptide PNGase F treatment and fractionation 
The enriched samples were dried in a lyophilizer overnight. The completely dried 
samples were dissolved in 40 mM ammonium bicarbonate in heavy-oxygen water (H218O) and 
treated with PNGase F (lyophilized powder from Sigma Aldrich) at 37 °C for 3 hours. For 
optimization experiments, after deglycosylation, peptide samples were purified using a stage 
tip. For all other experiments, enriched glycopeptides were desalted using a tC18 Sep-Pak 
cartridge, and then subjected to fractionation using high-pH reversed phase HPLC (pH=10). 
The sample was separated into 10 fractions using a 4.6×250 mm 5 µm particle reversed phase 
column (Waters) with a 40-min gradient of 5-50% ACN with 10 mM ammonium acetate. Every 
fraction was further purified with stage tip before LC-MS/MS. 
 
2.2.9 LC-MS/MS analysis 
Fractionated and purified peptide samples were resuspended in a solvent of 5.0% ACN 
and 4.0% FA, and 4 µL was loaded onto a microcapillary column packed with C18 beads 
(Magic C18AQ, 3 µm, 200 Å, 75 µm x 16 cm) using a WPS-3000TPLRS autosampler 
(UltiMate 3000 thermostatted Rapid Separation Pulled Loop Wellplate Sampler, Dionex). 
Peptides were separated by reversed-phase chromatography using an UltiMate 3000 binary 
pump with a 90-min gradient of 4-30% ACN (in 0.125% FA) and detected in a hybrid dual-
cell quadrupole linear ion trap - orbitrap mass spectrometer (LTQ Orbitrap Elite, ThermoFisher) 
using a data-dependent Top20 method. For each cycle, one full MS scan (resolution: 60,000) 
in the Orbitrap at 106 AGC target was followed by up to 20 MS/MS in the LTQ for the most 
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intense ions. The isolation window was 2 Da, which is the most commonly used, and the 
activation energy was 40% normalized collision energy (NCE), which was obtained through 
testing different NCEs to acquire the best results for the machine used here. Selected ions were 
excluded from further analysis for 90 s. Ions with a single or unassigned charge were not 
sequenced. Maximum ion accumulation times (Maximum IT) were 1000 ms for each full MS 
scan and 50 ms for MS/MS scans. For protein O-glycosylation analyses, the data was collected 
using a Q-Exactive Plus Orbitrap mass spectrometer with a two-hour LC gradient. Higher-
energy collisional dissociation (HCD) was used as the fragmentation method with the 
following parameters: 106 AGC target for full MS and 2×105 AGC target for MS2, 100 ms 
maximum IT, 2.0 Da isolation window, and 30% NCE. The dynamic exclusion time was set to 
60 sec. Both full MS and MS2 were collected in the Orbitrap cell with high mass accuracy and 
high resolution, which contribute to confident identification of O-glycopeptides.  
 
2.2.10 Database searches and data filtering  
The raw files were converted into mzXML format prior to the database search. The 
SEQUEST algorithm53 (version 28) was used to search all MS/MS spectra against either a 
database containing sequences of yeast (Saccharomyces cerevisiae) proteins downloaded from 
SGD (http://www.yeastgenome.org/) or human (Homo sapiens) proteins downloaded from 
UniProt. The following parameters were used for the database search: 10 ppm precursor mass 
tolerance; 1.0 Da product ion mass tolerance; fully tryptic digestion; up to two missed 
cleavages; variable modifications: oxidation of methionine (+15.9949) and 18O tag of Asn 
(+2.9883); fixed modifications: carbamidomethylation of cysteine (+57.0214). In order to 
estimate the false discovery rate (FDR) of peptide identification, both forward and reversed 
orientations of each protein sequence were listed in the database, and the target-decoy method 
was employed54. To distinguish between correct and incorrect peptide identifications, linear 
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discriminant analysis (LDA) was utilized with several parameters such as XCorr, ΔCn, and 
precursor mass error55. After scoring, peptides shorter than seven amino acid residues were 
discarded, and the remaining peptide spectral matches were controlled to have less than 1.0% 
FDR. When determining FDRs of the final data set, only glycopeptides were considered.  
For O-glycopeptide identification, we used ByonicTM software. Some parameters are 
similar as above. For yeast intact O-glycopeptide analysis, up to ten mannoses per glycan were 
searched for raw files. In order to control false positive rates, every peptide was required to 
have ≤0.001 for 1 D PEP (one dimensional posterior error probability) and >4 for |Log Prob| 
(the absolute value of the log10 of the posterior error probability)56. The Score of identified 
glycopeptide must be higher than 300, and the mass accuracy is less than 10 ppm. The PEP 
takes into account 10 features, including the ByonicTM score, delta score, precursor mass error, 
digestion specificity, etc. Requiring |Log Prob| to be larger than 4 means the P value is <10-4. 
These are very stringent criteria for filtering. For example, for protein O-GlcNAcylation 
analysis, after filtering, there was no reverse hit in the final datasets. For glycoproteins 
identified in each type of cells, we performed subcellular compartment analysis based on the 
protein location information downloaded from Uniprot (uniprot.org). 
 
2.2.11 Protein glycosylation site localization  
In order to evaluate the confidence of the glycosylation site assignment, a Modscore 
was calculated for each identified glycopeptides, which is similar to Ascore57. An algorithm 
considering all possible glycosylation sites of a peptide was used to generate the Modscore. It 
examines the presence or absence of MS/MS fragment ions unique to each glycosylation site 
and indicates the likelihood that the best site match is correct when compared with the next 




2.2.12 Data availability 
The datasets generated during the current study are available in the PeptideAtlas 
repository (Dataset Identifier: PASS00980; Password: KV788a), 
https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/PASS_View?identifier=PASS00980. 
In total, there are 142 raw files (20 files for the yeast N-glycosylation duplicate experiments, 
20 files for the MCF7 N-glycosylation duplicate experiments, 10 files for the HEK 293T N-
glycosylation experiment, 10 files for the Jurkat N-glycosylation experiment, 22 files for the 
mouse brain N-glycosylation duplicate experiments, 20 files for the yeast O-mannosylation 
duplicate experiment, 20 files for the MCF7 O-GlcNAcylation duplicate experiments, 10 files 




2.3.1 Enhancing glycopeptide enrichment with BA derivatives 
Boronic acid can form reversible covalent bonds with sugars and has been extensively 
used for sugar detection58-60. Therefore, BA-based methods have great potential in universally 
enriching glycopeptides and glycoproteins, and the reversible nature of the interaction leaves 
enriched glycopeptides intact after the release. However, the interaction between BA and sugar 
is relatively weak, preventing the enrichment of low-abundance glycoproteins. To effectively 
enrich low-abundance glycoproteins, which often contain important information, it is critical 
to strengthen the interaction.   
Reversible interactions between boronic acid and sugars have great potential to enrich 
glycopeptides/glycoproteins52, 61, 62. For global analysis of protein glycosylation, enrichment 
through strong interactions between boronic acid and glycopeptides is critical to cover low-
abundance glycopeptides.  
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There are several major factors that govern the interactions between boronic acid (BA) 
and sugars, including the pKa of BA, the solution pH, and steric/stereoelectronic effects58, 63. 
Although BA with a lower pKa is expected to have greater binding affinities at neutral pH, this 
is not always true for glycopeptide enrichment. Therefore, several BA derivatives with various 
pKa values were tested, and the optimum pH was found for each BA derivative. Previously, we 
demonstrated that phenylboronic acid conjugated beads were able to enrich glycopeptides from 
yeast whole cell lysates52. In yeast, high mannose glycans dominate, while glycans are more 
structurally diverse in mammalian cells. Here, we have designed and optimized a BA-based 
method to effectively enrich glycopeptides from mammalian cell lysates. The structures of 
several BA derivatives tested here are displayed in Figure 2.3a. Each of these BA derivatives 
was conjugated to magnetic beads containing either carboxylate or amine groups. After the –
NH2 or –COOH group reacts with the corresponding groups on the magnetic beads, the amide 
bond (–CONH–) between the beads and the benzene ring in each BA derivative should have a 





Figure 2.3 Structures of boronic acid derivatives and experimental results using different 
derivatives. Structures of boronic acid derivatives tested in this work (a), and the number of 
glycopeptides identified with each BA derivative at varying pH values from the parallel 
experiments (b). 
 
In parallel experiments starting with the same amount of purified peptides from human 
cells (HEK 293T), we examined these BA derivatives at different pH values and compared the 
number of unique identified N-glycopeptides. Very few glycopeptides were identified at pH=7 
or 8 with any BA derivative. For all derivatives, the optimal pH was 10 or 11, as shown in 
Figure 2.3b. The derivatives IV and V enriched slightly more unique glycopeptides compared 




































phenylboronic acid (9.0), enrichment with I resulted in the identification of more unique 
glycopeptides. One possible reason is that the adjacent nitrogen may form an extra hydrogen 
bond with a nearby hydroxyl group on the glycan, which enhances the interactions between the 
BA derivative and glycans and facilitates the enrichment.   
Among these five boronic acids tested, derivative II (benzoboroxole) allowed the 
identification of the greatest number of glycopeptides. The interactions between benzoboroxole 
and sugars were reported to be stronger than those between phenylboronic acid and sugars59, 64, 
65. For example, the binding constant (Ka) for the reaction between benzoboroxole and fructose 
is 606 M-1 at neutral pH, which is nearly ten times higher than that between phenylboronic acid 
and fructose (79 M-1) under identical conditions64.  The current experimental results are very 
consistent with previous findings, and stronger interactions between BA and glycans can more 
effectively enrich glycopeptides. For the first time, the method based on benzoboroxole was 
systematically optimized for site-specific and global analysis of glycoproteins in combination 
with MS, and the results were dramatically improved compared to any other boronic acids 
tested here.   
 
2.3.2 Synergistic interactions to increase glycopeptide coverage 
Strengthening the interactions between benzoboroxole and glycopeptides will further 
increase the coverage of low-abundance glycopeptides. One glycan typically contains multiple 
monosaccharides, which allows one glycopeptide to interact with multiple benzoboroxole 
molecules. The synergistic effect for the interactions between multiple BA derivative 
molecules and glycans is expected to further facilitate the enrichment of glycopeptides, 
especially those with low abundance. Here we synthesized a dendrimer as the platform for 
synergistic interactions because the number of benzoboroxole molecules bound to a dendrimer 
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can be easily adjusted. More importantly, the dendrimer branches also provide structural 
flexibility to enhance the synergistic interactions. 
 
 
Figure 2.4 The structure of BA derivative II (benzoboroxole) conjugated dendrimer. 
 
The dendrimer was first synthesized and bound to magnetic beads, and next the BA 
derivative, benzoboroxole, was conjugated to the dendrimer (Figure 2.1 and 2.2). Many 
benzoboroxole molecules were bound to one dendrimer, as shown in Figure 2.4, and the 
number of benzoboroxole molecules on one dendrimer bead is proportional to the dendrimer 
size. In this case, several sugars from one glycan may interact with multiple benzoboroxole 






Figure 2.5 An example of the synergistic interactions between multiple benzoboroxole 
molecules in a dendrimer and several sugars within one glycan of a glycopeptide. 
 
Dendrimer size is expected to have a large impact on the synergistic interactions, and 
the effect of dendrimer size was systematically evaluated in parallel experiments, where the 
number of benzoboroxole molecules on the beads attempted to remain the same, and the 
amount of starting materials (peptides from HEK 293T cells) was also the same. In Figure 2.6, 
when the number of cycles is zero, the magnetic beads are directly conjugated with 
benzoboroxole without a dendrimer. The dendrimer size increases with the number of rounds 
of synthesis, as well as the number of benzoboroxole molecules after conjugation. With 
dendrimer beads synthesized through one to four rounds of the reaction, the number of total N-
glycopeptides, unique N-glycopeptides, and N-glycoproteins increased linearly (Figure 2.6). 
After four rounds of synthesis, the numbers are very comparable, and the specificity results 
have a similar trend (Figure 2.7). Once the number of benzoboroxole molecules on a single 
bead reaches the threshold, larger dendrimers with more benzoboroxole molecules do not affect 





Figure 2.6 The effect of number of synthesis cycles and corresponding dendrimer size on the 




Figure 2.7 Specificity of the N-glycopeptide identifications increases with the number of the 
dendrimer synthesis cycles, and it levels off after the fourth cycle. The overall specificity of 
glycopeptide enrichment should be higher considering that O-glycopeptides were also enriched. 
 
Since the enrichment reaction is quick and the conditions are mild, prolonging the 
reaction time does not have negative effects on glycopeptide identification. As shown in Figure 












































incubation time varied between 10 minutes to 3 hours. We also assessed the residual N-glycans 
after PNGase F treatment, and duplicate experiments were performed to examine the 
percentage of residual N-glycans. The results demonstrated that the N-glycan removal 
efficiency with PNGase F within three hours was very high (Figure 2.9). Briefly, peptides from 
MCF7 whole cell protein digestion were subject to enrichment with the DBA beads. The 
enriched glycopeptides were then treated with PNGase F in H218O for three hours. The purified 
peptides were analyzed using an online LC-MS/MS system with a Q-Exactive Plus mass 
spectrometer, and both full MS and MS/MS were recorded in the Orbitrap cell. Higher-energy 
collisional dissociation (HCD) was used as the fragmentation method. We searched for the 
deglycosylated peptides (2.9883 Da mass shift on N) and the N-glycan-containing peptides 
using Byonic. As a result, 44 unique glycan-containing peptides and 1,866 deglycosylated 
peptides were identified in the first experiment; 45 unique glycan-containing peptides and 
1,871 unique deglycosylated peptides were identified in the second experiment. Overall, N-
glycopeptides with residual N-glycans are only around ~2%, demonstrating that the 3-hour 
PNGase F treatment was effective to remove N-glycans. 
 


































Figure 2.9 Duplicate experimental results for assessing residual N-glycans after PNGase F 
treatment. Only about 2% N-glycopeptides contained residual glycans after the three-hour 
treatment. 
 
We performed the control experiments previously66  and found that the effect of 
spontaneous deamidation is negligible under the treatment conditions (pH=7.5 and 37 oC) for 
three hours. For all our experiments for protein N-glycosylation analysis, we strictly controlled 
the treatment time within three hours. Although a longer treatment time may lead to more 
complete removal of N-glycans and result in the identification of more N-glycosylation sites, 
spontaneous deamidation will cause higher false positive rates for protein N-glycosylation site 
identification.  
 
2.3.3 Further optimization of experimental conditions for DBA enrichment   
Effect of different solvents on glycopeptide enrichment. A variety of solvent combinations were 
tested for glycopeptide enrichment with DBA beads (Figure 2.10). The pH of all aqueous 

























binding step of enrichment was performed for an hour in the first solution, and then the beads 
were washed five times in the second solution. The combination of “DMSO+DMSO” provided 
the highest enrichment efficiency with the identification of the most N-glycopeptides and 
glycoproteins. This is consistent with Le Chatelier's principle because water is the product of 
the reaction between the boronic acid derivative and sugars. Without water, the reaction shifts 
toward the direction of bond formation and becomes more complete. 
 
Washing buffer for glycopeptide enrichment optimization. Based on the results from Figure 
2.10, several washing buffers were tested, and the results are in Figure 2.11. We performed the 
enrichment in DMSO containing 0.5% trimethylamine (TEA) for one hour, and then washed 
the beads with different buffer combinations. The enriched peptides were subsequently 
deglycosylated and analyzed by LC-MS/MS. The washing buffer containing 50% DMSO and 
50% H2O (pH=11) outperformed all other combinations. The addition of water helped remove 
non-specifically bound peptides and increased the number of identified glycopeptides and 
glycoproteins.  
 
































Figure 2.11 Washing buffer optimization for glycopeptide enrichment. 
 
Number of washes for glycopeptide enrichment optimization. Based on the previous results, we 
further optimized the number of washes (0-9 washes). All parallel experiments started with 
about 0.25 mg mammalian peptides, which were enriched with the DBA beads in DMSO 
containing 0.5% TEA for one hour, and then the number of times the beads were washed with 
50% DMSO and 50% H2O (pH=11) was varied. From 0 to 4 washes, a linear trend was found 
for N-glycopeptide and glycoprotein identifications because increasing the number of washes 
removed non-specifically bound peptides. After washing four times, there was no obvious 
change (Figure 2.12). These results indicate that the interactions between DBA and glycans are 
very strong because washing more times did not result in the loss of glycopeptides. 
 






























































Effect of sample size on the identification of glycopeptides and glycoproteins. Different amount 
of cultured MCF 7 cells were used to evaluate the effect of sample size on the N-glycopeptide 
identification with the DBA enrichment. Duplicate experiments were performed. Cells in each 
group were harvested and the final protein amounts in the eight groups were around 10, 30, 60, 
100, 200, 300, 500, and 1000 µg, respectively. After protein precipitation and digestion, the 
peptides were subject to DBA enrichment. The enriched glycopeptides were then purified and 
analyzed by LC-MS/MS. The data is presented in Figure 2.13.  
The lowest number of glycoproteins we identified in one MS run was about 200 from 
the 10 µg group among the samples tested here. When the sample amount is very small, the 
sample loss coming from every step may be a problem. For instance, a very small volume of 
solvent (lysis buffer or digestion buffer) was used to transfer the sample from tube to tube, 
which could result in a considerable (relatively higher percentage) sample loss. However, even 
for 10 µg proteins, we were still able to identify about 200 glycoproteins. More samples 
allowed us to identify higher numbers of unique glycopeptides and glycoproteins. After the 
protein amount reached ~300 µg, the increasing trend of the number of identified glycopeptides 
and glycoproteins slowed down, and both the 500 µg and 1000 µg groups yielded almost the 
same results. Besides the sample loss, the MS sensitivity is also a major contribution factor for 
the results that fewer glycoproteins were identified using a low sample amount. A machine 
with higher sensitivity would allow us to identify more glycoproteins using the same amount 
of material or the same number of glycoproteins using a lower amount of material. Of note, 
normally the protein digestion efficiency and peptide purification efficiency are lower than 
100%, and therefore, the resulting peptide amounts subjected to the DBA enrichment in the 




2.3.4 Comparison DBA with existing lectin- and HILIC-based methods 
To test the effectiveness of the Dendrimer-conjugated Boronic Acid derivative (DBA) 
enrichment, triplicate parallel experiments were performed to compare the current method with 
the commonly used lectin (combining WGA and ConA) and zwitterionic hydrophilic 
interaction liquid chromatography (ZIC-HILIC) enrichment methods. Each experiment started 
from the same amount of peptides from MCF7 cell whole lysates (Figure 2.14). For these 
parallel experiments, except the enrichment method, every other step was kept the same.  Prior 
to this comparison, we compared 0.1% and 1% TFA as ion-pairing reagent for the ZIC-HILIC 
experiment and found that 1% TFA had slightly better performance (Figure 2.14b).. Therefore, 
we used 1% TFA in the comparison experiment. From the parallel experiments, the greatest 
number of unique N-glycopeptides were identified using the current DBA method, and more 
unique N-glycopeptides were identified with ZIC-HILIC than the lectin-based method.  
Regarding the specificity, we compared the numbers of glycopeptides and non-
glycopeptides identified in each of the parallel experiments, and the results showed that the 
DBA method had the highest specificity (Figure 2.14c). We reasoned that although ZIC-HILIC 
allows for enrichment of a broader spectrum of glycopeptides than lectin, the principle of the 
ZIC-HILIC method is based on the hydrophilic property difference between glycopeptides and 
non-glycopeptides. Therefore, some hydrophilic but non-glycosylated peptides can also be 
enriched, lowering the enrichment specificity. Based on the number of unique glycopeptides 
identified, DBA outperformed the other two methods, while ZIC-HILIC had better 







2.3.5 Global characterization of protein N-glycosylation in yeast 
Using the newly developed method, we performed biological duplicate experiments for 
the global analysis of protein N- and O-glycosylation in yeast. For N-glycoprotein analysis, we 
identified 881 sites on 400 proteins in one experiment and 836 sites on 404 proteins in the other. 
Overall, 1,044 N-glycosylation sites (Figure 2.15a) on 501 proteins (Figure 2.15b) were 
identified. For the first time, over 1,000 protein N-glycosylation sites were identified in yeast. 
To ensure that the sites were confidently identified, very stringent criteria were applied during 
analysis. First, the false positive rate at the N-glycopeptide level was well-controlled  under 
1.0%, based on the target-decoy method54. Additionally, all N-glycosylation sites were required 
to contain the motif NX[S/T/C], where X is any amino acid except proline. The N-
glycosylation site was also required to contain heavy oxygen (18O) as a tag45. To minimize 
possible spontaneous deamidation during PNGase F treatment in heavy-oxygen water, the 
reaction was run for only three hours. Our previous results demonstrated that within three hours 
under mild conditions, spontaneous asparagine deamidation is negligible66. 
 
 
Figure 2.13 Evaluation of the effect of sample size on the identification of glycopeptides and 




































Figure 2.14 Comparison of three enrichment methods (Lectin, ZIC-HILIC and DBA). (a) 
Optimization of the concentrations of TFA as the ion-pairing reagent for ZIC-HILIC 
enrichment. (b) The numbers of unique glycopeptides and glycoproteins identified using each 
of the three methods from parallel experiments. (c) Comparison of the enrichment specificity 















































































Figure 2.15 (a) N-glycopeptides and (b) N-glycoproteins identified from the yeast duplicate 
experiments 
 
In order to demonstrate that low-abundance glycoproteins can be identified with the 
current method, we compared the abundance distributions of identified N-glycoproteins and all 
proteins in the whole yeast proteome, and they were very similar (Figure 2.16a). We reanalyzed 
our previous dataset using phenylboronic acid magnetic beads in yeast52 with the same criteria 
as above, and 716 N-glycosylation sites on 297 proteins were identified. The abundance 
distributions for both datasets are shown in Figure 2.16b. More N-glycoproteins were identified 
in each bin with the current method, especially for low-abundance N-glycoproteins (abundance 
from the literature67). For example, for proteins with abundances less than 2,000 copies per cell, 

















demonstrated that the current method is more effective in enriching low-abundance 
glycopeptides due to strengthened interactions from the BA derivative and synergistic 
interactions of DBA. 
 
2.3.6 Analyzing protein O-mannosylation in yeast 
The reversible covalent interactions can leave enriched glycopeptides with intact 
glycans for site identification and glycan structure elucidation. In yeast, O-glycans consist of 
only mannose, but the number of mannose per glycan varies. The current enrichment method 
also enables us to globally analyze O-glycoproteins. In order to increase the identification 
confidence of intact O-glycopeptides, high-energy collisional dissociation (HCD) was 
employed for glycopeptide fragmentation, and the tandem mass spectra were recorded in the 
Orbitrap cell. Several important machine parameters, such as (automatic gain control) AGC 
target for MS and MS2, normalized collision energy, and maximum ion accumulation time for 
MS2, were optimized (Figure 2.17). We used ByonicTM to search the raw files for the 







Figure 2.16 (a) Abundance distributions of the whole proteome and N-glycoproteins identified 
here. (b) Comparison of the abundance distributions of yeast N-glycoproteins identified in this 
































N-glycoproteins in previous work







Figure 2.17 Machine parameters were optimized for yeast intact O-glycopeptide analysis using 
the Orbitrap cell to record tandem mass spectra of glycopeptides. (a) AGC target for full MS, 
(b) AGC target for MS2, (c) comparison of Top10 and Top15 methods, (d) normalized collision 



























































































































































































































































































































































































































































































































































































































































Figure 2.18 Examples of O-mannosylated peptides identified in this work. (a) Glycopeptide 
ANSLNELDVTATT[Hex9]VAK from protein GAS3. (b) Glycopeptide 
SYSAT[Hex8]TSDVACPATGK from protein GAS1. (c) Glycopeptide FSSSLS 
[Hex5]AQAFPR from protein EXG2. (d) Glycopeptide ISASSIDAS[Hex7]GFVQK  from 
protein SED4. (e) Glycopeptide TLDDFNNYS[Hex6]SEINK from protein GAS1. (f) 
Glycopeptide YPEAGPTAPVT[Hex2]K from protein YD056. (g) Glycopeptide K.DDTIS 
[Hex4]ATISYDK  from protein GAS3. (h) Glycopeptide R.VENGQTLT[Hex6]TFITK from 
protein PRY2. 
 
Several examples of the O-mannosylated peptides with different glycans identified here 
are displayed in Figure 2.18. Here, we identified 987 unique O-glycopeptides from 206 proteins 
in the first experiment and 971 unique O-glycopeptides from 196 proteins in the second 
experiments. In total, 234 O-glycoproteins were identified, and 168 proteins were identified in 
both experiments. The overlap was very high (81.5 and 85.7%), which further demonstrated 
that the identification of glycopeptides and glycoproteins were highly confident. The current 
results are proof-of-concept to demonstrate that the glycopeptide enrichment based on the 
reversible covalent interactions can keep enriched glycopeptides intact for site identification 
and glycan structure elucidation.  
The distribution of the number of mannose per glycan is in Figure 2.19. The number of 
unique glycopeptides with one mannose is the highest, and the second are those with four 
mannoses. For glycopeptides with glycans containing more than four mannoses, the number 
decreases with the increasing number of mannoses. The site localization confidence is lower 
than that of N-glycosylation due to the neutral loss of O-glycans and the presence of many 
serine and threonine residues on O-glycopeptides (Figure 2.20). Compared to the whole yeast 
proteome, both S and T were more frequent in the identified unique O-glycopeptides, and the 
occurrence of T was almost two times as many (9.0 vs. 11.8% for S and 5.9 vs. 10.7% for T). 
 
71 
Conversely, the frequency of N (N-glycosylation sites) in the identified O-glycopeptides was 
lower than the whole proteome (6.1 vs. 4.5%).  
In total, 234 O-glycoproteins were identified, and about one third were also N-
glycosylated (Figure 2.21). O-glycoproteins located on the cell wall (P=4.25E-32) are the most 
highly enriched when clustered using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID)68 (Figure 2.22). Seventy-three O-glycoproteins belong to the 
endomembrane system, and 55 are located in the ER. Clustering of O-glycoproteins based on 
molecular function indicates that proteins related to hydrolase activity (acting on glycosyl 
bonds) and transferase activity (transferring glycosyl groups) are most highly enriched (Figure 
2.23). Based on reversible covalent interactions between DBA and glycans, protein O-
glycosylation can be confidently identified, providing valuable glycan structural information.  
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2.3.7 Global analysis of protein N-glycosylation in human cells 
Due to the diversity of glycan structures, it is more challenging to globally analyze 
glycoproteins in human cells. The new DBA method was applied to globally analyze protein 
N-glycosylation in different types of human cells. Biological duplicate experiments were 
performed for MCF7 cells, and the number of glycosylation sites and glycoproteins identified 
in each experiment is shown in Figure 2.24. With the well-controlled FDR of <1.0% at the 
glycopeptide level and stringent criteria described above, we identified 2,710 N-glycosylation 
sites on 1,127 proteins in one experiment and 2,815 sites on 1,156 proteins in the other. Overall, 
2,340 common sites were identified in both experiments, which represent 86.3% and 83.1% of 
the total sites identified from each experiment, respectively. As expected, the overlap at the 
glycoprotein level was even higher: 981 common glycoproteins were identified. A total of 
3,185 glycosylation sites were identified on 1,302 proteins in MCF7 cells.  
The method was also employed to globally analyze protein N-glycosylation in HEK 
293T and Jurkat cells; 3,052 sites were identified on 1,301 proteins in HEK 293T cells, and 
2,120 sites on 948 proteins were found in Jurkat cells. The comparison of identified sites is in 
Figure 2.25. 
We further tested the effect of the dendrimer on glycopeptide enrichment by comparing 
DBA vs. benzoboroxole conjugated magnetic beads without the dendrimer (designated as BA). 
With the DBA beads, we were able to identify 88% more N-glycosylation sites and 79% more 
glycoproteins compared to the benzoboroxole conjugated magnetic beads (BA) (Figure 2.26a). 
The abundance distributions of all glycoproteins identified using either the DBA or BA beads 
are displayed in Figure 2.26b (abundances from an online database (PaxDb)69). Besides the 
number of glycoproteins identified using the DBA beads was higher than that with the BA 
beads in each abundance category, the DBA method was especially superior for glycoproteins 
with very low abundance (less than 10 ppm). For low-abundance proteins, over twice as many 
 
75 
N-glycoproteins were identified with the DBA beads (84 vs. 34 glycoproteins for <0.1 ppm, 
and 402 vs. 196 for 0.1-1.0 ppm). These results explicitly demonstrate that the synergistic 
interactions between multiple BA derivative molecules and glycans can greatly increase the 





Figure 2.24 (a) The N-glycosylation sites and (b) the glycoproteins identified from the MCF-






















Figure 2.25 Comparison of N-glycosylation sites identified in MCF7, HEK 293T and Jurkat 
cells. 
 
Combining the results from the three human cell lines, we identified a total of 4,691 N-
glycosylation sites on 1,906 proteins (Figure 2.28a). More than 10% of proteins (238) are 
highly glycosylated and contain at least five sites (Figure 2.27). In consideration of different 
cell types, there is a decent overlap among identified N-glycoproteins in human cell 
experiments (Figure 2.28a). One example highlighting differences between cell types are the 
N-glycoproteins (180) identified only in Jurkat cells, many of which are related to immune 
cell-specific activities, such as cell activation and cell immune response (Figure 2.27b). 
By clustering 1,906 N-glycoproteins according to molecular function, proteins related 
to glycosyl-transferase activity are the most highly enriched with a P value of 8.5E-35 (Figure 
2.29a), and 108 N-glycoproteins belong to this category. In yeast, this group of proteins is the 
second most highly enriched. The following groups of N-glycoproteins are also highly enriched 
in human cells: receptor binding, signaling receptor activity, growth factor binding proteins, 


















Figure 2.26 (a) Comparison of unique glycosylation sites and glycoproteins identified with the 
boronic acid derivative magnetic beads (designated as BA) and with the dendrimer beads 
conjugated with the boronic acid derivative (DBA). (b) Abundance distributions of N-






















































Figure 2.27 The distribution of unique N-glycosylation sites per glycoprotein in human cells. 
 
Figure 2.28 (a) Overlap of N-glycoproteins in three different types of cells (MCF7, HEK 293T 
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Many glycoproteins are known to be membrane proteins. Here, 1,251 out of 1,906 N-
glycoproteins are membrane proteins, which are highly enriched with an extremely low P value 
of 1.6E-192. Glycoproteins in the cell periphery, vesicle, ER, Golgi, and extracellular space 
are all enriched with very low P values (Figure 2.29b). Based on the information available on 
UniProt (uniprot.org), 524 of identified membrane proteins are type I membrane proteins, 177 
are type II, and 348 proteins contain multiple transmembrane domains (Figure 2.30). A total of 
301 receptors were identified among these N-glycoproteins (Figure 2.31a); glycosylation site 
locations for receptors identified as type I and II membrane proteins are shown in Figure 2.31b. 
All sites (1,079) were located in the extracellular space, which corresponds very well with the 
belief that glycans are located on the extracellular side of surface membrane proteins.  
 
 
Figure 2.30 Distribution of membrane proteins (Type I, II, III & IV, and multi-pass 



















Figure 2.31 (a) The number of receptors (N-glycoproteins) identified in each type of human 
cells, and (b) N-glycosylation site locations on 301 receptors with X-axis as the TM domain. 
Each glycoprotein sequence was aligned against the transmembrane (TM) domain, and the 
glycosylation sites are indicated as yellow dots. All sites are located in the extracellular space. 
 
Domain analysis shows that many N-glycoproteins contain different types of Ig 
domains (such as I-set, V-set and C1-set). Besides Ig domains, other domains related to cell-





















































(Figure 2.32). Domains corresponding with receptor activities, such as PTK (protein tyrosine 
kinase) and EGF (epidermal growth factor)-like domains, are also highly enriched. 
 
 
Figure 2.32 Domain analysis of N-glycoproteins showing the number of N-glycoproteins 
containing the most highly-enriched domains and their corresponding P values. 
 
2.3.8 Analysis of protein N-glycosylation in mouse brain tissues 
Without sample restriction, the current method can be applied for glycoprotein analysis 
in any other samples, including animal tissues and clinical samples. Here, we further applied 
this method to analyze protein N-glycosylation in mouse brain tissues, and biological duplicate 
experiments were performed. After protein extraction and digestion, glycopeptides were 
enriched using the DBA beads, and enriched glycopeptides were fractionated, followed by 
analysis with an online LC-MS system.  
In the first experiment, we identified 3,583 sites on 1,434 glycoproteins, and very 
similar results were obtained in the second experiment (3,685 sites on 1,443 proteins). In total, 
4,195 sites were identified on 1,608 proteins, and 3,073 common sites and 1,269 glycoproteins 
were found in both experiments, as shown in Figure 2.33. Considering the large-scale analysis 


























and 83.4% compared to the both experimental results, respectively) and protein (88.5 and 
88.0%) levels, which is consistent with the above results from duplicate experiments using 
human cells. The highly reproducible results further demonstrate that the current method is 
effective. 
Glycoproteins identified in the mouse brain tissues were clustered using DAVID based 
on biological process. About one quarter of identified glycoproteins (396) are related to cell 
surface receptor signaling pathway, which is the most highly enriched with a P value of 1.1E-
61. Proteins related to brain-specific functions such as nervous system development (P=4.1E-
61), axon development (P=1.9E-54), and synapse assembly (P=2.6E-30) were also highly 
enriched, as shown in Figure 2.34.  
 
2.3.9 Synergistic interactions to identify protein O-GlcNAcylation 
 Protein O-GlcNAcylation was discovered more than three decades ago, and it has been 
reported to be involved in many cellular events, from regulating cell signaling to gene 
expression70-72. Using BA-based methods, it is challenging to enrich O-GlcNAcylated proteins 
because only one sugar (GlcNAc) is bound to S or T, and this sugar does not contain a cis-1,2-
diol. Although boronic acid can interact with sugars without cis-1,2-diols, such as glucose and 
GlcNAc, the interaction is weak58, and enrichment is therefore less effective.  
In this work, we identified 510 total glycopeptides with HexNAc(1) and 304 unique 
glycopeptides located on 131 proteins in HEK 293T cells with the DBA enrichment Figure 
2.35. In striking contrast, with the BA derivative magnetic beads, only 18 total glycopeptides 
with HexNAc and 13 unique glycopeptides were found on 12 proteins. Among 131 
glycoproteins, 81 were located in the nucleus (Figure 2.36), and typically, these proteins are 
O-GlcNAcylated because only glycoproteins with O-GlcNAc have been reported in the nucleus. 
 
84 
Similarly, 131 O-glycoproteins with HexNAc(1) were identified in MCF7 cells, and 119 O-




Figure 2.33 The number of protein N-glycosylation sites (a) and glycoproteins (b) identified 


























Figure 2.35 Comparison of glycoproteins with one HexNAc identified with BA and DBA, 
which clearly shows that the results from DBA are substantially better. 
 
The effective enrichment of O-GlcNAcylated peptides may be attributed to the 
synergistic interactions with DBA beads. As discussed above, multiple sugars from one glycan 
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synergistically interact with different benzoboroxle molecules on a single dendrimer bead. 
Although there is no cis-1,2-diol in GlcNAc, multiple hydroxyl groups in each GlcNAc may 
form reversible covalent bonds with several benzoboroxle molecules on a dendrimer bead, as 
shown in Figure 2.37. The synergistic interactions can dramatically facilitate the enrichment of 
O-GlcNAcylated peptides with DBA. The results are highly reproducible in different types of 
human cells (HEK 293T, MCF7 and Jurkat). The greatest number of identified glycoproteins 
(about 50%) are located in the nucleus of each cell type Figure 2.38 and about 30% of them 
are in the cytoplasm. Glycoproteins in the nucleus and the cytoplasm are normally O-
GlcNAcylated. In addition, ~12% of them are in the ER/Golgi. Only a small portion of 
glycoproteins (~7%) are secreted proteins, which are likely to be O-GalNAcylated.  
 
 
Figure 2.36 Distribution of O-glycoproteins modified with HexNAc(1) identified in HEK 















Figure 2.37 Proposed mechanism of the interactions between DBA and GlcNAc benefiting 




Figure 2.38 Cellular compartment distribution of glycoproteins containing one HexNAc 
































Based on universal and reversible covalent interactions between boronic acid and 
sugars, BA-based enrichment methods have great potential in enriching glycopeptides for 
global analysis of protein glycosylation. However, the relatively weak interactions prevent the 
enrichment of glycopeptides with low abundance. In order to effectively enrich glycopeptides 
in complex biological samples, it is critical to strengthen the interactions between BA and 
glycans.  
In this work, we enhanced the interactions between BA and glycans through two ways. 
First, we employed the BA derivative (benzoboroxole) to form stronger interactions with 
glycans, which was able to dramatically increase the coverage of low-abundance glycopeptides, 
as shown in Figure 2.3b and Figure 2.17. Second, based on the common features of a glycan 
containing multiple monosaccharides and one sugar bearing several hydroxyl groups, we 
benefited from synergistic interactions by conjugating many benzoboroxole molecules onto a 
dendrimer bead. The synergistic interactions between several benzoboroxole molecules on a 
bead and different sugars within a glycan make the enrichment much more effective, which is 
clearly demonstrated from the current results (Figure 2.26). The dendrimer provides an 
excellent platform to conjugate many benzoboroxole molecules onto the same bead. The 
dendrimer size is readily adjustable, and correspondingly, the number of benzoboroxole 
molecules can be controlled on each bead. Furthermore, the dendrimer provides structural 
flexibility to form stronger interactions with glycans. 
The reversible nature of the interactions between BA and glycans allows enriched 
peptides to be released with intact glycans. The direct analysis of intact glycopeptides provides 
valuable information about protein glycosylation sites and glycan structures. We systematically 
analyzed O-mannosylated proteins and their glycan structures in yeast, and overall, 234 O-
glycoproteins were identified. With stringent criteria for analysis, the identifications of O-
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glycopeptides and O-glycoproteins are highly confident. However, compared to protein N-
glycosylation site identification, O-glycosylation sites were less confidently localized because 
of the possible neutral loss of glycans during intact O-glycopeptipe analysis and high 
percentages of S and T in glycopeptides.  
Synergistic interactions can enhance not only the interactions between benzoboroxole 
and glycans containing multiple monosaccharides but also the interactions with O-
GlcNAcylated peptides. It is well-known that BA can form stronger interactions with sugars 
containing cis-1,2-diols because two covalent bonds are formed. The interaction between BA 
with glucose or GlcNAc without cis-1,2-diols is much weaker58. Here, due to the flexible nature 
of the dendrimer, one GlcNAc may form multiple covalent bonds with different benzoboroxle 
molecules, as shown in Figure 2.37. Compared to BA beads, DBA is much more effective in 
enriching O-GlcNAcylated peptides (Figure 2.35).  
Cluster of differentiation (CD) molecules are those located on the cell surface that 
provide immunophenotyping targets for cell classification73. Two examples of glycoproteins 
identified in Jurkat cells are shown in (Figure 2.39), and the majority of identified N-
glycosylation sites are located in extracellular domains. In our experiment, 188 CD proteins 
were identified as N-glycoproteins. There were more CDs identified in Jurkat cells (137) than 
MCF7 (115) or HEK 293T (129) cells (Figure 2.40), despite the fact that the total N-
glycoproteins identified in Jurkat cells were fewer. However, this result is consistent with the 
fact that more CDs are relevant to immune-related cells, including Jurkat cells. CDs with site-
specific information may be more meaningful for cell classification and serve as effective 
biomarkers for disease detection. 
Benefiting from the common features of a glycan containing multiple monosaccharides 
and one sugar bearing several hydroxyl groups, the current method can dramatically enhance 
the interactions between boronic acid and glycans, which is critical in analyzing glycoproteins 
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with low abundance. Furthermore, there are several other advantages. First, this method is 
quick and easy to operate. As shown in Figure 2.8, the results from 10-min incubation are 
almost the same as those from two- or three-hour incubation. Glycopeptides are captured under 
basic conditions and released in an acidic solution. Second, this method is highly reproducible 
and robust. Third, because the enrichment is based on the reversible interactions, the enriched 
glycopeptides remain intact, which allows us to analyze glycan structures and also to identify 
protein O-glycosylation, as demonstrated by the analyses of protein O-mannosylation in yeast 
and O-GlcNAcylation in human cells. Fourth, because there are no sample restrictions, this 
method can be extensively applied to analyze different types of samples, from whole cell 




Figure 2.39 Two examples of glycoproteins (CD30 and CD96) with domain and glycosylation 






















Figure 2.40 The numbers of CD N-glycoproteins (a), and the percentage of CD glycoproteins 
with respect to all N-glycoproteins (b) identified in each type of human cells. 
 
2.5 Conclusions 
The current method is based on the universal and reversible interactions between 
hydroxyl groups in glycans and boronic acid. The experimental results for yeast and human 
cells and mouse tissue demonstrated that this method is highly effective in enriching 
































interactions keep enriched glycopeptides intact for both site identification and glycan structure 
analysis. Due to the biological importance of glycoproteins, their global analysis will aid in a 
better understanding of glycoprotein functions and the molecular mechanisms of diseases, and 
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CHAPTER 3. QUANTITATIVE ANALYSIS OF GLYCOPROTEINS BY 
COMBINING BORONIC ACID ENRICHMENT AND MS-BASED 
PROTEOMICS 
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3.1 Simultaneous Quantitation of Glycoprotein Degradation and Synthesis Rates by 
Integrating Isotope Labelling, Chemical Enrichment and Multiplexed Proteomics 
 
3.1.1 Introduction 
Protein glycosylation plays vital roles in a variety of cellular processes.1-4 The functions 
of glycoproteins are intrinsically related to their dynamics, and the presence of glycans on 
proteins create a steric hindrance that prevents proteases from approaching,5 thus impacting 
protein dynamics. Modern mass spectrometry (MS)-based proteomics has offered a unique 
opportunity for global analysis of glycoproteins,6-15 but it is still challenging due to the low 
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abundance of glycoproteins and the heterogeneity of glycan structures.16-23 Studying protein 
glycosylation and its dynamics not only advances our knowledge of the underlying 
mechanisms of many cellular activities and diseases, but also enables us to identify 
glycoproteins as disease biomarkers and drug targets.24-28  
There have been many reports about the global analysis of glycoproteins, and 
considerable progress has been made in recent years.6, 29-34 However, few of them focused on 
glycoprotein dynamics on a large scale in spite of its importance.35 Stable isotope labelling 
with amino acid in cell culture (SILAC) has been widely used for protein turnover study.36, 37 
Using pulse-chase SILAC, the newly-synthesized proteins can be distinguished from the 
existing background through incorporation of the heavy (or light) isotopic amino acid residues. 
The labelling can allow us to generate valuable information about protein degradation and 
synthesis through mass spectrometric analysis.  
In this work, we combined pulse-chase SILAC, chemical enrichment of glycopeptides, 
and multiplexed proteomics to globally quantify the degradation and synthesis rates of 
glycoproteins simultaneously. Pulse-chase labelling allowed us to track the protein abundance 
changes, and in combination with chemical enrichment of glycopeptides we were able to 
quantify glycoprotein dynamics. After enrichment, we labelled the enriched glycopeptides 
from multiple time points with the tandem mass tag (TMT) reagents38 for quantitation with 
MS-based proteomics and used their abundances to calculate the degradation and synthesis 
rates of glycoproteins.    
 
3.1.2 Experimental section 
3.1.2.1 Cell culture, heavy isotope labeling, and time course-based cell collection 
MCF-7 cells (ATCC) were grown in a humidified incubator at 37 °C and 5.0% CO2 in 
high glucose Dulbecco's modified eagle's medium (DMEM) (Sigma-Aldrich) with 10% fetal 
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bovine serum (FBS) (Corning) for each of the triplicate experiments. Heavy isotope labeling 
of cells was performed with 13C6, 15N2 L-lysine (Lys8) and 13C6 L-arginine (Arg6) (Cambridge 
Isotopes) in SILAC DMEM with 10% dialyzed FBS for about six generations. Media was then 
switched to normal media with Lys0 and Arg0 to begin the time-course experiment. Cells were 
collected separately at five time points (0, 6, 12, 24 and 48 hours).  
 
3.1.2.2 Cell lysis and protein digestion 
Cells were washed twice with phosphate buffered saline (PBS) and pelleted by 
centrifugation at 500 g for 3 minutes and washed twice with cold PBS. Cell pellets were lysed 
through end-to-end rotation at 4 ºC for 45 minutes in the lysis buffer (50 mM N-2-
hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) pH=7.4, 150 mM NaCl, 0.5% 
sodium deoxycholate (SDC), and 25 units/ mL benzonase and 1 tablet/ 10 mL protease 
inhibitor). Lysates were centrifuged, and the resulting supernatant was transferred into new 
tubes. Proteins were subjected to disulfide reduction with 5 mM dithiothreitol (DTT) (56 ºC, 
25 minutes) and alkylation with 14 mM iodoacetamide (room temperature, 20 minutes in the 
dark). Detergent was removed by the methanol-chloroform protein precipitation method. The 
purified proteins were digested with 10 ng/ µL Lys-C (Wako) in 50 mM HEPES pH 8.6, 1.6 
M urea, 5% ACN at 31 ºC for 16 hours, followed by further digestion with 8 ng/ µL Trypsin 
(Promega) at 37 ºC for 4 hours. 
 
3.1.2.3 Glycopeptide enrichment, TMT labeling, and deglycosylation 
Protein digestions were quenched by addition of trifluoroacetic acid (TFA) to a final 
concentration of 0.1%, followed by centrifugation to remove the precipitate. The peptides were 
desalted using a tC18 Sep-Pak cartridge (Waters) and lyophilized, subjected to boronic acid-
conjugated beads-based enrichment as described previously.39 The peptides were then eluted 
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twice by incubating the beads in a solution containing acetonitrile, water, and trifluoroacetic 
acid at a respective ratio of 50:49:1 for 30 minutes at 37 ºC. Eluates were desalted using tC18 
Sep-Pak cartridges and lyophilized. Purified glycopeptides from each time point were labeled 
with each channel (126, 128, 129, 130, or 131) of the multiplexed TMT reagents (Thermo) 
following the manufacturer’s protocol. Briefly, purified and lyophilized peptides were 
dissolved in 100 µL of 100 mM triethylammonium bicarbonate (TEAB) buffer, pH= 8.5. Each 
tube of TMT reagents was dissolved in 41 µL of anhydrous ACN, and 7 µL was transferred 
into the peptide tube with another 34 µL of ACN. The reaction was performed for 1 hour at 
room temperature, quenched by adding 8 µL of 5% hydroxylamine and shaking for 15 min. 
Peptides from all tubes were then mixed, desalted using a tC18 Sep-Pak cartridge, and 
lyophilized overnight. The dried peptides were deglycosylated with three units of peptide-N-
glycosidase F (PNGase F, Sigma-Aldrich)40 in 60 µL buffer containing 40 mM NH4HCO3 
(pH=9) in heavy-oxygen water (H218O) for 3 hours at 37 °C. The reaction was quenched by 
adding formic acid (FA) to a final concentration of 1%, and peptides were desalted again using 
tC18 Sep-Pak cartridges and dried. 
 
3.1.2.4 Glycopeptide fractionation and LC-MS/MS analysis  
Purified and dried peptides were separated by high pH reversed-phase high-
performance liquid chromatography (HPLC) into 10 fractions with a 40-min gradient of 5-55% 
ACN in 10 mM ammonium acetate (pH=10), dried and purified using the stage-tip method, 
and dissolved in a 10 µL solution with 5% ACN and 4% FA. 4 µL were loaded onto a 
microcapillary column packed with C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, 
Michrom Bioresources) by a Dionex WPS-3000TPLRS autosampler (UltiMate 3000 
thermostatted Rapid Separation Pulled Loop Wellplate Sampler). Peptides were separated by 
reversed-phase chromatography using an UltiMate 3000 binary pump with a 128 min gradient. 
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Peptides were detected with a data-dependent Top15 method41 in a hybrid dual-cell quadrupole 
linear ion trap - Orbitrap mass spectrometer (LTQ Orbitrap Elite, Thermo Scientific, with 
Xcalibur 3.0.63 software). For each cycle, one full MS scan (resolution: 60,000) in the Orbitrap 
at 106 automatic gain control (AGC) target was followed by up to 15 MS/MS in the Orbitrap 
again for the most intense ions. The selected ions were excluded from further analysis for 90 
seconds. Ions with singly or unassigned charge were not sequenced.  
 
3.1.2.5 Database Search and Data Filtering 
All MS2 spectra were converted into a mzXML format and searched using the 
SEQUEST algorithm (version 28).42 Spectra were matched against a database containing 
sequences of all proteins in the Human (Homo sapiens) database downloaded from the UniProt.  
The following parameters were used during the search: 10 ppm precursor mass tolerance; 0.1 
Da product ion mass tolerance; fully digested with trypsin; up to three missed cleavages; fixed 
modification: carbamidomethylation of cysteine (+57.0214); variable modifications: oxidation 
of methionine (+15.9949), O18 tag of asparagine (+2.9883). For heavy TMT-labeled proteins, 
these following fixed modifications were also added to the search: TMT plus heavy isotope for 
lysine (+237.1771), heavy arginine (+6.0201), N-terminal TMT (229.1629). For light TMT-
labeled proteins, TMT (+229.1629) was added to both lysine and N-terminal as fixed 
modification. False discovery rates (FDR) of glycopeptide and glycoprotein identifications 
were evaluated and controlled to less than 1% by the target-decoy method43 through linear 
discriminant analysis (LDA),44 using parameters such as XCorr, precursor mass error, and 
charge state, to control the glycopeptide identification quality.45 The consensus motif 
N#X[S/T/C] (# stands for the glycosylation site and X represents any amino acid residues other 
than proline) was also required to guarantee the reliability of the N-glycosylation analysis. 
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Peptides fewer than seven amino acid residues in length were deleted. The dataset was 
restricted to glycopeptides when determining FDRs for glycopeptide identification.46  
 
3.1.2.6 Glycosylation Site Localization 
We assigned and measured the confidence of glycosylation site localizations by 
calculating their ModScores, which applies a probabilistic algorithm46 that considers all 
possible glycosylation sites in a peptide and uses the presence of experimental fragment ions 
unique to each site to assess the localization confidence. Sites with ModScore > 13 (P < 0.05) 
were considered as confidently localized. If the same glycopeptide was quantified several times, 
the median value was used as the glycopeptide abundance change.  
 
 
3.1.3 Results and discussion 
3.1.3.1 Experimental procedure for simultaneous measurement of glycoprotein degradation 
and synthesis rates  
The experimental procedure is shown in Figure 3.1, and the detailed description is 
included in the Experimental Section. Briefly, MCF-7 cells were cultured with SILAC 
Dulbecco's Modified Eagle's Medium (DMEM) containing Lys8 and Arg6 for six generations 
for full heavy isotope incorporation, and then were equally passaged for the time-course 
experiments. When the cells were approaching nearly full confluency (to minimize the dilution 
effect from cell growth), we switched the media to normal DMEM with Lys0 and Arg0 and 
began the time course. Upon the media switch (0 h), the numbers of cells across different 
groups were kept as similar as possible. For each sample, there were also very similar amount 
of heavy isotope-labelled proteins (heavy proteins) and nearly no light isotope-labelled proteins 
(light proteins). We then harvested cells at each time point until the completion of the 48 h time 
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course. As time went by, heavy proteins were degraded and newly-synthesized proteins were 
theoretically all light proteins. Therefore, the abundance changes of heavy glycoproteins can 
be used to calculate the degradation rates while the abundance changes of light glycoproteins 
as a function of time are glycoprotein synthesis rates. We performed biological triplicate 
experiments to evaluate the reproducibility and ensure the technical rigor. 
Proteins were reduced, alkylated, and digested by Lys-C and trypsin. Purified peptides 
were subjected to the chemical enrichment of glycopeptides through incubation with boronic 
acid-conjugated magnetic beads, as reported previously.39, 47 The beads were then washed to 
remove nonglycopeptides, and elution was performed twice using a buffer containing water: 
acetonitrile: trifluoroacetic acid= 49:50:1. Glycopeptides from each time point were purified 
using C18 cartridges, labelled with the TMT reagents and mixed. Glycopeptides were treated 
with PNGase F in heavy oxygen water (H218O) to create a common tag on the N-glycosylation 
sites for MS analysis.48, 49 After purification, the deglycosylated peptides from each experiment 
were separated into 10 fractions using high-pH reversed-phase high performance liquid 
chromatography. Each fraction was further purified by the stage-tip method, followed by LC-





Figure 3.1 The experimental procedure for the simultaneous quantification of the glycoprotein 
degradation/synthesis rates. 
 
3.1.3.2 Glycoprotein identification 
After glycopeptides were treated with PNGase F in heavy oxygen water (H218O), a 
common and unique tag (+2.9883 D) on the N-glycosylation sites was created for MS analysis. 
The deamidation of asparagine happens in vivo and in vitro. The tag containing the heavy 
oxygen can allow us to distinguish the real N-glycosylation sites from spontaneous 
deamidation of asparagine. However, the spontaneous deamidation of asparagine could occur 
during the PNGase F treatment in heavy water, resulting in the false positive identification. In 
order to minimize this, we carried out the reaction for only three hours. As tested previously, 
the spontaneous deamidation of asparagine is negligible for three hours under the mild 
enzymatic reaction conditions.48 
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The glycopeptides were filtered to <1% false discovery rate. Additionally they are 
required to have the consensus motif, i.e. N#X[S/T/C] (# stands for the glycosylation site and 
X represents any amino acid residues other than proline). Among biological triplicate 
experiments, we identified 1,373, 1,342, and 1,280 unique light glycopeptides (listed in a table 
online at doi.org/ 10.1021/acs.analchem.7b02241), respectively. They overlapped very well, 
and 790 glycopeptides were found in all three experiments (Figure 3.2a). Totally, 1,875 unique 
light glycopeptides were identified. Slightly fewer number of heavy glycopeptides were 
identified, i.e. 866, 1,048 and 1,097 in each of the three experiments (listed in a table online at 
doi.org/ 10.1021/acs.analchem.7b02241). Finally, 1,515 unique heavy glycopeptides were 
identified with site-specific information, and the comparison is displayed in (Figure 3.2b). 
 
3.1.3.3 Calculation of the glycoprotein degradation and synthesis rates 
We calculated the degradation/synthesis rates based on the abundance changes of 
glycopeptides as a function of time simulated by the following exponential decay/growth 
equation (1) or (2), as performed previously: 50, 51 
Based on the abundance changes of heavy glycopeptides, the degradation rates were 
calculated: 
Ph(t) = Ph0*exp(-kdt)        (1) 
According to the abundance changes of light glycopeptides, the synthesis rates were 
obtained using the following equation: 
Pl(t) = Pl0*exp(kst)        (2) 
where Ph0 or Pl0 is the abundance of the heavy or light glycopeptide at the first time point 
(represented by the intensity of the reporter ion), Ph(t) or Pl(t) is the abundance of the heavy or 
light glycopeptide at each subsequent time point, t stands for time. kd is the degradation rate 
constant while ks is the synthesis rate constant. The different time points at 0, 6, 12, 24, and 48 
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h were also designed to provide convenience for the exponential simulation and to be 





Figure 3.2 The overlap of the unique glycopeptides identified in the biological triplicate 





























An example of glycopeptide quantification is shown in Figure 3.3. Glycopeptide 
KWGHN#ITEFQQR is from protein ERO1A, an oxidoreductase involved in disulfide bond 
formation and preventing the accumulation of reactive oxygen species in the endoplasmic 
reticulum (ER). This glycopeptide was confidently identified with an XCorr of 3.8, and the 
glycosylation site was localized on N280, which was also reported on the UniProt 
(www.uniprot.org). We quantified its synthesis rate based on the reporter ion intensities. 
Through using this method, we quantified the synthesis rates of 847 glycoproteins (listed in a 
table online at doi.org/ 10.1021/acs.analchem.7b02241) and the degradation rates of 704 
glycoproteins (listed in a table online at doi.org/ 10.1021/acs.analchem.7b02241) from the 




Figure 3.3 An example of glycopeptide identification and quantification.  
 
3.1.3.4 Evaluation of the experimental reproducibility 
The reproducibility was evaluated based on the biological triplicate experiments 
(Figure 3.4 and 3.5). The comparison of the synthesis rates from triplicate experiments is shown 
in Figure 3.5. A total of 1,330 (71%) unique light glycopeptides were identified in at least two 
















































experiments (Figure 3.2a) displaying high reproducibility given that all experiments were 
performed independently from cell culture to LC-MS/MS analysis. In addition, the calculated 
synthesis rates of the light glycoproteins from the three experiments were in reasonably good 





Figure 3.4 Reproducibility evaluation of the heavy glycopeptides/glycoproteins: (a) 
Comparison of the degradation rates of the N-glycoproteins quantified in the experiments 1 & 
2, and (b) Comparison of the degradation rates of the N-glycoproteins quantified in the 





























































Figure 3.5 Comparison of the synthesis rates of the glycoproteins quantified in experiments 1 
& 2. (b) Comparison of the synthesis rates of the glycoproteins quantified in experiment 2 & 
3. (c) Examples of glycopeptide quantification: red- KPN#ATAEPTPPDR from protein MRC2, 
green- RELYN#GTADITLR from protein RPIEZO1, purple- TCDWLPKPN#MSASCK from 
protein PSAP, and blue- QPMAPNPCEANGGQGPCSHLCLINYN#R from protein LRP1. 
The heavy glycopeptide identification and quantification were also proved to be 









































































rates are generally lower, resulting in a more condensed distribution pattern for the heavy 
glycoproteins, which is further discussed below. 
We quantified both the synthesis (listed in a table online at doi.org/ 
10.1021/acs.analchem.7b02241) and degradation rates (listed in a table online at doi.org/ 
10.1021/acs.analchem.7b02241) for 639 glycoproteins (Figure 3.6). We illustrated the dynamic 
abundance changes over the time course for several light glycopeptides as examples in Figure 
3c. Due to the fact that the raw intensities for each peptide can vary within a range of several 
orders of magnitudes, we used the normalized ratio of intensity at each time point, i.e. the 
intensity (It) divided by the initial intensity (I0). Therefore, the values of all glycopeptides are 
1 at the first time point. The glycopeptides are from proteins MRC2, PIEZO1, PSAP, and LRP1, 





Figure 3.6 The overlap of the glycoproteins with the degradation and synthesis rates quantified.  
Since the time course lasted for 48 h, the accumulation of light glycoproteins made their 
abundance higher than heavy glycoproteins, rendering slightly fewer heavy glycoproteins 










with a very slow degradation or synthesis rate (k<0.0034 h-1, t1/2>200 h) were still not able to 
be accurately quantified, thus we annotated the rates for these proteins as “very slow” in the 
Supplementary Tables. For glycoproteins quantified in multiple experiments, we used their 
median synthesis and degradation rates for further data analysis in this work.  
 
3.1.3.5 Clustering of glycoproteins 
We clustered the identified glycoproteins according to cellular compartment using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (Figure 
3.7a).52 Many categories, ranging from cell surface to organelle membranes, were highly 
enriched with low P values and high glycoprotein counts. We also clustered the glycoproteins 
with a relatively high synthesis rate (ks>0.03 h-1) according to molecular function . Interestingly, 
the highly enriched categories are receptor binding and transportation. The most highly 
enriched are those with glycosylation enzymatic activity, including transferase activity 
(transferring hexosyl groups) and hydrolase activity (hydrolyzing O-glycosyl compounds) 
(Figure 3.7b) 
Here we quantified the synthesis rates of 83 CD glycoproteins (listed in a table online 
at doi.org/ 10.1021/acs.analchem.7b02241), and twelve of them also belong to the family of 
cell adhesion molecules (CAMs), which are listed in Table 3.1. Many of them are integrins, 
which are typically a group of important transmembrane receptors that participate in the 
interactions between cells and extracellular matrix. For instance, ITGB1 was confidently 
quantified in the current experiments based on 11 unique glycopeptides. It is known to be 
conjoining with integrin alpha subunits to form various cell-surface receptors, such as forming 
a laminin receptor with integrin alpha subunit 6 (ITGA6). The latter is also quantified with a 
synthesis rate of 0.0380 h-1. The four integrins (ITGB1, ITGB2, ITGAV, and ITGA6) 
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quantified all have similar synthesis rates, ranging from 0.0377 h-1 to 0.0483 h-1, correlating 
well with the fact that they adjoin one another to form the receptor complex on the cell surface. 
 
 
Figure 3.7 Clustering of (a) the quantified glycoproteins according to cellular compartment 
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CD58 CD58 P19256 1 0.0552 
Lymphocyte function-
associated antigen 3 
CD54 ICAM1 P05362 3 0.0538 




M Q13740 9 0.0517 CD166 antigen 
CD29 ITGB1 P05556 11 0.0483 Integrin beta-1 
CD276 CD276 Q5ZPR3 4 0.0427 CD276 antigen 
CD51 ITGAV P06756 8 0.0412 Integrin alpha-V 
CD171 
L1CA
M P32004 6 0.0388 
Neural cell adhesion molecule 
L1 
CD49f ITGA6 P23229 5 0.0380 Integrin alpha-6 
CD18 ITGB2 P05107 3 0.0377 Integrin beta-2 
CD62l SELL P14151 1 0.0272 L-selectin 
CD275 
ICOSL
G O75144 3 0.0205 ICOS ligand 




3.1.3.6 Comparison of the difference between the synthesis and degradation rates 
We then analyzed the difference between the synthesis and degradation rates for 
glycoproteins (listed in a table online at doi.org/ 10.1021/acs.analchem.7b02241), and the rate 
differences are plotted in Figure 3.8. To ensure the analysis confidence, we only analyzed the 
glycoproteins with their synthesis/degradation rates accurately quantified (without “very slow” 
annotation) in at least two experiments, where 400 proteins fall into this category. Since cells 
were still growing throughout the time course, we anticipated that the majority of the proteins 
would have a faster synthesis rate than degradation rate. This was proved by the results (Figure 








Figure 3.8 The difference between the synthesis and degradation rates for 400 glycoproteins 
with both rates quantified; (b) the biological processes in which 48 glycoproteins with a lower 




































































Interestingly, 48 proteins had lower synthesis rates, and they mostly participated in the 
biological processes of adhesion, locomotion, localization, and signaling (Figure 3.8b). We 
reasoned that at the end of the time course, as the cells were approaching a static state due to 
high confluence, these biological processes were not supposed to robustly continue, and thus 
the related glycoproteins were down-regulated. Another possible explanation arises from the 
current approach to calculate these two rates. The absolute glycoprotein degradation rate was 
calculated based on the abundance changes of heavy glycoproteins, and the contribution from 
heavy protein synthesis was negligible since heavy isotopic lysine and arginine were not 
supplied during the 48 h time course. However, light glycoproteins were used to calculate the 
synthesis rates while they were synthesized and degraded simultaneously. Since the starting 
light protein abundance was extremely low, we neglected the contribution from light protein 
degradation, but this contribution accumulated throughout the whole time course. Therefore, 
the real protein synthesis rates are likely slightly higher than the rates obtained in this work. 
 
3.1.4 Conclusions 
Evolution has endowed cells the ability to synthesize proteins in a conservative and 
low-risk pattern.53 In this study, we integrated pulse-chase SILAC, chemical enrichment of 
glycopeptides, and multiplex proteomics to simultaneously investigate the glycoprotein 
synthesis and degradation rates in human cells on a large scale. Rigorous criteria were applied 
for glycopeptide filtering, and 3,390 unique heavy and light glycopeptides with site-specific 
information led to the simultaneous quantitation of the degradation and/or synthesis rates of 
many glycoproteins. We quantified the synthesis rates of 847 N-glycoproteins and the 
degradation rates of 704 N-glycoproteins, and demonstrated this method to be reproducible 
based on the results from the biological triplicate experiments. The glycoproteins related to 
binding, transportation, and enzyme activity were determined to have higher synthesis rates. 
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The majority of the quantified glycoproteins were synthesized faster than degraded due to the 
cell growth. In combination with pulse-chase SILAC and glycopeptide enrichment, we can 
simultaneously quantify the synthesis and degradation rates of glycoproteins. This method can 
be extensively applied to investigate glycoprotein dynamics, which will aid in a better 






















3.2 Quantification of Tunicamycin-Induced Protein Expression and N-Glycosylation 
Changes in Yeast 
 
3.2.1 Introduction 
Glycosylation is a prevalent protein modification in eukaryotic cells that plays essential 
roles in regulating protein folding, trafficking and stability.27, 54, 55 Aberrant glycosylation is 
frequently related to human disease, including cancer and infectious diseases.27, 56-62 In 
eukaryotic cells, N-glycosylation typically begins with the synthesis of the dolichol-linked 
precursor oligosaccharide (GlcNAc2Man9Glc3), followed by en bloc transfer of the precursor 
oligosaccharide to newly synthesized peptides in the endoplasmic reticulum (ER).1, 63 Then 
oligosaccharide is further trimmed and modified by many enzymes in the Golgi apparatus.64 
The pathway for N-glycosylation synthesis is conserved from yeast to mammalian cells.65 
Although yeast primarily contains high-mannose glycans which differ from those in 
mammalian cells,66 it can still be used as an excellent model system to study protein N-
glycosylation.4 
 Tunicamycin (TM), a glucosamine-containing antibiotic, blocks N-linked 
glycosylation by inhibiting the formation of the N-acetylglucosamine-dolichol-phosphate 
intermediate and thus traps cells in the G1 phase of the cell cycle.4, 67 TM was originally isolated 
and utilized for its antiviral activity by suppressing viral glycoprotein synthesis and membrane 
genesis.68, 69 Now tunicamycin is extensively used for protein N-glycosylation manipulation. 
In yeast, the presence of TM has been reported to disrupt the formation of the external 
glycoprotein invertase, acid phosphatase, and cell wall mannan.67 Although the mechanism 
responsible for TM-initiated inhibition of protein N-glycosylation has long been appreciated, 
a comprehensive and quantitative analysis of the affected proteome and glycoproteome in cells 
has yet to be conducted. 
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 In recent years, MS-based proteomics methods have become increasingly powerful to 
systematically study protein expression and modification changes in complex biological 
samples.29, 70-77 However, it is still challenging to investigate low-abundance proteins, which 
requires effective fractionation or other sample preparation.78-82 Furthermore, the global 
analysis of glycoproteins in complex biological samples is extraordinarily difficult because of 
the high heterogeneity of glycans and low abundance of many glycoproteins.32 Enrichment of 
glycopeptides and the generation of a common mass tag on glycosylation sites are required 
prior to MS analysis. In our recent study, based on a common feature of glycans, i.e. multiple 
hydroxyl groups in each glycan, boronic acid-based enrichment was used to effectively enrich 
glycopeptides in yeast whole cell lysates.39 By incorporating this enrichment method, it is 
possible to comprehensively quantify protein glycosylation changes with quantitative 
proteomics. 
Using yeast as a model system, we systematically investigated the cell response to TM 
at the proteome and N-glycoproteome levels. We quantified 4,259 proteins, which nearly 
covers the entire yeast proteome. Many proteins related to several glycan metabolism and 
glycolysis-related pathways were down-regulated in TM-treated cells. We also globally 
quantified protein N-glycosylation changes as a result of the TM treatment.  Among down-
regulated glycoproteins, those related to glycosylation, glycoprotein metabolic processes, 
carbohydrate processes, and cell wall organization were highly enriched. The current results 
clearly demonstrate that there are dramatic protein expression and N-glycosylation changes 







3.2.2 Experimental section 
3.2.2.1 Yeast strains, SILAC labeling, and TM treatment conditions 
Yeast (Saccharomyces cerevisiae) cells were seeded in “heavy” (Lys8 (13C6 and 15N2); 
Arg6 (13C6) Cambridge isotopes) or “light” (Lys0, Arg0) media (synthetic complete medium 
with lysine and arginine drop-out) and cultured overnight. Tunicamycin (TM) (Cayman 
Chemicals) stock solution (10 mg/mL) was prepared by dissolving TM in dimethyl sulfoxide 
(DMSO). When the cell population had undergone more than ten doubling times and reached 
the exponential growth phase (OD=0.3 at 600 nm), TM (2 µg/mL) was added into the “heavy” 
media while the “light” cells were treated by the same amount of DMSO as a vehicle control. 
After treatment for three hours, cells were harvested and mixed at a 1:1 ratio based on measured 
protein concentrations. 
 
3.2.2.2 Cell lysis, protein extraction and digestion 
Cells were washed twice with deionized water, pelleted by centrifugation at 4,000 g for 
5 minutes, and then resuspended in lysis buffer (50 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH=7.6, 150 mM NaCl, 0.5% sodium deoxycholate 
(SDC), 20 U/mL benzonase, and 1 protease inhibitor tablet per 10 mL buffer). Cell lysis was 
performed using a MiniBeadbeater (Biospec), three 30 second cycles at maximum speed, with 
2 minute pauses on ice in between each cycle. Lysates were then centrifuged at 15,000 g for 
10 minutes and the resulting supernatant was transferred into a new tube. The protein 
concentration was measured by a bicinchoninic acid (BCA) assay (Pierce) and proteins were 
subjected to disulfide reduction with 5 mM dithiothreitol (DTT) (56 ºC, 25 minutes) and 
alkylation with 14 mM iodoacetamide (RT, 20 minutes in the dark). Detergents were removed 
by methanol-chloroform protein precipitation. The purified proteins were digested with 10 
ng/µL Lys-C (Wako) in buffer containing 50 mM HEPES pH=8.6, 1.6 M urea, and 5% ACN, 
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at 31 ºC for 16 hours, followed by further digestion with 8 ng/uL Trypsin (Promega) at 37 ºC 
for 4 hours. 
 
3.2.2.3 Peptide separation, fractionation, and glycopeptide enrichment 
Protein digestions were acidified by the addition of trifluoroacetic acid (TFA) to a final 
concentration of 0.1%, followed by centrifugation to remove the precipitate. Then peptides 
were desalted using a tC18 Sep-Pak cartridge (Waters). Purified peptides were aliquoted into 
two portions: ~0.5 mg for protein analysis and a ~8 mg for glycosylation analysis. For protein 
analysis, lyophilized peptides were fractionated into 20 fractions by high pH reversed-phase 
high-performance liquid chromatography (HPLC) with a 40 minute gradient of 5-55% ACN in 
10 mM ammonium acetate (pH=10), and then desalted again using stage-tips. For glycosylation 
analysis, the separation and enrichment of glycopeptides was carried out by utilizing the 
covalent interaction between boronic acid and glycans containing multiple hydroxyl groups, as 
described previously.39 Peptides were directly subjected to glycopeptide enrichment without 
HPLC fractionation. Then we separated the glycopeptides into three fractions during the later 
stage-tip step. Briefly, the peptide mixture was dissolved in 200 mM ammonium acetate buffer 
(pH=10), and incubated with boronic acid-conjugated magnetic beads at 37 ºC for 1 h. The 
beads were then washed five times with the binding buffer to remove non-specifically bound 
peptides. Glycopeptides were eluted by incubating the beads in a solution containing 
acetonitrile, water, and trifluoroacetic acid at a respective ratio of 50:49:1 for 30 minutes at 37 
ºC. Eluates were desalted using tC18 Sep-Pak cartridges and lyophilized overnight.  
 
3.2.2.4 PNGase F treatment for glycopeptides 
Glycopeptides were deglycosylated with five units of peptide-N-glycosidase F 
(PNGase F, Sigma-Aldrich) in 100 µL buffer containing 50 mM NH4HCO3 (pH=9) in heavy-
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oxygen water (H218O) for 3h at 37 °C.83, 84 The reaction was quenched by adding formic acid 
(FA) to a final concentration of 1%. Peptides were further purified via stage tip and separated 
into 3 fractions using 20%, 50% and 80% ACN containing 1% HOAc. 
 
3.2.2.5 LC-MS/MS analysis  
All purified and dried peptide fractions were dissolved in a solvent containing 5% ACN 
and 4% FA, and a fraction of each sample was loaded onto a microcapillary column packed 
with C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, Michrom Bioresources) by a 
Dionex WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid Separation Pulled 
Loop Wellplate Sampler). For protein analysis, peptides were separated by reversed-phase 
liquid chromatography using an UltiMate 3000 binary pump with a 90-minute gradient of 4-
30% ACN containing 0.125% FA.  For the enriched glycopeptide samples, a 110-minute 
gradient of 3-25%, 8-38%, 10-50% ACN with 0.125% FA was used for each of the three 
fractions. Peptides were detected with a data-dependent method41, 85 in a hybrid dual-cell 
quadrupole linear ion trap – Orbitrap mass spectrometer (LTQ Orbitrap Elite, ThermoFisher, 
with Xcalibur 3.0.63 software). For each cycle, one full MS scan (resolution: 60,000) in the 
Orbitrap (106 AGC target) was followed by up to 20 MS/MS in the LTQ for the most intense 
ions. The selected ions were excluded from further sequencing for 90 seconds. Ions with single 
or unassigned charges were not selected for MS/MS scans. Maximum ion accumulation times 
were 1000 ms for each full MS scan and 50 ms for MS/MS scans. 
 
3.2.2.6 Database search and data filtering 
Raw mass spectra were converted into mzXML format, and then searched using the 
SEQUEST algorithm (version 28).42  The following parameters were used during the search: 
10 ppm precursor mass tolerance; 1.0 Da product ion mass tolerance; fully digested with 
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trypsin; up to three missed cleavages; fixed modifications: carbamidomethylation of cysteine 
(+57.0214); variable modifications: oxidation of methionine (+15.9949), 18O tag on asparagine 
(+2.9883, for glycosylation analysis), heavy lysine (+8.0142) and heavy arginine (+6.0201). 
The target-decoy method43, 86 was employed to determine the false discovery rate (FDR). 
Linear discriminant analysis (LDA) was then performed to control the quality of peptide 
identifications using parameters such as XCorr, charge state and precursor mass accuracy,45 
which is also similar to the previous report.44 Peptides fewer than seven amino acid residues in 
length were considered unreliable and deleted. Peptide spectral matches were filtered to a <1% 
FDR. For protein analysis, the peptide-level FDR was calculated based on all identified 
peptides. For glycoprotein analysis, the dataset was restricted to glycopeptides when 
determining FDRs for glycopeptide identification.46, 87 Furthermore, an additional protein-level 
filter was applied in each dataset to reduce the protein-level FDRs (<1%) for proteins and 
glycoproteins. Consequently, the FDRs at the peptide level were much less than 1%. 
 
3.2.2.7 Glycosylation site localization and peptide quantification 
We used ModScores to assign glycosylation sites and measure the confidence of their   
localizations.46, 88 The ModScore software considers all possible glycosylation sites in a peptide 
and uses the presence of experimental fragments unique to each site to determine the actual 
glycosylation site and calculated ModScore value based on the binominal probability P 
(!"#$%"&' = −10×-"./0 1 ).	We considered ModScore > 13 (P < 0.05) as confidently 
localized. If the same peptide was quantified several times, the median heavy-to-light (H/L) 
value was used as the peptide abundance change. For peptides used for proteome analysis, we 
required that either its heavy or light isotope peak had a signal-to-noise ratio (S/N) greater than 
3. If the S/N of the heavy peak was less than 3, then we required that the light peak had an S/N 
great than 5, and vice versa. Two criteria were applied for glycosylation site quantification: (1) 
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the quantified glycopeptide must contain only one glycosylation site; (2) the site must be 
confidently localized with a ModScore >13. 
 
3.2.3 Results and Discussion 
3.2.3.1 Tunicamycin treatment and glycoprotein enrichment 
Tunicamycin has been widely used to model specific types of stress that affect protein 
folding in the ER.89, 90 However, the protein abundance changes in tunicamycin-treated cells 
have remained unexplored on a large scale. Our first aim was to study the proteome changes 
resulting from the TM treatment. Because TM is known to inhibit the formation of the N-
acetylglucosamine-dolichol-phosphate intermediate and thus prevents protein N-glycosylation, 
we also systematically investigated N-glycoproteome alterations in TM-treated yeast cells. 
Since many membrane proteins are known to be glycosylated, 0.5% sodium deoxycholate 
(SDC) was added into the lysis buffer to increase membrane protein extraction. As a detergent, 
SDC can disrupt and dissociate many types of protein interactions, and also increase the 
solubility of membrane proteins. After cell lysis, protein extraction and purification, 0.5 mg of 
digested peptides were separated into 20 fractions using high-pH reversed phase liquid 
chromatography (Figure 3.9). In combination with further separation under acidic conditions 
during on-line LC-MS/MS analysis, two-dimensional orthogonal separation can minimize 








Figure 3.9 Experimental procedure for the global analysis of proteins and N-glycoproteins in 
TM-treated yeast cells vs. untreated cells.  
 
Two technical challenges must be overcome to globally study protein N-glycosylation 
by using MS-based proteomics techniques: the low expression levels of many glycoproteins, 
and the heterogeneity of glycan structures. Therefore, an effective enrichment method and an 
efficient approach to generate a common tag on glycosylation sites for subsequent database 
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searching are required. Based on one common features of glycoproteins, i.e. glycan structures 
bearing multiple hydroxyl groups, we globally enriched glycoproteins and/or glycopeptides 
through the universal boronic acid-cis diol recognition.39 Boronic acid was immobilized onto 
magnetic beads to capture glycopeptides, and the reversible nature of the covalent interactions 
between boronic acid and diols made it possible to release glycopeptides (after the removal of 
non-specifically bound peptides) for further analysis. After enrichment, peptides were treated 
with PNGase F in heavy-oxygen water (H218O) to remove N-glycans, which converted 
asparagine (Asn) to aspartic acid (Asp) containing heavy oxygen and created a mass shift of 
+2.9883 Da.30, 40 Heavy oxygen on Asp allows us to easily distinguish authentic N-
glycosylation sites from those caused by deamidation occurring in vitro and in vivo. Treatment 
time was shortened to only 3 hours to minimize possible deamidation that occurs during the 
PNGase F cleavage process. 
 
3.2.3.2 Examples of peptide and glycopeptide identification and quantification 
In order to accurately quantify the protein expression and glycosylation changes, an 
Orbitrap mass spectrometer with high resolution and mass accuracy (Thermo hybrid LTQ-
Orbitrap Elite MS) was used in this study. Figure 3.10 shows examples of peptide and 
glycopeptide identifications and quantifications. Both peptides are from the protein PDI1 
(YCL043C), which is a disulfide isomerase essential for the formation of disulfide bonds in 
secretory and cell-surface proteins, and may unscramble non-native disulfide bonds. In 
addition, it participates in the processing of unfolded protein-bound Man8GlcNAc2 
oligosaccharides to Man7GlcNAc2, thereby promoting degradation in unfolded protein 
response (http://www.yeastgenome.org). This protein was determined to be up-regulated by 
2.6 fold in TM-treated yeast cells, possibly as a result of TM interrupting the proper 
glycosylation of various proteins, and unfolded or misfolded proteins accumulating in the ER.  
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Heavy isotope peaks of the peptide GLMNFVSIDAR are shown to be more than twice as 




Figure 3.10 Examples of full and tandem mass spectra of peptides. (a) The full and (c) tandem 
mass spectra of the peptide GLMNFVSIDAR and (b) the full and (d) tandem mass spectra of 
the glycopeptide RLAPTYQELADTYAN*ATSDVLIAK. Both peptides are from the protein 
PDI1. (c) and (d) demonstrated that the two peptides were confidently identified with high 
XCorr values. (@-heavy arginine, #-heavy lysine, *-glycosylation site) 
 
In TM-treated yeast cells, the glycosylation site N425 on this protein was down-
regulated by 2.5 fold. The tandem mass spectra corresponding to the identification of the 
glycopeptide R@LAPTYQELADTYAN*ATSDVLIAK# (@-heavy arginine, #-heavy lysine 
and *-glycosylation site) is shown in Figure 3.10b; this glycopeptide was confidently identified 
with an XCorr of 5.04 and a ModScore of 1000. The two ratios of peptides and glycopeptides 
from the same protein are excellent examples of differential protein expression and 
glycosylation changes resulting from the TM treatment. Several other glycosylation sites (N82, 
(a) (b) 
(c) (d) 





































































































































































N117, N155 and N174) on this protein were also down-regulated (listed in a table online at 
doi.org/10.1039/C6AN00144K). 
 
3.2.3.3 Global analysis of protein abundance changes 
After protein samples were fractionated into 20 samples, they were measured using an 
online LC-MS system. With these powerful MS-based proteomics techniques, we were able to 
confidently quantify 4,259 yeast proteins (listed in a table online at 
doi.org/10.1039/C6AN00144K), which nearly covered the entire yeast proteome.91, 92 
Moreover, 95% of identified glycoproteins were also identified in the proteome experiments 
(Figure 3.11a). Due to their low abundances, seven glycoproteins were not identified in 
proteome analysis without efficient enrichment. The protein abundance change distribution is 
shown in Figure 3.11b and most protein abundances did not have marked changes. Overall, 
400 proteins were up-regulated while 226 proteins were down-regulated by at least 2 fold in 
TM-treated yeast cells. We then clustered them separately according to biological process or 
pathway using the Database for Annotation, Visualization, and Integrated Discovery 6.7 
(DAVID 6.7).93 Several glycan metabolism pathways, including starch and sucrose metabolism, 
fructose and mannose metabolism, the pentose phosphate pathway, and glycolysis-related 
pathways were significantly enriched among up-regulated proteins (Figure 3.12a)). This 
phenomenon may be due to excess glycans present in cells as a result of protein glycosylation 
inhibition by TM. We have quantified the majority of the proteins involved in the canonical 
unfolded protein response pathway,94 including Ero1 (YML130C), an essential oxidoreductase 
that produces disulfide bonds in the ER, which was up-regulated by 5.2 fold. Other related 
proteins, including Hrd3 (YLR207W), Gcn2 (YDR283C), and Ire1 (YHR079C), had increased 





         
Figure 3.11 Protein identification and quantification results. (a) The overlap between proteins 
and glycoproteins identified in this work. (b) The ratio distribution of quantified proteins. 
 
For down-regulated proteins, ribosome and RNA processing-related biological 
processes were notably enriched, which meant that protein translation was reduced. This 
correlates very well with previous studies in the literature.95, 96 For example, Steffen et al. found 
that ribosomal deficiency protects yeast cells against ER stress, which was a result of many 
secretory proteins getting trapped in the ER due to the inhibition of their glycosylation. The 
treatment of the ribosomal protein gene deletion strains with TM showed significant ER stress 
resistance.95 In addition, protein transportation between the Golgi and plasma membrane was 
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participates in protein transportation to the membrane, and cell wall biogenesis and 
degradation, and its expression was reduced to 6.6% as a result of a drug treatment. The 
dramatic down-regulation of this protein suggests that cell wall formation may be impacted in 
the TM-treated cells because  protein N-glycosylation regulated protein folding and trafficking 
and here it was inhibited by TM. Therefore, cell wall proteins cannot be transported to the cell 
wall. 
 
3.2.3.4 Site-specific glycoprotein identification 
The common tag generated by PNGase F deglycosylation in heavy-oxygen water 
(H218O) allowed the global and site-specific identification of protein N-glycosylation. As 
shown in Figure 3.10b, fragments in the tandem mass spectrum enabled us to confidently 
localize protein glycosylation sites. A total of 448 glycosylation sites were identified in the 
current experiment (listed in a table online at doi.org/10.1039/C6AN00144K). Here we 
assessed the confidence of site localizations with the calculation of ModScore values, which 
take all possible glycosylation sites in a peptide into account and uses the existing experimental 
fragment ions unique to each site to determine the actual glycosylation site.39, 41, 46 For instance, 
two possible glycosylation sites located next to each other without adequate fragment ions to 
distinguish them will result in a low Modscore. A ModScore greater than 13 represents a P 
value less than 0.05, which we considered to be well-localized. Figure 3.13a shows that the 
majority of the glycosylation site identified in this experiment are well-localized, and 68.5% 








Figure 3.12 Clustering of up- and down-regulated proteins in tunicamycin-treated cells. (a) 
Enriched pathways for up-regulated proteins. (2) Enriched biological processes among down-
regulated proteins. 
 
Many proteins carried multiple N-glycosylation sites (Figure 3.13b) and more than 30 
proteins contained at least five glycosylation sites. For example, a total of 15 possible 
glycosylation sites were identified from the protein Rax2 (YLR084C). Rax2 is required for the 
maintenance of the bipolar budding pattern, and is involved in selecting bud sites.97 It was 
reported that Rax2 is a glycosylated type I membrane protein, with its long N-terminal domain 
in the extracellular space.98 In TM-treated yeast cells, Rax2 was down-regulated by 2.07 fold 
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while its four singly glycosylated peptides were down-regulated with ratios of 0.45, 0.46, 0.51, 
and 0.51, respectively. 
We further investigated the correlation between the number of identified glycosylation 
sites and the glycoprotein length (Figure 3.13c). It seems plausible that longer proteins could 
carry statistically more glycosylation sites which would allow a greater number of 
glycosylation sites to be identified. When we plotted the number of glycosylation sites as a 
function of the protein length, there was no significant correlation between the two. 
Next we considered whether protein and glycoprotein identifications in this work were 
biased for highly abundant proteins. Based on the number of copies (abundances) of yeast 
proteins reported in the literature,99 we plotted the abundance distribution of proteins and 
glycoproteins identified here with the protein abundance distribution from the literature in 
Figure 3.13d. The x-axis represents the number of protein molecules per cell, and the y-axis 
shows the percentage of proteins. Despite all three protein datasets having similar distributions 
over various amounts of protein molecules, we quantified a considerable amount of proteins 
and glycoproteins that were not quantified by the tandem affinity purification (TAP) coupled 
to immune-detection method in the literature.99 This means that modern MS methods are very 
sensitive and can detect proteins with very low abundances. In addition, the median length of 
glycoproteins identified in this experiment is 581 amino acid residues, while the yeast whole 
proteome (http://www.yeastgenome.org/) has a median of 359 amino acid residues. This 
suggested that glycoproteins are generally longer than other proteins, although the number of 






Figure 3.13 The results of site-specific N-glycosylation identification. (a) The ModScore 
distribution for the identified glycosylation sites. (b) The number of glycosylation sites 
identified in glycoproteins. (c) The correlation between the number of glycosylation sites and 
the length of glycoproteins. (d) The abundance distribution of proteins and glycoproteins in the 
literature99 and quantified in this work. 
 
3.2.3.5 Quantification of glycopeptides and singly-glycosylated peptides 
In this work, a total of 465 unique glycopeptides were quantified, among which more 
than one third (162 glycopeptides) were down-regulated by more than 2 fold, while only 40 
glycopeptides were up-regulated (listed in a table online at doi.org/10.1039/C6AN00144K).  
These results are agreeable with the known glycosylation inhibition effects of TM. The 
distribution of glycopeptide abundances is shown in Figure 3.14a. Glycopeptides are not 
expected to be up-regulated as a result of tunicamycin treatment, however this could occur 































































short period after treatment, or if the corresponding parent proteins are up-regulated. For 
instance, glycopeptide R.TPLVAWGAGLNK#PVHNPFPVSDN*YTENWE LSSIK#.R has 
an up-regulation ratio of 2.01, while the corresponding protein YKL165C were up-regulated 
for 3.47 fold. The regulation ratio for this peptide is determined to be 0.58 after calibration. 
Meanwhile, peptide K.SPVETVSDSLQFSFNGN*QTK (2.34 fold) from protein YDR055W 
(4.65 fold) has a ratio of 0.50 after calibration. Here we only treated cells for three hours, but 
more glycopeptides are anticipated to be down-regulated if cells are treated for a longer time.  
Glycoproteins containing down-regulated glycopeptides were clustered according to 
biological processes using DAVID 6.7 (Figure 3.14b). The glycosylation, glycoprotein 
metabolic processes, carbohydrate processes, and cell wall organization were highly enriched. 
Compared to proteome analysis results, these more directly reflect the primary impact of 
inhibiting protein N-glycosylation by TM in yeast cells. Interestingly, several proteins 
containing down-regulated N-glycopeptides were related to protein O-glycosylation. A total of 
five glycoproteins in the current results were involved in this process, among which three were 
also involved in protein N-glycosylation. The other two glycoproteins, dolichyl-phosphate-
mannose-protein mannosyltransferase 2 (PMT2, YAL023C) and PMT5 (YDL093W) are 
glycosyltransferases that specifically participate in protein O-glycosylation (especially O-
linked mannosylation). The current results suggest that TM treatment could also interfere  







Figure 3.14 The ratio distribution of glycopeptides and glycoprotein clustering. (a) Ratio 
distribution of the quantified glycopeptides. (b) Clustering of the down-regulated glycoproteins 
according to biological processes. 
 
Finally, we extracted all the singly-glycosylated glycopeptides with a ModScore larger 
than 13, and performed quantification at the glycosylation site level. The ratio distribution 
(Figure 3.15a) of quantified glycosylation sites is largely similar to that of quantified 
glycopeptides. A total of 253 sites were quantified, among which 81 were down-regulated and 
18 were up-regulated. Clustering analysis also revealed that glycosylation was impacted 
(Figure 3.15b). The high-mannose type N-glycan biosynthesis pathway was found to be down-
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(Table 3.2). Powerful MS-based proteomics methods allowed us to systematically and site-
specifically quantify protein N-glycosylation changes in TM-treated cells, offering valuable 
insight into tunicamycin-cell interactions. 
 
                          
 
Figure 3.15 (a) Ratio distribution of the quantified glycosylation sites. (b) Clustering of the 
down-regulated glycosylation sites according to biological processes. 
 
3.2.4 Conclusions 
Tunicamycin has been widely used to manipulate protein N-glycosylation, but the 
global analysis of protein expression and N-glycosylation changes as a result of tunicamycin 



































investigated the protein abundance and N-glycosylation changes by powerful MS-based 
proteomics techniques.  Through combination with quantitative proteomics, we have quantified 
4,259 proteins in tunicamycin-treated yeast cells. The majority of protein abundances changed 
very little if at all, but nearly 10% of quantified proteins were down-regulated by >2 fold, 
among which proteins related to several glycan metabolism and glycolysis-related pathways 
were highly enriched. In addition, several proteins in the canonical unfolded protein response 
pathway were up-regulated because the inhibition of N-glycosylation dramatically impacts the 
proper folding and subsequent trafficking of some proteins.  
We comprehensively quantified protein N-glycosylation changes in yeast cells induced 
by tunicamycin by combining boronic acid-based glycopeptide enrichment, enzymatic 
deglycosylation in heavy-oxygen water, and MS-based proteomics. More than one third (168) 
of 465 quantified unique glycopeptides were down-regulated in yeast cells with three-hour 
treatment. Among down-regulated glycoproteins, those related to glycosylation, glycoprotein 
metabolic processes, carbohydrate processes, and cell wall organization were highly enriched. 
The high-mannose type N-glycan biosynthesis pathway was also found to be down-regulated. 
For the first time, we systematically and quantitatively investigated protein expression and N-
glycosylation changes in tunicamycin-treated yeast cells. These results will provide a better 









Table 3.2 Down-regulated glycosylation sites involved in the high-mannose type N-glycan 
biosynthesis pathway (P=1.2E-4) 
 
Reference Peptide Site 
Mod 










SDVLEVGN*K.T 155 1000 0.16 3.33 0.44 
YER001W 
K.MFPFINN*FTTE









383 38.3 -3.16 5.77 0.17 
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4.1 Analysis of Cell-Surface N-Glycoproteome and Site-specific Quantification of Surface 
N-glycoproteins in Statin-treated Liver Cells 
 
4.1.1 Introduction 
Glycosylation is one of the most important protein modifications and is essential for 
cell survival.1 There are two major types of protein glycosylation: N-linked glycosylation and 
O-linked glycosylation. For O-glycosylation, glycans are bound to the side chains of serine and 
threonine, while N-glycosylation involves glycans covalently attached to the side chain of 
asparagine. In eukaryotic cells, there is machinery in the endoplasmic reticulum (ER) 
responsible for attaching the initial glycan block ((GlcNAc)2(Mannose)9(Glucose)3) to nascent 
peptides. It is well known that N-glycosylation plays determinant roles in protein folding and 
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trafficking, and N-glycosylated proteins are especially important in regulating extracellular 
activities, including cell-cell communication and cell-matrix interactions.2 Aberrant protein N-
glycosylation is frequently related to human disease,3 including Alzheimer’s disease (AD),4 
cancer,5 and infectious diseases.6 
        Half a century ago, early mammalian cell morphology studies discovered abundant 
carbohydrates on the external surface of the cell membrane.7, 8 To date, numerous research 
results have indicated that the majority of cell surface proteins are glycosylated.9, 10 Despite the 
number of glycoproteins located on the cell surface and their importance in biological functions, 
the global analysis of surface glycoproteins is extraordinarily challenging.11, 12 Modern mass 
spectrometry (MS)-based proteomics techniques provide the capacity to comprehensively 
analyze protein modifications.13-23 These methods can be employed to systematically identify 
modified proteins, localize the modification sites, and quantify their abundance changes.24-28 
However, the heterogeneity of glycans and low abundance of many glycoproteins make the 
global analysis of glycoproteins extraordinarily difficult.29 It is even more challenging to 
specifically and comprehensively analyze N-glycoproteins only on the cell surface because it 
requires the selective separation and enrichment of surface N-glycoproteins.  
Statins have been widely used to lower cholesterol levels in patients by inhibiting 3-
hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR),30 an enzyme in the upstream 
portion of the mevalonate pathway. Besides cholesterol, the synthesis of many intermediate 
and end products in this pathway, including ubiquinone and dolichol, are significantly affected 
by the inhibition of this enzyme.31 Dolichol plays an essential role in protein N-glycosylation, 
and functions as a membrane anchor for the formation of a precursor oligosaccharide.32 The 
effect of statin on surface protein glycosylation is still unknown which may contribute to the 
pleiotropic effects of statins. The systematic and quantitative analysis of surface glycoproteins 
in statin-treated cells will potentially shed light on the molecular mechanisms behind the 
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pleiotropic effects of statins, which will allow patients to receive the full benefits of this 
medicine.  
        In this work, we systematically evaluated metabolic labeling with three sugar analogs, i.e. 
GalNAz, GlcNAz and ManNAz, for the identification of cell surface N-glycoproteins by 
combining copper-free click chemistry and MS-based proteomics. The parallel experiments 
showed that GalNAz labeling resulted in the greatest number of protein N-glycosylation sites 
identified, while GlcNAz resulted in the smallest number of protein N-glycosylation sites. Thus, 
GalNAz labeling was employed for the global quantification of surface glycoproteins in HepG2 
liver cells treated with statin. Systematic and quantitative analysis of surface proteins in statin-
treated cells clearly demonstrated that many glycosylation sites were down-regulated compared 
to untreated cells. This method offers a means to globally, site-specifically and quantitatively 
study protein N-glycosylation on the cell surface. 
 
4.1.2 Experimental section 
4.1.2.1 Cell culture and metabolic labeling 
HepG2 (C3A) cells ( Hep G2 [HEPG2] (ATCC® HB-8065™)) were grown in a 
humidified incubator at 37 °C and 5.0% CO2 in Dulbecco's modified eagle's medium (DMEM) 
(Sigma-Aldrich) containing low glucose and 10% fetal bovine serum (FBS) (Thermo). For the 
glycoprotein identification experiments, when cells reached about 40% confluency, 100 µM 
GalNAz, GlcNAz or ManNAz (Click Chemistry Tools) was added to the media. Cells were 
further cultured for 24 h. In each case, duplicate biological experiments were performed. 
For the quantification experiment, “heavy” and “light” stable isotope labeling by amino 
acids in cell culture (SILAC) (Sigma-Aldrich) media were freshly prepared by adding 0.146 
g/L 13C615N2 L-lysine (Lys-8) and 0.84 g/L 13C6 L-arginine (Arg-6) (Cambridge Isotopes Inc.) 
or the corresponding non-labeled lysine (Lys-0) and arginine (Arg-0) to DMEM and 
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supplemented with 10% dialyzed FBS (Corning). Cells were cultured for about six generations 
before the atorvastatin treatment. 40 mM atorvastatin (Cayman Chemical) stock solution was 
prepared in DMSO (Sigma-Aldrich). About 2 × 107 cells were treated with 15 µM atorvastatin 
in serum-free heavy medium for 48 h. A similar number of light cells were treated by DMSO 
in serum-free light medium as a control. 100 µM GalNAz was added in after 24 h of atorvastatin 
or DMSO treatment.  
 
4.1.2.2 In-flask copper-free click reaction, cell lysis and protein digestion 
Cells were washed twice with phosphate buffered saline (PBS) before 100 µM 
dibenzocyclooctyne (DBCO)-sulfo-biotin in PBS was added into the cell culture flasks. 
Surface glycoproteins were tagged with biotin through the specific click reaction between 
DBCO and the azido group in the sugar analogs under physiological conditions33-35. Cells were 
incubated for 1 h with gentle agitation at 37 °C, then harvested by scraping in PBS. For the 
quantification experiments, heavy and light cells were equally combined based on the protein 
ratio of 1:1 from a trial run. The cell mixtures were pelleted by centrifugation at 500 g for 3 
minutes and washed twice with cold PBS. Cytosol proteins were removed by incubating in a 
buffer containing 150 mM NaCl, 50 mM HEPES pH=7.6, 25 µg/mL digitonin, and 1 tablet/ 10 
mL protease inhibitor (complete mini, EDTA-free, Roche) on ice for 10 minutes. After 
incubation, samples were centrifuged at 2000 g for another 10 minutes.  Cell pellets were 
washed with the previous buffer, then lysed through end-over-end rotation at 4 ºC for 45 
minutes in lysis buffer (50 mM HEPES pH=7.6, 150 mM NaCl, 0.5% SDC, 10 units/mL 
benzonase and 1 tablet/10 mL protease inhibitor). Lysates were centrifuged, and the resulting 
supernatant was transferred to new tubes. Proteins were subjected to disulfide reduction with 
5 mM DTT (56 ºC, 25 minutes) and alkylation with 14 mM iodoacetamide (RT, 20 minutes in 
the dark). Detergent was removed by methanol-chloroform protein precipitation. The purified 
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proteins were digested with 10 ng/µL Lys-C (Wako) in 50 mM HEPES pH 8.6, 1.6 M urea, 
5% ACN at 31 ºC for 16 hours, followed by further digestion with 8 ng/uL Trypsin (Promega) 
at 37 ºC for 4 hours. 
 
4.1.2.3 Glycopeptide separation and enrichment 
Digestion mixtures were acidified by the addition of trifluoroacetic acid (TFA) to a 
final concentration of 0.1%, clarified by centrifugation and desalted using a tC18 Sep-Pak 
cartridge (Waters). Purified peptides were dried and then enriched with NeutrAvidin beads 
(Thermo) at 37 °C for 30 min. The samples were transferred to spin columns, followed by 
thoroughly washing according to the manufacturer’s protocol. Peptides were then eluted from 
the beads three times by 2 min incubations with 200 µL of 8 M guanidine-HCl (pH = 1.5) at 
56 °C. Eluates were combined, desalted using tC18 Sep-Pak cartridge and lyophilized 
overnight. Completely dry peptides were deglycosylated with eight units of peptide-N-
glycosidase F (PNGase F, Sigma-Aldrich) in 40 µL buffer containing 50 mM NH4HCO3 
(pH=9) in heavy-oxygen water (H218O) for 3 h at 37 °C. The reaction was quenched by adding 
formic acid (FA) to a final concentration of 1%. Peptides were further purified via stage tip and 
separated into 3 fractions using 20%, 50% and 80% ACN containing 1% HOAc. 
 
 
4.1.2.4 LC-MS/MS analysis  
Purified and dried peptide samples were each dissolved in a 10 µL of 5% ACN and 4% 
FA, and 4 µL of the resulting solutions were loaded onto a microcapillary column packed with 
C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, Michrom Bioresources) by a Dionex 
WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid Separation Pulled Loop 
Wellplate Sampler). Peptides were separated by reversed-phase chromatography using an 
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UltiMate 3000 binary pump with a 110 min gradient of 3-25%, 8-38%, 10-50% ACN (with 
0.125% FA) for the three fractions, respectively. Peptides were detected with a data-dependent 
Top20 method36 in a hybrid dual-cell quadrupole linear ion trap – Orbitrap mass spectrometer 
(LTQ Orbitrap Elite, ThermoFisher, with Xcalibur 3.0.63 software). For each cycle, one full 
MS scan (resolution: 60,000) in the Orbitrap at 106 AGC target was followed by up to 20 
MS/MS in the LTQ for the most intense ions. The selected ions were excluded from further 
analysis for 90 seconds. Ions with singly or unassigned charge were not sequenced. Maximum 
ion accumulation times were 1000 ms for each full MS scan and 50 ms for MS/MS scans. 
 
4.1.2.5 Database searching and data filtering 
All MS2 spectra were converted into an mzXML format, and then searched using the 
SEQUEST algorithm (version 28).37 Spectra were matched against a database containing 
sequences of all proteins in the UniProt Human (Homo sapiens) database (downloaded in 
February 2014).  The following parameters were used during the search: 20 ppm precursor 
mass tolerance; 1.0 Da product ion mass tolerance; fully digested with trypsin; up to three 
missed cleavages; fixed modifications: carbamidomethylation of cysteine (+57.0214); variable 
modifications: oxidation of methionine (+15.9949), O18 tag of asparagine (+2.9883), heavy 
lysine (+8.0142) and heavy arginine (+6.0201). False discovery rates (FDR) of peptide and 
protein identifications were evaluated and controlled by the target-decoy method.38 Each 
protein sequence was listed in both forward and reversed orders. Linear discriminant analysis 
(LDA), which is similar to other methods in the literature,39 was used to control the quality of 
peptide identifications using parameters such as XCorr, precursor mass error, and charge 
state.40 Peptides fewer than seven amino acid residues in length were deleted. Furthermore, 
peptide spectral matches were filtered to a 1% FDR. The dataset was restricted to glycopeptides 
when determining FDRs for glycopeptide identification.41 Furthermore, an additional protein-
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level filter was applied in each dataset to reduce the protein-level FDRs (<1%) for 
glycoproteins. Consequently the FDRs at the peptide level were much less than 1%. 
 
4.1.2.6 Glycosylation site localization and peptide quantification 
We assigned and measured the confidence of glycosylation site localizations by 
calculating their ModScores, which applies a probabilistic algorithm41 that considers all 
possible glycosylation sites in a peptide and uses the presence of experimental fragment ions 
unique to each site. Sites with a ModScore > 13 (P < 0.05) were considered confidently 
localized. For peptide quantification, we required an S/N value >3 for both heavy and light 
peptides. If the S/N value of a certain heavy peptide was less than 3, then that of the 
corresponding light peptide was required to be greater than 5, and vice versa. If the same 
glycopeptide was quantified several times, the median value was used as the glycopeptide 
abundance change. Glycosylation site quantification had the following criteria: first, the 
quantified glycopeptide contain only a single glycosylation site; second, the site be well-
localized with a ModScore >13. If multiple unique singly glycosylated peptides containing the 
same glycosylation site were identified, the ratio of the glycosylation sites was the median 
value of these glycopeptide ratios. 
4.1.3 Results and discussion 
4.1.3.1 Metabolic labeling, surface glycoprotein enrichment and MS analysis  
In recent years, unnatural sugars containing a bio-orthogonal group have been used to 
label glycosylated proteins.9, 42 Glycoproteins bearing the biologically inert azido or alkyne 
group can be bound to a fluorescence probe to visualize them. This metabolic labeling can also 
be used to selectively enrich glycoproteins based on the unique bio-orthogonal group. Several 
sugar analogs, including GlcNAz, GalNAz and ManNaz (structures are in Figure 4.1b), have 
been reported to label cells.9, 43, 44 Here, in parallel experiments, we labeled cells using each of 
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the three sugar analogs,, and evaluated their effectiveness for the global and site-specific 
analysis of N-glycoproteins on the cell surface in combination with MS-based proteomics.  
After cells were cultured in low glucose media containing each of these three sugar 
analogs, surface glycoproteins containing the azido functional group on living cells were 
selectively bound to DBCO-sulfo-biotin via in-flask copper-free click chemistry under 
physiological conditions for 1 h, as shown in Figure 4.1a. Because the hydrophilic DBCO-
sulfo-biotin cannot penetrate the cell plasma membrane, only glycoproteins located on the cell 
surface were tagged under mild conditions. After cell lysis and protein digestion, surface 
glycoproteins tagged with a biotin group allowed further enrichment to be performed based on 
strong and specific interactions between biotin in glycopeptides and NeutrAvidin, which was 
conjugated to beads. Non-modified peptides were removed by washing the beads several times. 
Non-specific binding is a drawback of the streptavidin enrichment method, however, the 






Figure 4.1 (a) Experimental procedure for the global analysis of the N-glycoproteome on the 
cell surface. (b) The structures of three sugar analogs used: GalNAz, GlcNAz and ManNAz. 
(c) A sample tandem mass spectrum of the peptide TCVSN#CTASQFVCK from LRP1. (d) 
Another sample MS2 of YFFN#VSDEAALLEK from ITGA2 (# denotes the glycosylation site). 
 
In order to generate a common tag for MS analysis, enriched peptides were treated with 
PNGase F in H218O to remove N-glycans, which converted asparagine (Asn) to heavy-oxygen 



























































































identification.45, 46 This strategy was similar to a previous method for proteolytic stable isotope 
labeling, in which heavy-oxygen water was used to label digested peptides with trypsin and 
individual proteins from two proteome samples were quantitatively analyzed.47 In this case, 
heavy oxygen on Asp enabled us to distinguish authentic N-glycosylation sites from those 
caused by deamidation on non-glycosylated asparagines in vitro and in vivo. Deamidation on 
non-glycosylated asparagines could also occur during PNGase F treatment, which may result 
in false positive identifications, which is why we ran the reaction for 3 h to minimize false 
positive identification. Control experiments showed that the effect of uncontrolled deamidation 
within the three-hour PNGase F treatment was nearly negligible, which is described in more 
detail below. In addition, after glycopeptide enrichment, the presence of non-glycosylated 
peptides was significantly decreased, therefore the chance of any deamidation from non-
glycosylated peptides was dramatically reduced. Overall, the PNGase F treatment in heavy 
oxygen water increased the confidence of glycopeptide identification. 
An Orbitrap mass spectrometer with high resolution and mass accuracy provides the 
capability to confidently identify glycopeptides. For example, two tandem mass spectra for two 
glycopeptides in cluster of differentiation (CD) proteins, which are very important for 
differentiation and classification of cells, are shown in Figure 4.1c and d. The glycopeptide 
TCVSN#CTASQFVCK (# represents the glycosylation site) from LRP1 (CD91), prolow-
density lipoprotein receptor-related protein 1, was identified with an XCorr of 4.2 and a mass 
accuracy of -0.47 ppm. LRP1 is a single-pass type I membrane protein and is involved in 
endocytosis and in phagocytosis of apoptotic cells. It may modulate cellular events, such as 
kinase-dependent intracellular signaling, neuronal calcium signaling, and neurotransmission. 
As shown in Figure 4.1d, YFFN#VSDEAALLEK was also very confidently identified with an 
XCorr of 4.6 and a mass accuracy of 0.13 ppm. This peptide is from the protein ITGA2, integrin 
alpha-2, which is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-
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cadherin. It is an extremely important surface protein that regulates cell adhesion, cell-matrix 
interactions and host-virus interactions. In this work, we have confidently identified several 
glycosylation sites, i.e., N105, N112, N343, N432, N1057, and N1074 in ITGA2. 
 
4.1.3.2 Evaluation of glycopeptides and glycosylation Sites Identified in cells labeled with 
different sugar analogs  
The procedure for our parallel experiments differed only in the sugar analogs, which 
allowed us to objectively evaluate the effectiveness of three sugar analogs for global surface 
glycoprotein analysis. The number of identified glycosylation sites and glycoproteins and their 
overlap between biological duplicate experiments using each of the three sugar analogs are 
displayed in Figure 4.2. Theoretically, each sugar analog labels a different group of 
glycoproteins based on glycan structure and the enzymes responsible for glycan synthesis, 
therefore the results of from these three labeling experiments are expected to be different.  
Overall, 590 glycosylation sites were identified on 274 proteins in the GalNAz labeling 
experiments (listed in a table online at doi.org/10.1021/acs.analchem.5b04871), including 261 
proteins (95.3%) which were either secreted, located on the cell membrane or exported by 
extracellular vesicular exosomes based on the information from Uniprot (www.uniprot.org). 
Meanwhile, 446 glycosylation sites on 219 proteins, and 117 sites on 91 proteins were 
identified in the duplicate ManNAz (listed in a table online at 
doi.org/10.1021/acs.analchem.5b04871) and GlcNAz (listed in a table online at 





Figure 4.2 Reproducibility assessment in duplicate labeling experiments of (a) GalNAz, (b) 
GlcNAz, and (c) ManNAz.  
 
The GlcNAz labeling covered the fewest number of glycosylation sites and 
glycoproteins, which corresponds very well to previous work showing better incorporation of 
GalNAz or ManNAz over GlcNAz.48 Among 434 and 467 N-glycosylation sites identified in 
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glycoprotein level, as expected, the overlap was even higher. In the two experiments, 217 and 
231 glycoproteins were identified, and the number of overlapped proteins was 174. 
Considering the large-scale analysis, this level of overlap is within a reasonable range. Since 
we ran biological duplicate experiments for each sugar analog, the inconsistencies between 
duplicates could be due to the sample differences, the dynamic nature of protein glycosylation, 
sample preparation (sample loss) or false positive identifications. The comparison of surface 
glycosylation sites and glycoproteins identified in the three parallel experiments using different 
sugar analogs is displayed in Figure 4.3. The majority of the glycosylation sites and 
glycoproteins identified in ManNAz labeling experiments (335 of 446 sites, 176 of 219 
proteins) and GlcNAz labeling experiments (90 of 119 sites, 70 of 91 proteins) were also 
identified in the GalNAz experiments, demonstrating the highest coverage of surface 
glycosylation sites and glycoproteins. Based on these results, GalNAz was employed for the 
quantification of surface proteins in statin-treated cells in order to obtain higher glycoprotein 
coverage, as described below. Overall, 725 cell-surface glycosylation sites on 337 
glycoproteins were identified combining all these experimental results. 
 
Figure 4.3 Comparison of (a) surface N-glycosylation sites, and (b) N-glycoproteins identified 













































In order to verify that the results were reliable, we designed two controls to run in 
parallel with the GalNAz labeling experiment.  The experimental procedure for the first control 
was consistent with the GalNAz labeled experiment, except the click reaction was omitted; the 
second control omitted the PNGase F deglycosylation reaction. We identified 886 unique 
glycopeptides in the GalNAz labeling experiment, and only 20 glycopeptides in the first control. 
These 20 unique glycopeptides may have resulted from non-specific binding of the 
NeutrAvidin enrichment, non-glycosylated Asn deamidation in heavy-oxygen water during 
PNGase F treatment, or false positive identification of glycopeptides. However, any non-
glycosylated Asn deamidation before or after the PNGase F treatment would result in a mass 
difference of 0.9840 Da, not 2.9883 Da, so they would be easily distinguishable during data 
analysis. Only non-glycosylated Asn deamidation within the three-hour PNGase F treatment 
in heavy-oxygen water would contribute to false positive identification. In the second control 
experiment without PNGase F, only 7 unique glycopeptides were identified, likely due to the 
deamination of free Asn. This is less than 1% compared to the 886 unique glycopeptides 
identified in the parallel GalNAz labeling experiment, which indicates that the effect of non-
glycosylated Asn deamidation within the three hour reaction was nearly negligible. These 
control experiments clearly verified the reliability of the current results. 
 
4.1.3.3 Clustering of surface N-glycoproteins identified in GalNAz labeling experiments 
Most of the identified glycoproteins contain a single glycosylation site. There were also 
some proteins with more than ten sites; for example, 21 N-glycosylation sites were identified 
on LRP1. The clinical importance of LRP1 in Alzheimer’s disease and cardiovascular disease 
also brings extensive attention to this protein. Glycosylation may stabilize this receptor-related 
protein, and also differentiates the protein’s functions in different tissues.49  
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In order to further evaluate the specificity of our method, the identified glycoproteins 
in the GalNAz labeling experiments were clustered according to molecular function and 
biological process using the Database for Annotation, Visualization, and Integrated Discovery 
6.7 (DAVID 6.7).50 We investigated the molecular functions of the identified glycoproteins 
and the biological processes they are involved in. The molecular functions with the highest 
level of enrichment were receptor activity, signal transducer activity, and binding, with 
remarkably low P values (Figure 4.4). Among biological processes, cell adhesion was 
prominently enriched with a P value of 3.6E-20 and 48 proteins involved. Integrin-mediated 
signaling pathway and cell motion were also notably enriched with P values of 1.8E-10 and 
4.1E-10, respectively. These are consistent with the well-known molecular functions and 
biological processes of surface proteins, which demonstrated that the current method for 






Figure 4.4 Clustering of identified surface N-glycoproteins based on (a) molecular functions 
and (b) biological processes. 
 
4.1.3.4 Quantification of surface protein N-glycosylation changes in atorvastatin-treated 
HepG2 cells  
Surface glycoproteins play critical roles in cell-cell and cell-matrix interactions. 
Systematic and quantitative analysis of surface proteins can help us better understand surface 
protein functions and cellular activities, which will lead to a better understanding of the 
molecular mechanisms of disease, the discovery of biomarkers, and elucidating the side effects 
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of drugs. Statins are the most popular and effective drugs for lowering patients’ cholesterol. As 
effective cholesterol-lowering HMGCR inhibitors, statins inhibit the rate-limiting step of the 
cholesterol biosynthesis pathway, known as the mevalonate pathway. It has been extensively 
documented that these drugs have pleiotropic effects,51 but their molecular mechanisms remain 
to be explored. The inhibition of HMGCR also prevents the synthesis of other products in this 
pathway, including ubiquinone, dolichol and farnesyl-pyrophosphate (farnesyl-PP). Dolichol 
is essential to protein N-glycosylation in the form of dolichyl phosphate (Dol-P). Dol-P serves 
as the carrier in pyrophosphate-linked oligosaccharide assembly as well as acting as the 
acceptor in the synthesis of the sugar donors Dol-P-Man and Dol-P-Glc from GDP-Man and 
UDP-Glc, respectively. Upon the inhibition of dolichol, protein N-glycosylation is expected to 
be dramatically impacted due to the inability to process lipid-linked oligosaccharide 
biosynthesis and transportation. However, systematic and quantitative analysis of surface N-
glycoproteins in statin-treated cells has yet to be reported. 
        Based on the optimized sugar analog labeling method discussed above, surface protein N-
glycosylation changes in atorvastatin-treated cells were analyzed by combining GalNAz 
labeling and a quantitative proteomics method. Since the primary organ target of statins is the 
liver, HepG2, a human liver carcinoma cell line, was used in this work. Stable isotope labeling 
by amino acids in cell culture (SILAC)52 was employed to evaluate the surface N-glycoprotein 
changes between statin-treated and untreated cells. Cells were treated by atorvastatin for 24 h 
to inhibit dolichol synthesis, then labeled with GalNAz for another 24 h in the presence of 
atorvastatin. An in-flask copper-free click reaction with DBCO-sulfo-biotin was then 
performed to specifically tag surface N-glycoproteins (Figure 4.5a).  Subsequent cell lysis, 
protein digestion, and enrichment of surface glycopeptides with NeutrAvidin beads were 
performed as described above. The selectively enriched surface N-glycopeptide samples were 
analyzed by LC-MS. An example of peptide quantification is shown in Figure 4.5, and the full 
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MS and elution profile of a peptide (VASVININPN*TTHSTGSCR, where * is the 
glycosylation site) from LAMP2 (CD107) are shown in Figure 4.5b and c, respectively. 
LAMP2 is a single-pass type I membrane protein that regulates cell adhesion and 
inter/intracellular signal transduction when expressed on the cell surface. Based on the elution 
profiles, we can very accurately quantify the abundance changes of this peptide in statin-treated 
cells vs. untreated cells, i.e. the ratio of the areas under the curves for heavy and light versions 
of the peptide (H/L = 0.38). 
The combination of GalNAz labeling and SILAC led to the quantification of 360 unique 
N-glycopeptides from 178 cell-surface glycoproteins (listed in a table online at 
doi.org/10.1021/acs.analchem.5b04871). Among quantified unique glycopeptides, the 
majority only contained a single N-glycosylation site, while only 20 contained two sites, as 
shown in Figure 4.6a. The distribution of 360 quantified unique glycopeptides is shown in 
Figure 4.6b. Based on the two criteria described above, 280 singly glycosylated sites (listed in 
a table online at doi.org/10.1021/acs.analchem.5b04871) were quantified with a similar 





Figure 4.5 (a) Overview of labeling and tagging workflow in quantification experiments, and 
(b, c) the quantification of the heavy and light versions of an example glycopeptide from 
LAMP2: (b) full MS (* represents glycosylation site and @ represents heavy arginine) and (c) 
extracted elution profiles for both versions of the peptides. 









































In this quantification experiment, we identified significantly more down-regulated 
glycopeptides or glycosylation sites (103 sites) than up-regulated glycopeptides or 
glycosylation sites (37 sites) in atorvastatin-treated cells. Although dolichol biosynthesis was 
inhibited by atorvastatin for one day before GalNAz labeling, dolichol can be recycled in cells 
after sugar transportation is completed.53 Therefore, statin treatment for a short time can impact 
but not entirely prevent protein N-glycosylation. Another possible explanation for site up-
regulation could be due to the up-regulation of the corresponding parent protein. Namely, if a 
protein is dramatically up-regulated in treated cells while N-glycosylation sites from this 
protein are largely unaffected or even slightly down-regulated, we could still find these sites 
up-regulated. For instance, the abundance of the N1523 site on APOB changed by 1.6 fold in 
the treated cells, whereas the protein ratio was found to be up-regulated 2.0 fold, as reported 
previously.54 Similar effects have been found in protein phosphorylation studies reported in the 
literature.55 
 
4.1.3.5 Analysis of Down-regulated Surface N-glycosylation Sites in Atorvastatin-treated Cells 
Among 84 surface proteins bearing 103 down-regulated glycosylation sites, we 
performed protein clustering using DAVID 6.7.50 Glycoproteins in the Alzheimer’s disease 
pathway were highly enriched, and glycoproteins and sites in this pathway are listed in Table 
4.1. Previous studies have shown inconsistent effects of statin use in AD.56 Some studies found 
beneficial effects,57 but others did not.58 Glycosylation defects in amyloid precursor protein 
(APP), tau, nicastrin and other proteins in AD were reported previously,59 and defective 
glycosylation may be important in AD pathogenesis, A prior study found that N-glycosylation 
of human nicastrin was required to interact with lectins, including calnexin and ERGIC-53.60 
In this study, N417 on nicastrin was quantified to be down-regulated by 5.4 fold. Furthermore, 
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proteins participating in immune response processes, such as response to wounding, external 





Figure 4.6 (a) Distribution of the quantified glycosylation sites on each peptide and protein, 
(b) ratio distribution of quantified unique glycopeptides, and (c) domain analysis of IGF2R and 













































We also performed domain analysis to correlate the localization of glycosylation sites 
and functional domains of proteins.61 Domains on proteins carry out a wide variety of functions 
or interactions. Investigating glycosylation site regulations within domains may provide useful 
information in biological events. For example, CD222, also called IGF2R, is a transporter of 
phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to the 
lysosome, and has 15 repeating cation-independent mannose-6-phosphate receptor domains 
(CIMR) (shown in green in Figure 4.6c). These domains specifically bind the 
phosphomannosyl residues on lysosomal enzymes. IGF2R also has a fibronectin type II domain 
(FN2) (shown in red) which serves as the binding site for collagens. All these domains are 
located in the extracellular space, as shown on the left of the transmembrane domain (TM), 
which is integrated into the cell plasma membrane. We have quantified four glycosylation sites 
(N112, N581, N1757, and N2136), among which three are localized within the CIMR domains 
with the other located at the N-terminal tail. These site abundances decreased to 53%, 42%, 
65%, and 45%, respectively, under the statin treatment, which may affect the interactions 
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By combining GalNAz labeling, click chemistry tagging, and MS-based proteomics, 
we found that many glycosylation sites on surface proteins were down-regulated in 
atorvastatin-treated HepG2 cells. Patients are typically prescribed the drug long-term (months 
to years). Here, we found that many surface protein glycosylation sites were down-regulated 
when cells were treated for only two days. Further studies, including time-course experiments 
and animal model experiments, will help us better understand the protein glycosylation changes 
caused by statin and the molecular mechanisms of its pleiotropic effects. 
 
Table 4.1 Down-regulated glycosylation sites quantified from proteins in the Alzheimer’s 
disease pathway (P=0.027) 
Gene 










SCK 1.89 4.69 594 76.7 0.03 
Disintegrin and 
metalloproteinase domain-
containing protein 17 KCQEAIN*ATCK -0.99 2.41 539 1000 0.21 
NCSTN RPN*QSQPLPPSSLQR 4.69 2.61 417 1000 0.18 
Nicastrin, Essential 






2.01 3.17 1050 5.3 0.24 
Prolow-density lipoprotein 
receptor-related protein 1 
QSGDVTCN*CTDGR -2.61 1.43 4364 1000 0.27 
CTQQVCAGYCAN*NS
TCTVNQGNQPQCR 0.55 5.40 4278 6.6 0.32 
CTQQVCAGYCANN*S
TCTVNQGNQPQCR@ -1.68 4.82 4279 6.6 0.32 
FAS CKPNFFCN*STVCEHCDPCTK 0.1 4.27 136 28.5 0.19 
Tumor necrosis factor 
receptor superfamily 
member 6 





*- glycosylation site; @-heavy arginine 
 
4.1.4 Conclusions  
Glycosylation changes on cell-surface proteins are hallmarks of many diseases, but 
global and site-specific analysis of cell-surface N-glycoproteins is extraordinarily challenging. 
In-depth analyses of the surface glycoproteome changes will potentially lead to clinical 
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applications, such as the identification of diagnostic and therapeutic targets. In this work, we 
compared labeling with three sugar analogs (GalNAz, ManNAz and GlcNAz) for the global 
analysis of surface glycoproteins, in combination with click chemistry tagging, selective 
enrichment, and MS analysis. The results clearly demonstrated that more protein glycosylation 
sites on the cell surface were identified with GalNAz labeling compared to GlcNAz or 
ManNAz. By using GalNAz labeling, surface protein N-glycosylation changes between statin-
treated and untreated cells were comprehensively and site-specifically analyzed in combination 
with quantitative proteomics. Many glycopeptides were down-regulated in statin-treated 
HepG2 cells compared to untreated cells because statin prevents the synthesis of dolichol, 
which is essential for the formation of dolichol-linked precursor oligosaccharides. Several N-
glycosylation sites on surface proteins related to Alzheimer’s disease were found to be down-
regulated. Site-specific information regarding surface proteins will provide insight into protein 
functions and also lead to a better understanding of the molecular mechanisms of statin’s 














4.2 Quantitative Investigation of Human Cell Surface N-Glycoprotein Dynamics 
  
4.2.1 Introduction 
Nearly all proteins on the cell surface are glycosylated, and surface glycoproteins are 
essential for cell survival.1 Protein glycosylation play crucial roles in a wide variety of 
extracellular activities, including antibody recognition, cell adhesion, microorganism binding, 
facilitating ligand binding and affecting receptor multimerization.62-68 Aberrant surface protein 
glycosylation impacts cellular properties, such as cell solubility and mobility, which is related 
to human disease,3, 69, 70 including cancer,5, 71 congenital disorders and infectious diseases.6, 72 
It has been long understood that the covalent attachment between glycans and proteins is 
extremely complicated because of the heterogeneity of glycan structures, which makes the 
comprehensive analysis of protein glycosylation challenging.14, 16, 45, 73-78 It is even more 
difficult to analyze glycoproteins only located on the cell surface. The elegant and pioneering 
work of using sugar analogs to engineer cell surface glycans and glycoproteins has opened a 
new avenue to study cell surface glycoproteins.9, 79 
Surface glycoproteins are dynamic for cells to adapt the ever-changing extracellular 
environment. The presence of glycans on proteins not only facilitates protein folding and 
trafficking, but also protects proteins from degradation.80-83 Glycans create a steric hindrance 
around the peptide backbone, which mechanically prevents proteases from properly binding to 
proteins. In addition, protein glycosylation also protects the protein backbone from being 
damaged or degraded through oxidation, chemical crosslinking, precipitation, and 
denaturation.84, 85 However, systematic study of glycoprotein dynamics and half-lives has yet 
to be reported, including the dynamics of crucial cell surface glycoproteins, due to the lack of 
effective methods. In recent years, MS-based proteomics enable the global analysis of proteins 
and protein modifications, including glycosylation.55, 86-95 Due to the complexity of biological 
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samples, effective separation and enrichment are required to comprehensively analyze every 
type of protein modification.71, 96, 97 In order to analyze glycoproteins located only on the cell 
surface, it is essential to selectively separate and enrich them from high abundance intracellular 
proteins prior to MS analysis.  
In this work, we have designed a method to target surface N-glycoproteins and quantify 
their half-lives by combining pulse-chase metabolic labelling, click chemistry, and multiplexed 
proteomics. A sugar analog, N-azidoacetylgalactosamine (GalNAz), was employed to label 
cells to generate a chemical handle for further surface glycoprotein tagging via copper-free 
click chemistry under mild physiological conditions. Pulse-chase labelling allowed us to track 
the abundance changes of cell surface glycoproteins while avoiding contribution from newly 
synthesized glycoproteins during the cell growth because they were not labelled with the 
functional azido group. After enrichment of tagged glycopeptides, six-plexed Tandem Mass 
Tag (TMT) reagents98 were used to label enriched glycopeptides at six different time points for 
quantification with MS-based proteomics. Eventually the glycoprotein abundance changes as 
a function of time were measured, and their half-lives were globally determined. This 
integrated method specifically targeting surface glycoproteins can be extensively applied to 
biological and biomedical research. 
 
4.2.2 Experimental section 
3.2.2.1 Cell culture, metabolic labeling, and copper-free click reaction 
MCF-7 cells (from American type culture collection (ATCC)) were equally seeded into 
twelve T175 cell culture flasks (Thermo) with Dulbecco's Modified Eagle's Mmedium 
(DMEM) (Sigma-Aldrich) containing 10% fetal bovine serum (FBS) (Thermo). Cells were 
grown in a humidified incubator with 5.0% CO2 at 37 °C. When cells reached 50% confluency, 
100 µM GalNAz (Click Chemistry Tools) was added to the media and cells were cultured for 
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another 24 h. Click reaction was then performed for all flasks. Briefly, cells were gently washed 
twice with phosphate buffered saline (PBS), then 100 µM dibenzocyclooctyne (DBCO)-sulfo-
biotin in DMEM was added into the cell culture flasks. Cells were incubated for 1 h at 37 °C, 
and then washed twice using PBS. The media were then switched to normal DMEM with 10% 
FBS and different flasks were further cultured for 0, 2, 4, 6, 8, and 10 hours. Cells were pelleted 
by centrifugation at 300 g for 5 minutes, and washed twice with cold PBS. Cells were then 
incubated in a buffer containing 150 mM NaCl, 50 mM HEPES pH=7.6, 25 µg/mL digitonin, 
and 1 tablet/ 10 mL protease inhibitor (Complete mini, EDTA-free, Roche) on ice for 10 
minutes. Cytosolic proteins were removed by centrifuging the samples at 2500 g for another 
10 minutes and discarding the supernatant.  Cell pellets were lysed through end-over-end 
rotation at 4 ºC for 45 minutes in lysis buffer (50 mM HEPES pH=7.6, 150 mM NaCl, 0.5% 
SDC, 10 units/mL benzonase and 1 tablet/ 10 mL protease inhibitor). Lysates were centrifuged, 
and the resulting supernatant was transferred to new tubes. Proteins were subjected to disulfide 
reduction with 5 mM DTT (56 ºC, 25 minutes) and alkylation with 14 mM iodoacetamide (RT, 
20 minutes in the dark). Detergent was removed by methanol-chloroform protein precipitation. 
The purified proteins were digested with 10 ng/µL Lys-C (Wako) in 50 mM HEPES pH=8.6, 
1.6 M urea, 5% ACN at 31 ºC for 16 hours, followed by further digestion with 8 ng/uL Trypsin 
(Promega) at 37 ºC for 4 hours. 
 
4.2.2.2 Glycopeptide separation and enrichment  
Digestion mixtures were acidified by addition of trifluoroacetic acid (TFA) to a final 
concentration of 0.1%, clarified by centrifugation and desalted using a tC18 Sep-Pak cartridge 
(Waters). Purified peptides were dried and then enriched with NeutrAvidin beads (Thermo) at 
37 °C for 30 minutes. The samples were transferred to spin columns, followed by thoroughly 
washing according to the manufacturer’s protocol. Peptides were then eluted from the beads 
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three times by 2-min incubations with 200 µL of 8 M guanidine-HCl (pH = 1.5) at 56 °C. 
Eluates were combined, desalted using tC18 Sep-Pak cartridge, and lyophilized.  
 
4.2.2.3 TMT labelling and PNGase F cleavage 
Purified peptides from each of the six time points were labelled with one of the sixplex 
TMT reagents (Thermo) following the manufacturer’s protocol. Briefly, purified and 
lyophilized peptides were dissolved in 100 µL of 100 mM triethylammonium bicarbonate 
(TEAB) buffer, pH= 8.5. Each tube of TMT reagents was dissolved in 41 µL of anhydrous 
DMSO and transferred into the peptide tube. The reaction lasted for 1 h at room temperature, 
and then was quenched by adding 8 µL of 5% hydroxylamine. Peptides from all six tubes were 
then mixed, desalted again using a tC18 Sep-Pak cartridge, and lyophilized overnight. 
Completely dried peptides were deglycosylated with eight units of peptide-N-glycosidase F 
(PNGase F, Sigma-Aldrich) in 40 µL buffer containing 50 mM NH4HCO3 (pH=9) in heavy-
oxygen water (H218O) for 3 h at 37 °C. The reaction was quenched by adding formic acid (FA) 
to a final concentration of 1%. Peptides were further purified via stage tip and separated into 
three fractions using 20%, 50% and 80% ACN containing 1% HOAc, respectively.  
 
4.2.2.4 LC-MS/MS analysis  
Purified and dried peptide samples were dissolved in 13 µL of solvent containing 5% 
ACN and 4% FA, and 4 µL of dissolved sample were loaded onto a microcapillary column 
packed with C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, Michrom Bioresources) 
by a Dionex WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid Separation 
Pulled Loop Wellplate Sampler). Peptides were separated by reversed-phase chromatography 
using an UltiMate 3000 binary pump with a 112-minute gradient of 1-12%, 3-14%, or 3-24% 
ACN (with 0.125% FA) for the three fractions. Peptides were detected with a data-dependent 
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Top15 method 99  in a hybrid dual-cell quadrupole linear ion trap – Orbitrap mass spectrometer 
(LTQ Orbitrap Elite, ThermoFisher, with Xcalibur 3.0.63 software). For each cycle, one full 
MS scan (resolution: 60,000) in the Orbitrap at 106 AGC target was followed by up to 15 
MS/MS for the most intense ions. The selected ions were excluded from further analysis for 90 
seconds. Ions with single or unassigned charge were discarded. MS2 scans were performed in 
the orbitrap cell by activating with high energy collision dissociation (HCD) at 40% normalized 
collision energy with 1.2 m/z isolation width.  
 
4.2.2.5 Database search and data filtering 
All MS2 spectra were converted into an mzXML format, and then searched using the 
SEQUEST algorithm (version 28).37 Spectra were matched against a database containing 
sequences of all proteins in the UniProt Human (Homo sapiens) database (downloaded in 
February 2014).  The following parameters were used during the search: 10 ppm mass 
tolerance; fully digested with trypsin; up to 2 missed cleava ges; fixed modifications: 
carbamidomethylation of cysteine (+57.0214), TMT modification of lysine (+229.1629) and 
N-terminus (+229.1629); variable modifications: oxidation of methionine (+15.9949), 18O tag 
on asparagine (+2.9883). False discovery rates (FDR) of peptide and protein identifications 
were evaluated and controlled by the target-decoy method.38 Each protein sequence was listed 
in both forward and reversed orders. Linear discriminant analysis (LDA), which is similar to 
other methods in the literature,39 was used to control the quality of peptide identifications using 
parameters such as Xcorr, precursor mass error, and charge state.40 Peptides fewer than seven 
amino acid residues in length were deleted. Furthermore, peptide spectral matches were filtered 
to <1% FDR. The dataset was restricted to glycopeptides when determining FDRs for 
glycopeptide identification.41 Furthermore, an additional protein-level filter was applied in 
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each dataset to reduce the protein-level FDRs (<1%) for glycoproteins. Consequently the FDRs 
at the glycopeptide level were much less than 1%. 
 
4.2.2.6 Glycosylation site localization, glycopeptide quantification, and bioinformatics 
analysis 
The confidence associated with each glycosylation site localization was represented by their 
ModScore, which is calculated from a probabilistic algorithm.41 ModScore is similar to 
AScore,41 and it considers all possible modification sites in a modified peptide, and matches 
the fragments with theoretical fragments from the peptide with potential modification sites. If 
the ModScore for a residue is relatively high, then the probability of modification occurred on 
that site is also high. Conversely, there may be a low score for potential sites, which means that 
there are not sufficient fragments to confidently locate the modification site. Sites with 
ModScore > 13 (P <0.05) were considered as confidently localized. The TMT reporter ion 
intensities obtained in MS2 were recorded and calibrated prior to performing glycopeptide 
quantification. If the same glycopeptide was quantified several times, the median value was 
used as the glycopeptide abundance change. The protein ratio was calculated based on the 
median ratios of all unique glycopeptides. Protein annotations were extracted from the UniProt 
database (http://www.uniprot.org). The Database for Annotation, Visualization and Integrated 
discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/home.jsp)100 was employed to perform 
functional analysis. All raw files and annotated spectra are accessible in the following public 








4.2.3.1 The principle of surface glycoprotein enrichment and identification 
The incorporation of bio-orthogonal groups into proteins or modified proteins has 
recently been demonstrated to be very effective to study proteins in complex biological 
systems.9, 33, 101-108 In this work glycoproteins were labelled with a sugar analog containing a 
biologically inert but chemically functional azido group, and the labelled surface glycoproteins 
in living cells were specifically tagged with biotin via copper-free click chemistry (Figure 4.8). 
Here we performed click reaction prior to medium switch, which can eliminate potential 
negative effects from cells using stored GalNAz and protein internalization on protein half-life 
quantification. After cell lysis and protein digestion, only biotin-tagged glycopeptides were 
selectively enriched with NeutrAvidin beads through specific biotin-avidin interactions. 
Enriched and purified samples were analyzed by an online LC-MS system, and both full MS 
and MS2 were recorded in the Orbitrap cell with high resolution and high mass accuracy.  
The TMT method enables the identification and quantitation of glycopeptides and 
glycoproteins in different samples in combination with tandem mass spectrometry (MS). The 
tags contain four regions, namely a mass reporter region, a cleavable linker region, a mass 
normalization region and a protein/peptide reactive group. In this case, the reactive group of 
N-hydroxysuccinimide (NHS) can react quickly with the amine group at the N-terminus and 
the side chain of the lysine residue for every peptide. Each of six samples was tagged with one 
channel of TMT reagents, then mixed. For the same peptide in six samples, they all carry 
isobaric tags, and have the same elution time and m/z in the full mass spectra. When peptides 
are fragmented, the reporter ion generated from tagged peptide will have an intensity 
proportional to the peptide amount in each sample. Eventually peptide backbone fragments 
allow us to identify peptides and the reporter ion intensities enable us to quantify the peptide 





Figure 4.8 Experimental procedure for studying surface glycoprotein dynamics and measuring 
their half-lives.  
 
An example of peptide identification and quantification is displayed in Figure 4.9(a). 
The peptide N#VSVAEGK (# denotes the glycosylation site) was confidently identified with 
an XCorr of 3.2. The XCorr value is the cross-correlation value from the SEQUEST search, 
which reflects how good the match between theoretical and experimental tandem mass spectra 
is. XCorr values are usually higher for well-matched, large peptides, and lower for smaller 
peptides. Considering the short length of this peptide, this XCorr value can allow us to 
confidently identify this glycopeptide, and as shown in Figure 4.9(a), nearly all y and b ions 
were detected. The ModScore for the glycosylation site (N286) is 1000 because there is only 
one possible site localization. This peptide is from PTGFRN, which is a well-known receptor 
regulator located on the cell surface.109 The reporter ion intensities enabled us to accurately 
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quantify the glycopeptide abundance changes as a function of time (Figure 4.9(a), left insert). 
Correspondingly we were able to calculate the half-life of 15.5 h based on the abundance 
changes (Figure 4.9(a), right insert).  
Here in duplicate experiments, we identified a total of 545 unique glycosylation sites 
on 265 glycoproteins (listed in tables online at doi.org/10.1039/C6SC01814A), and most of 
them (480 sites) were well localized with a ModScore >13. The overlap of unique glycosylation 
sites identified between two replicates is around 80% across all identification and 
quantification results (Figure 4.9(b) and (c)), which demonstrated that the current method is 
highly reproducible. The majority of unique glycopeptides contained a single glycosylation 
site, and there are a small group of proteins bearing more than five sites, including IGF1R, 
ECE1, LAMP1, CELSR2, PLXNB2, CEACAM5, ITGB1, and PTPRJ. For example, IGF1R, 
a receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1) located 
on plasma membrane. Here we identified eleven glycosylation sites: N244, N314, N607, N622, 
N638, N640, N747, N756, N764, N900, and N913. All these sites exist in the extracellular 




Figure 4.9 An example of glycopeptide identification and quantification and the comparison 
of identified unique glycosylation sites and quantified surface glycoproteins. (a) Example MS 
showing peptide identification and quantification. Based on the fragments, we were able to 
confidently identify the glycopeptide N#VSVAEGK (# denotes the glycosylation site) from 
the protein PTGFRN, and based on the reporter ion intensities, the half-life of this glycopeptide 
was 15.5 hours. (b) Comparison of the unique surface protein glycosylation sites identified in 
two parallel experiments. (c) Comparison of the quantified surface glycoproteins in duplicate 
experiments. 
 
We clustered the identified glycoproteins according to cellular compartment and 
pathway using the Database for Annotation, Visualization, and Integrated Discovery 6.7 




































































highly enriched, including intrinsic to membrane (P=1.80*10-81), plasma membrane (8.50*10-
49), cell surface (6.20*10-20), external side of the plasma membrane (5.50*10-14), and receptor 
complex (6.20*10-11). Among the pathways, the ECM-receptor interactions (5.60*10-11) and 
cell adhesion molecules (CAMs) (1.30*10-10) pathways were prominently enriched. CAMs are 
cell-surface proteins involved in binding with the extracellular matrix (ECM) or with other 
cells during cell adhesion. These enriched categories are consistent with the expected functions 
of cell-surface glycoproteins. 
 
Figure 4.10 Clustering of surface glycoproteins identified in this work. (a) Cellular 
compartments, and (b) pathways. 
 
4.2.3.2 Site location of type I and II glycoproteins based on the transmembrane domain 
The site-specific virtue of our method allowed us to localize each glycosylation site in 
this experiment. In Figure 4.11, we illustrated the site localization on type I and II 
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transmembrane glycoproteins identified in this experiment. Type I transmembrane proteins 
have their N-termini located in the extracellular space while type II transmembrane proteins 
have their C-termini located in the extracellular space. As shown in Figure 4.11, the x-axis 
represents the transmembrane (TM) domain of any proteins, and the y-axis denotes the number 
of amino acid residues away from the transmembrane domain. The space above the x-axis is 
the extracellular space and below is the intracellular space. Each line depicts a protein, and the 
yellow dots represent the glycosylation sites.  
 
 
Figure 4.11 Site location of the type I and II N-glycoproteins based on the transmembrane 
domain (TM). We aligned each glycoprotein according to their transmembrane domain, which 
is known to be anchored in the plasma membrane, and each yellow dot refers to one 
glycosylation site. 
 
All glycosylation sites are clearly located in the extracellular space, which is in 
agreement with the experimental design and the common belief that glycans on surface proteins 










































type II, which corresponds well to the ratio of type I and II transmembrane proteins in UniProt 
(www.uniprot.org). 
 
4.2.3.3 Quantification of surface glycoprotein abundance changes 
Enriched peptides in each sample were labelled with one of six TMT reagents. TMT 
labelling allowed us to quantify multiple samples at once. Here we measured six samples from 
six time points simultaneously. This can dramatically increase the experimental throughput and 
reduce potential quantification errors. The starting amount of labelled surface glycoproteins 
was similar for each sample before the medium was switched. Based on this, we then quantified 
these surface glycoprotein abundance changes as a function of time. The six groups of TMT-
labelled glycopeptides were mixed and subjected to PNGase F cleavage in heavy-oxygen water 
(H218O) to generate a common tag (+2.9883 Da) for MS analysis.45 This enabled us to 
distinguish authentic N-glycosylation sites from those caused by the naturally occurred 
deamidation of Asn. Finally, the peptide mixture was purified and loaded into an online LC-
MS system for further analysis.  
The TMT reporter ion intensities in the MS2 provided us an opportunity to accurately 
measure the abundance changes of glycopeptides from different time points. Potential 
interferences from TMT labelling were likely avoided in this experiment because these samples 
were much simpler than whole cell lysates since surface glycoproteins only represent a very 
small portion of the whole proteome, and we also further fractionated the mixed sample into 
three fractions. Furthermore, long LC gradients were used to separate each fraction. Because 
the abundances of the same glycopeptide from six samples can be measured in one MS2 
spectrum, this dramatically lowered the measurement error. In some cases, for instance, if one 
of the six TMT channels has abnormal signal intensity, then it will be dropped and the half-life 




4.2.3.4 Measurement of surface glycoprotein half-lives 
Based on the abundance changes of glycopeptides at six time points, their half-lives 
were simulated by the following exponential decay equation, as performed previously:99, 110 
P(t) = P0*exp(-kt) 
where P0 is the intensity of the reporter ion at the first time point, P(t) is the intensity of the 
reporter ion at each subsequent time point, k is the degradation rate constant and t is time. In 
duplicate experiments, we quantified 522 unique glycopeptides(ModScore>13); the vast 
majority of them (484 glycopeptides) contained a single glycosylation site. 
In the duplicate experiments, we quantified 386 glycosylation sites (listed in tables 
online at doi.org/10.1039/C6SC01814A) based on two criteria: glycopeptides were singly 
glycosylated and the ModScore was larger than 13. If a glycoprotein contained two or more 
unique glycosylation sites, the half-life refers to the median half-life of the mixed different 
glycoforms. The half-life values for the 248 glycoproteins were determined, and are listed in 
tables online at doi.org/10.1039/C6SC01814A. We plotted the half-lives of glycosylation sites 
in replicate 1 against those in replicate 2 (Figure 4.12(a)), and good linear simulation and a 
high R2 value were obtained. The reproducibility is much better when the half-lives are 




Figure 4.12 (a) Distribution of the half-lives of surface glycoproteins. (b) Comparison of the 
half-lives of surface protein glycosylation sites measured in the duplicate experiments. (c) The 
median half-lives of glycoproteins with different molecular functions. Proteins with receptor 
and transducer activities have the shortest median half-life (17.8 h), while proteins with 



































































The distribution of the half-lives of surface glycoproteins is shown in Figure 4.12(b). 
Most proteins have a half-life between 10-30 h. A total of 39 glycoproteins have a half-life of 
less than 10 h, while about one fifth of glycoproteins (46) have a half-life of longer than 100 h. 
The median half-life of all glycoproteins quantified in our experiment was 19.6 h, which is 
much longer than the half-life of 8.7 h for over 800 newly synthesized proteins in our previous 
work,99 and also longer than a half-life of 8.2 h for 100 proteins measured with a MS-
independent method.111 This is consistent with the assumption that glycans can stabilize 
proteins by preventing them from being degraded.   
The functions associated with relatively long- or short-lived proteins were also 
investigated. Proteins with a half-life longer than 100 h or shorter than 10 h were clustered 
according to biological processes (Figure 4.13). While cell adhesion is enriched in both 
categories, notably, positive regulation of catalytic activity is enriched among long-lived 
proteins.  
The median half-lives for proteins with various molecular functions were examined. As 
shown in Figure 4.12(c), the median half-life of proteins with receptor activity (17.8 h), 
molecular transducer activity (17.8 h), and binding activity (19.5) is very similar to the overall 
protein median half-life (19.6 h), while proteins related to catalytic activity (do not include 
receptor tyrosine kinases since they only have intracellular catalytic activities) have a longer 
median half-life of 40.0 h, which suggests that glycan may protect enzymes on the cell surface 







Figure 4.13 (a) Biological processes of relatively short-lived glycoproteins (half-life <10 h). 
(b) Biological processes of relatively long-lived glycoproteins (half-life >100 h).   
 
4.2.3.5 Half-lives of glycosylation sites within or outside of domains 
Among 386 quantified glycosylation sites, nearly half of them (170 sites) were located 
in different domains based on the domain information on UniProt, while 216 sites were not 
located in any protein domains. The median half-life for the 216 sites located outside of any 
domain is 21.5 h, which is 21% longer than that the median half-life of 170 sites located within 
a specific domain (17.7 h), as shown in Figure 4.14(a). The domains containing the greatest 
number of quantified glycosylation sites are Ig-like, fibronectin type-III, cadherin, and sema 
domains, which are shown in Figure 4.14(b), along with their median half-lives. These domains 
are frequently contained in cell surface proteins, and play crucial roles in regulating cell-matrix 



















like domain with a median half-life of 19.0 h. The median half-life of sites located in the 
cadherin domain is only 11.0 h, which is dramatically shorter than the median half-life of 21.5 
h for sites located outside of any domain. These results suggest that glycans located within a 
domain may play a major role in regulating protein interactions with other molecules, while 





Figure 4.14 (a) Comparison of median half-lives for sites located outside domains and within 





















































4.2.3.6 Half-lives of CD proteins and receptors 
Cluster of differentiation (CD) molecules are of great biomedical significance because 
they serve as cell markers in immunophenotyping to distinguish and classify cells.112 CDs refer 
not only to proteins but can also be assigned to lipid and glycans on the cell surface. Among 
all of the glycoproteins quantified here, 62 are CD proteins (Table 4.2 and a table online at 
doi.org/10.1039/C6SC01814A). The site-specific nature of this method provides an avenue to 
quantify the real glycosylated form of proteins. For example, we identified the glycosylation 
site N365, N381, and N424 on CD98, which is involved in sodium-independent, high-affinity 
transport of large neutral amino acids. The half-life of the glycosylated form of CD98 is 27.2 
h, which is much longer than the half-life (10.1 h) in the literature.99 Furthermore, the half-life 
of CD71 (Transferrin receptor protein 1) is 18.3 h in this work for its glycoform on the cell 
surface, while the half-life of this protein was reported to be 4.4 h previously.99 Glycosylated 
and non-glycosylated forms of a protein coexist at any given time. Traditional gel-based or 
MS-based methods measure the half-life of the mixed glycosylated and non-glycosylated forms 
of a protein, but here we were able to measure the half-lives of only the glycosylated form of 
each protein because only surface glycoproteins were separated and analyzed.  
 
4.2.4 Discussion 
Mammalian cell surface is typically covered with sugars, and these sugars may be 
bound to lipids or proteins. Glycoproteins located on the cell surface regulate nearly every 
extracellular activity. Systematic and quantitative analysis of surface glycoproteins can aid in 
a better understanding of protein structure, properties and functions and also cellular activities. 
Due to the heterogeneity of glycans and low abundance of many glycoproteins, it is extremely 
challenging to globally identify and quantify glycoproteins in complex biological samples.97 It 
is even much more challenging to specifically analyze surface glycoproteins. Fluorescence 
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experiments have obtained very valuable information about cell surface glycans.113 However, 
it is hard to identify which proteins are bound to glycans and the exact glycosylation sites. MS-
based proteomics provides the possibility to identify and quantify glycoproteins, but in order 
to analyze surface glycoproteins, selective enrichment of surface glycoproteins is required prior 
to MS analysis. It has remained a daunting task to systematically investigate cell surface 
glycoproteins dynamic, and to date, it has yet to be reported. Integrating pulse-chase metabolic 
labelling, selective enrichment of surface glycoproteins, and multiplexed proteomics, for the 
first time, we site-specifically and systematically quantified surface glycoprotein abundance 
changes as a function of time, and measured their half-lives.  
 












P02786 TFRC CD71 18.3 4.499 Transferrin receptor protein 1 
P05556 ITGB1 CD29 24.2  Integrin beta-1 
P08069 IGF1R CD221 12.6  Insulin-like growth factor 1 
receptor 
P08195 SLC3A2 CD98 27.2 10.199 4F2 cell-surface antigen heavy 
chain 
P08962 CD63 CD63 24.2  CD63 antigen 
P25445 FAS CD95 39.1  Tumor necrosis factor receptor 
superfamily member 6 
P26006 ITGA3 CD49c 37.3  Integrin alpha-3 
P48960 CD97 CD97 13.2  CD97 antigen 
P54709 ATP1B3 CD298 61.1  Sodium/potassium-transporting 
ATPase subunit beta-3 
P78536 ADAM17 CD156b 112.7  Disintegrin and metalloproteinase 
domain-containing protein 17 
[a] Half-lives of corresponding proteins reported in the literature. 
  
Besides protein degradation, other contributions to cell surface glycoprotein dynamics 
include protein internalization/recycling, and deglycosylation. By tagging surface 
glycoproteins immediately before the medium switch, the effect of protein internalization on 
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the measurement of protein half-lives was able to be avoided because even though a protein 
was internalized, the biotin tag can ensure that it will be eventually analyzed. In other cases, 
when deglycosylation event happens, the protein will turn into a non-glycoprotein, which does 
not fit into our experimental subject and thus will not be enriched and analyzed. 
One limitation of this method is that proteins with very long half-lives might not be 
accurately determined because the full length of the time course may only cover the very 
beginning of the simulation curve, thus a minor variation could result in a large error. We 
applied a 200 h cut-off value to those long-lived proteins, namely, any protein with a half-life 
longer than 200 h was included in the >200 h category. Although this category did not present 
actual half-life values, it still indicates that these glycoproteins are very stable. Since the 
majority of the glycoproteins have half-lives shorter than 200 h, this category did not affect the 
calculation of the median half-life nonetheless. 
The current experimental results have clearly demonstrated that glycans can more 
effectively protect enzymes than receptors and binding proteins located on the cell surface from 
being degraded, because proteins related to catalytic activity have a long median half-life of 
40.0 h (quantified surface enzymes are listed in a table online at 
doi.org/10.1039/C6SC01814A). It is well-known that there are many proteases in the 
extracellular space, but these quantified surface enzymes were still relatively more stable. For 
example, for GAPDH (glycerolaldehyde-3-phosphate dehydrogenase), it has both 
glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thus playing a role in 
glycolysis and nuclear functions, respectively. In our previous work, its half-life was measured 
to be 10.4 h.99 Here its glycoform located on the cell surface are extraordinarily stable with a 
half-life of more than 200 h. Proteins in the mitochondria or nuclei typically have a longer half-
life because proteins located in these compartments may avoid being accessed by many 
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proteases. Cell surface proteins are exposed to different environments, but glycans on surface 
proteins may provide one layer of protection, especially for proteins with catalytic activity. 
 
4.2.5 Conclusions 
We have designed the first method to target surface glycoproteins, site-specifically 
study their dynamics and measure their half-lives by incorporating metabolic labelling, click 
chemistry, and TMT tagging. The current method has several advantages. Firstly, only surface 
glycoproteins were selectively tagged and enriched for MS analysis. Secondly, site-specific 
protein glycosylation information was obtained in this work, and only authentic glycosylated 
forms of proteins were analyzed. Thirdly, multiplexed proteomics enabled to quantify 
glycoproteins at several time points simultaneously, increasing the accuracy of measuring 
protein abundance changes and the corresponding half-lives. Furthermore, the high throughput 
MS-based experiment allowed us to systematically study surface glycoprotein dynamics.  
By using this new method, we quantified 248 surface glycoprotein dynamics with the 
median half-life was 19.6 h, which is over two times longer than that of newly synthesized 
proteins measured in our recent work (8.7 h).99 The median half-life of glycopeptides with sites 
located outside of any domain is longer than that of glycopeptides with sites within different 
domains. Surface glycoproteins corresponding to catalytic activities were more stable with the 
median half-life of 40.0 h. Although there are many proteases outside of the cells, glycans can 
effectively protect surface enzymes from being degraded. Investigation of surface glycoprotein 
dynamics can aid in better understanding their properties and functions. This method can be 
extensively applied to investigate surface glycoproteins and their dynamics in biological and 
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CHAPTER 5. GLOBAL AND SITE-SPECIFIC ANALYSIS REVEALING 
UNEXPECTED AND EXTENSIVE PROTEIN S-GLCNACYLATION 
IN HUMAN CELLS 
 
Partially adapted with permission from American Chemical Society  
Xiao, H. P., and Wu, R. H. Global and Site-Specific Analysis Revealing Unexpected and 
Extensive Protein S-GlcNAcylation in Human Cells. Analytical Chemistry, 2017, 89, 3656-
3663. Copyright 2017 American Chemical Society.  
 
5.1 Unexpected Observation of Protein S-GlcNAcylation in Human Cells 
 
5.1.1 Introduction 
Glycosylation is one of the most common and diverse protein modifications, and is 
essential for mammalian cell survival.1-3 Heterogeneous protein glycosylation contains a 
wealth of information regarding the cellular developmental and diseased statuses. Aberrant 
protein glycosylation is directly related to human disease, such as cancer and infectious 
diseases.4, 5 However, heterogeneity of glycosylation renders their study much more 
challenging compared to many other types of protein modification.6, 7 Investigation of protein 
glycosylation can aid in a better understanding of protein function, cellular activity, and the 
molecular mechanisms of disease.  
N-acetylglucosamine (GlcNAc) was discovered to be bound to the side chains of serine 
and threonine over three decades ago,8 termed O-GlcNAcylation, and was regulated by O-
GlcNAc transferase (OGT)9 and O-GlcNAc amidase (OGA).10 This modification is involved 
in many cellular events, from regulation of signal transduction to gene expression.10, 11 The 
same glycan (GlcNAc) has recently been found to be attached to the side chain of cysteine in 
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bacteria,12 which is named as protein S-GlcNAcylation. Glycocin F, a 43-amino acid 
bacteriocin from Lactobacillus plantarum, contains two beta-linked GlcNAc moieties, attached 
through side chain linkages to a serine via oxygen, and to a cysteine via sulfur.12 This 
modification has just been reported in rat and mouse samples, and 14 modification sites in 11 
proteins were identified.13 In the same report, recombinant Host Cell Factor 1 isolated from 
HEK cells was identified to be S-GlcNAcylated.13 Compared to O-GlcNAcylation, S-
GlcNAcylation remains to be explored.  
Modern mass spectrometry (MS)-based proteomics provides a unique opportunity to 
comprehensively and site-specifically analyze protein modifications,14-26 which is beyond the 
reach of conventional biochemistry methods. Due to the fact that many modified proteins have 
low abundance, it is critical to separate and enrich proteins or peptides with the modified group 
of interest prior to MS analysis.27-32 In order to globally analyze protein O-GlcNacylation, 
several methods were reported to enrich O-GlcNAcylated proteins/peptides from complex 
biological samples. Mild beta-elimination followed by Michael addition with dithiothreitol 
(BEMAD) was employed for global analysis of protein O-GlcNAcylation.33 Lectins or 
antibodies were also used to enrich glycoproteins/glycopeptides for MS analysis. 14, 34, 35 An 
elegant chemoenzymatic approach was developed by exploiting an engineered 
galactosyltransferase enzyme to selectively label O-GlcNAc proteins with a ketone-biotin tag, 
which permits enrichment of low-abundance O-GlcNAc species from complex mixtures.36, 37 
The enzymatic reaction combined with click chemistry was further developed to enrich O-
GlcNAcylated peptides for MS analysis.15, 38 A sugar analog (N-azidoacetylglucosamine 
(GlcNAz)) was also used to feed cells and label glycoproteins for visualization and MS analysis. 
39, 40 Currently bio-orthogonal chemistry is very powerful in investigating proteins and protein 
modifications.41-44 In combination with metabolic labeling and MS-based proteomics, global 
analysis of protein modification may be achieved. In order to analyze protein modification site-
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specifically, an effective cleavable linker is required, and the tag after cleavage must be 
relatively small to be compatible with MS analysis. Site-specific analysis provides not only 
valuable information about the modification site but also solid experimental evidence of protein 
modification.  
In this work, unexpected S-GlcNAcylation on cysteine residues was demonstrated to 
extensively exist in human cells through global and site-specific analysis of protein 
GlcNAcylation. This result was further confirmed by different independent experiments. Motif 
analysis showed that the modified cysteine sites surrounded with an acidic amino acid residue 
(D or E) are highly enriched, which strongly suggests that a particular type of enzyme is 
responsible for this modification and has a preference for the sites surrounded by acidic amino 
acids. Protein clustering results showed that glycoproteins with well-localized S-
GlcNAcylation sites are involved in the regulation of cell-cell interactions and gene expression. 
For the first time, the global and site-specific analysis unraveled extensive protein S-
GlcNAcylation existing in human cells.   
 
5.1.2 Experimental section 
5.1.2.1 Cell culturing and metabolic labeling 
MCF-7 cells (from American type culture collection (ATCC)) were grown in a 
humidified incubator at 37 °C and 5.0% CO2 in Dulbecco's modified eagle's medium (DMEM) 
(Sigma-Aldrich) containing 10% fetal bovine serum (FBS) (Thermo). When cells reached 
~60% confluency, the media was switched to DMEM containing 10% dialyzed FBS with 250 
µM N-azidoacetylglucosamine-tetraacylated (GlcNAz) (Click Chemistry Tools). Cells were 
metabolically labeled in this media for 36 h and then treated with 50 µM O-(2-Acetamido-2-
deoxy-D-glucopyranosylidenamino)N-phenylcarbamate (PUGNAc) (Cayman Chemicals) for 
two hours before harvest. 
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5.1.2.2 Cell lysis, Copper-catalyzed azide alkyne cycloaddition (CuAAC), and protein 
digestion 
Cells were washed three times with phosphate buffered saline (PBS) to remove GlcNAz 
and then harvested by scraping. The cell mixtures were pelleted by centrifugation at 300 g for 
5 minutes and washed twice with cold PBS. Cell pellets were lysed through end-over-end 
rotation at 4 ºC for 45 minutes in lysis buffer (50 mM HEPES pH=7.4, 150 mM NaCl, 0.5% 
sodium deoxycholate (SDC), 25 units/mL benzonase, 100 µM PUGNAc, and 1 tablet/ 10 mL 
protease inhibitor (Roche)). Lysates were centrifuged, and the resulting supernatant was 
transferred to new tubes to perform CuAAC. Briefly, bis-N-[1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)ethyl]  (DDE)-biotin-alkyne (Click Chemistry Tools) was dissolved in 
DMSO and added to the cell lysate to a final concentration of 250 µM. For the experiment 
using the photocleavable (PC) linker, PC-biotin-alkyne (Click Chemistry Tools) was added 
into the cell lysate to the same final concentration. At the same time, CuSO4 and tris(3-
hydroxypropyltriazolylmethyl) amine (THPTA) were added to the lysate to final 
concentrations of 1 mM and 5 mM, respectively. Finally, sodium ascorbate was freshly 
prepared and added to the lysis mixture at a concentration of 15 mM to initiate the reaction. 
The reaction vessel was covered with aluminum foil, and then placed onto an end-over-end 
rotor at room temperature, and rotated for 2 h. Since DDE-biotin-alkyne is cleavable by strong 
reducing reagent such as dithiothreitol (DTT), reduction and alkylation of disulfide bonds were 
not performed. SDC was removed by the methanol-chloroform protein precipitation method. 
The purified proteins were digested with 10 ng/µL Lys-C (Wako) in 50 mM HEPES pH 8.6, 
1.6 M urea, 5% ACN at 31 ºC for 16 hours, followed by further digestion with 8 ng/uL Trypsin 





5.1.2.3 Glycopeptide separation and enrichment 
Digestion mixtures were acidified by the addition of trifluoroacetic acid (TFA) to a 
final concentration of 0.1%, clarified by centrifugation, and desalted by using a tC18 Sep-Pak 
cartridge (Waters). Purified peptides were dried and then enriched with NeutrAvidin beads 
(Thermo) at 37 °C for 30 min in 100 mM PBS. The samples were transferred to spin columns 
and washed thoroughly according to the manufacturer’s protocol. Peptides were then eluted 
from the beads through incubation with 2% hydrazine in 100 mM sodium phosphate for 2 
hours, and then washed twice with the elution buffer. Eluates were combined and acidified by 
adding TFA, desalted using tC18 Sep-Pak cartridge, and lyophilized. Dried peptides were 
dissolved in 1% formic acid (FA), purified further with a stage-tip, and separated into 3 
fractions using 20%, 50% and 80% ACN containing 1% HOAc. 
 
5.1.2.4 LC-MS/MS analysis  
Purified and dried peptide samples were dissolved in a 9 µL solution of 5% ACN and 
4% FA each. 4 µL of the resulting solutions were loaded onto a microcapillary column packed 
with C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, Michrom Bioresources) by a 
Dionex WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid Separation Pulled 
Loop Wellplate Sampler). Peptides were separated by reversed-phase chromatography using 
an UltiMate 3000 binary pump with a 110 min gradient of 3-22%, 8-35%, 12-45% ACN (with 
0.125% FA), respectively, for three fractions. Peptides were detected with a data-dependent 
Top20 method in a hybrid dual-cell quadrupole linear ion trap - Orbitrap mass spectrometer 
(LTQ Orbitrap Elite, ThermoFisher, with Xcalibur 3.0.63 software). For each cycle, one full 
MS scan (resolution: 60,000) in the Orbitrap at 106 AGC target was followed by up to 20 
MS/MS in the LTQ for the most intense ions. The selected ions were excluded from further 
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analysis for 90 seconds. Ions with singly or unassigned charge were not sequenced. Maximum 
ion accumulation times were 1000 ms for each full MS scan and 50 ms for MS/MS scans. 
5.1.2.5 Database search and data filtering 
All MS2 spectra were converted into mzXML files, and then searched using the 
SEQUEST algorithm (version 28).45 Spectra were matched with sequences of all proteins in 
the UniProt Human (Homo sapiens) database.  The following parameters were used during the 
search: 10 ppm precursor mass tolerance, 1.0 Da product ion mass tolerance, fully digested 
with trypsin, up to three missed cleavages. The variable modifications: oxidation of methionine 
(+15.9949), tag of GlcNAcylation on serine, threonine, and cysteine (+299.12297). False 
discovery rates (FDR) of peptide and protein identifications were evaluated and controlled by 
the target-decoy method.46, 47 Each protein sequence was listed in both forward and reverse 
orders. Linear discriminant analysis (LDA) was used to control the quality of peptide 
identifications using the following parameters: XCorr, differential sequence dCN, missed 
cleavages, ppm, precursor mass error, peptide length, and charge states. Peptides shorter than 
seven amino acid residues in length were deleted. Furthermore, peptide spectral matches were 
filtered to 1% FDR. The dataset was restricted to GlcNAcylated peptides when determining 
FDR for glycopeptide identification. In order to increase the identification confidence, we 
further filtered the dataset to less than 1% FDR at the glycoprotein level, and in this case, the 
FDR for glycopeptide identification is much less than 1%. 
 
5.1.2.6 GlcNAcylation site localization and quality control 
We assigned and measured the confidence of glycosylation site localizations by 
calculating the corresponding ModScores, which applies a probabilistic algorithm that 
considers all possible glycosylation sites in a peptide and uses the presence of experimental 
fragment ions unique to each site.48, 49 Sites with ModScore > 13 (P < 0.05) were considered 
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as confidently localized. All sites and peptides were then manually checked; sites on peptides 
with low mass accuracy (>5 ppm) or low XCorr (<1.5) were manually removed to ensure the 
quality of our results.  
 
5.1.2.7 Motif Analysis 
In the motif analysis, only well-localized S-GlcNAcylation sites were used, and 
sequences were centered on each site, extended to 13 aa (6 residues on each side of the site), 
and analyzed with the Motif-X algorithm.50 The number of occurrences is set to at least 20, and 
the significance is 0.0001. The Homo sapiens protein database was used as a background.  
 
5.1.2.8 Data Availability 
All raw files are accessible in the following public accessible website 
(http://www.peptideatlas.org/PASS/PASS00981, pass- word: MV9545qx).  
 
5.1.3 Results and discussion 
5.1.3.1 Principle of the enrichment of GlcNAcylated peptides 
Usage of sugar analogs to label cells has recently been proven to be effective for protein 
glycosylation investigation, which has been well documented.51, 52 Labeled glycoproteins with 
sugar analogs can be bound to fluorophoric groups for visualization and also be enriched for 
further analysis by MS.53-55 Here, we used a sugar analog (Ac4GlcNAz) to label glycoproteins 
in MCF-7 cells, as shown in Figure 5.1. After cell lysis and protein extraction, we incubated 
proteins with DDE-biotin-alkyne with Cu(I) as the catalyst.56 GlcNAcylated proteins with the 
functional azido group were tagged with biotin. After digestion, glycopeptides tagged with 
biotin were enriched with NeutrAvidin beads. After removing non-glycopeptides, we released 
the enriched glycopeptides using hydrazine (N2H4). The cleavable linker was cleaved and an 
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amine group was left on glycopeptides for MS analysis. Finally, the mass tag of 299.1230 Da 
is well-suited for glycopeptide identification and site localization by LC-MS/MS. 
 
Figure 5.1 Experimental procedure of selectively enriching GlcNAcylated peptides for MS 
analysis (The curves with different colors represent peptides). 
 
5.1.3.2 Integration of a cleavable linker for site-specific identification of protein 
GlcNAacylation 
To perform site-specific analysis of protein GlcNAcylation, a cleavable linker is 
required, which is different from the analysis of protein N-glycosylation because N-glycans 
can be removed with an enzyme, such as PNGase F, to generate a common tag for MS 
analysis.27, 57 Ideally, the cleavable linker needs to be compatible with the experimental 




conditions, including click reaction conditions. Furthermore, after cleavage, the remaining tag 
should be small for MS analysis. Cleavable linkers based on disulfide bond are extensively 
reported in the literature.58 However, this type of cleavable linker is incompatible with the 
current experiment because the disulfide bond may not survive under reductive conditions of 
the Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC) reaction. 
Here a DDE-based cleavable linker was used due to its advantages. First, the linker is 
stable under reductive CuAAC conditions. Second, after the cleavage, the remaining tag is 
small with a mass of 95 Da, as marked in a red circle in Figure 5.1. Third, the tag containing 
an amine group will increase the ionization efficiency of glycopeptides, facilitating the MS 
analysis of glycopeptides. In addition, with this specific sugar analog and the remaining tag, 
the final mass (299.1230 Da) can distinguish this modification from any other modifications. 
This cleavable linker allows us to site-specifically identify protein GlcNAcylation, and the tag 
on the peptides also provides solid experimental evidence for the protein modification.  
 
5.1.3.3 Identification of protein GlcNAcylation 
By using the cleavable linker, a small tag on glycopeptides enabled us to confidently 
identify glycopeptides and localize the glycosylation sites. Two examples are shown in Figure 
5.2. The glycopeptide VS#VCAETYNPDEEEEDTDPR (# - glycosylation site) was identified 
with a mass accuracy of 0.98 ppm and XCorr of 3.86. This peptide is from protein PRKAR2A, 




Figure 5.2 Examples of glycopeptide identification. (A) The peptide 
VS#VCAETYNPDEEEEDTDPR (# - glycosylation site) was identified, which is from protein 
PRKAR2A. (B) The peptide KLEEEQIILEDQNC#K from Myh9 was confidently identified 
with an XCorr of 3.88 and mass accuracy of 1.45 ppm, and the site C1002 was bound to the 
glycan. 
 
Unexpectedly, we identified many sites located on cysteine, which is discussed in 
details below, and one example is shown in Figure 5.2B. The glycopeptide 
KLEEEQIILEDQNC#K was confidently identified with an XCorr of 3.88 and mass accuracy 
of 1.45 ppm. It is from protein MYH9, and GlcNAc is bound to the site of cysteine 1002. 
Furthermore, the lack of any serine or threonine residue in this peptide excludes the possibility 
of protein O-GlcNAcylation. From the fragments, the tag neutral loss occurred (the highest 
m/z


















































































peak in Fig. 4.2B). Nevertheless, there was enough energy left to further fragment the peptide 
for confident identification.   
 
Figure 5.3 ModScore distribution of the GlcNAcylation sites identified in the DDE experiment.  
 
In this experiment, we identified 537 unique glycopeptides, and correspondingly 507 
sites were assigned on 367 proteins (listed in a table online at 
doi.org/10.1021/acs.analchem.6b05064). Among 507 sites, 269 were well-localized with 
ModScore>13 (Figure 5.3). The portion of sites being well localized is relatively low because 
of the following reasons. First, the sugar (GlcNAc) was bound to peptides, thus the neutral loss 
frequently occurred under collision induced dissociation (CID), as shown in Figure 5.2, which 
results in the relatively low rate of the site localization. Furthermore, there are multiple possible 
glycosylation sites, i.e. STC, and many peptides contain several of these residues. Sometimes 







Figure 5.4 Motifs identified from the well-localized protein O-GlcNAcylation sites 
(ModScore>13), using only ST as possible modification sites to perform SEQUEST search. 
 
 
4.1.3.4 Confident identification of protein S-GlcNAcylation on cysteine residues 
Initially, we used ST as dynamic modification sites for SEQUEST search because it is 
well-known that protein O-GlcNAcylation occurs on serine and threonine. Subsequently, we 
observed that cysteine is commonly located around S or T. When we conducted motif analysis, 
several motifs with cysteine around the sites were highly enriched, as shown in Figure 5.4. This 
results in a consideration that the cysteine residue may be modified with GlcNAc, and 
correspondingly, we used STC as dynamic modification sites to perform the search. 
Surprisingly, we found many sites (even greater than S and T, see below) were located on 
cysteine. In order to demonstrate the reliability of S-GlcNAcylation, we further performed the 
following experiments and data analysis. 
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1). S-GlcNAc is not from possible chemical reaction during sample preparation: 
The free thiol group of cysteine is reactive and could undergo reactions during sample 
preparation. To avoid the potential reactions during the sample preparation, we alkylated free 
thiol groups for the subsequent experiment by adding 1 mM IAA in the solution 20 minutes 
before and during the two-hour click reaction. Similar results were obtained, including the 
number of total and unique glycopeptides with S-GlcNAc. The comparison of the results is 
included below. 
2). S-GlcNAc is not produced by the cleavable linker: In order to further confirm 
that S-GlcNAcylation is authentic, we employed a completely different type of cleavable linker, 
photocleavable linker (the structure is in Figure 5.5). After enrichment, glycopeptides were 
cleaved under UV radiation at 350 nm for one hour. Because the remaining tag is the same, it 
has all the advantages described above. Similarly, we identified many glycopeptides with S-
GlcNAc, as compared below. 
 
 
Figure 5.5 The structure of the photocleavable (PC) linker. After enrichment, the linker was 
cleaved using radiation at 350 nm for one hour, which generates the same tag as the DDE linker. 
 
3). S-GlcNAc is not due to false assignment: To exclude the possibility of wrong 
assignment, we checked whether there are some identified glycopeptides without any S or T. 
Among the glycopeptides identified in the DDE experiment, 26 unique glycopeptides did not 
contain any serine or threonine. Among 269 well-localized glycosylation sites, 199 sites (74%) 
were localized on cysteine while only 20 sites were located on threonine and 50 sites on serine 
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(Figure 5.6). These results further demonstrated that S-GlcNAcylation is not due to wrong 
assignment.  
 
Figure 5.6 Distributions of well-localized sites on cysteine (C), serine (S) and threonine (T) in 
three independent experiments (DDE, DDE-Alk and PC).  
 
5.1.3.5 Comparison of glycopeptides identified in three independent experiments  
Among the three experiments (DDE-biotin-alkyne without alkylation (DDE), with 
alkylation (DDE-Alk), and photocleavable linker (PC)), we obtained very comparable results. 
In the DDE experiment, 74% of well-localized sites (199/269) were located on cysteine. With 
alkylation (DDE-Alk) experiment, 71% sites (174/244) belonged to S-GlcNAcylation (All 
identified sites are listed in a table online at doi.org/10.1021/acs.analchem.6b05064). In the PC 
experiment, 247 well-localized sites were identified (listed in a table online at 
doi.org/10.1021/acs.analchem.6b05064), and most of them (183 sites, 74%) were also located 
on cysteine (Figure 5.6). From the independent experiments, the number of protein S-
GlcNAcylation sites from each experiment was very similar. Well-localized S-GlcNAcylation 
sites in three independent experiments were listed in a table online at 


















glycoproteins with well-localized sites were compared in Figure 5.7. Relatively, the overlap 
was not exceptionally high, but this is also common for large-scale analysis of protein 
modification considering that the modification may be dynamic and these are biologically 
independent experiments with different linker molecules and the presence or absence of 




Figure 5.7 Comparison of glycoproteins with well-localized S-GlcNAcylation sites identified 
in three independent experiments. 
 
5.1.3.6 Motif Analysis of Well-Localized S-GlcNAcylation Sites  
Motif analysis was performed only for well-localized S- GlcNAcylation sites (357), 
among which 45 sites contain the motif of EC, and 40 sites with a motif of CXE (X - any amino 
acid residue). In addition, there are 26 sites with a cysteine followed by an aspartic acid residue, 
and 29 sites have a motif of CXXXE. As shown in Fig. 4.8B, the sites surrounded by an acidic 
amino acid are highly enriched. Protein modification can result from enzymatic or chemical 













by a chemical reaction. It is uncertain whether S-GlcNAcylation is due to chemical or 
enzymatic reactions. However, the identification of these motifs strongly suggests that some 
enzymes are responsible for this type of modification, and the enzyme’s binding pocket has a 
preference for acidic residues. It will be of great interest to identify the enzyme(s) responsible 
for S-GlcNAcylation. 
5.1.3.7 Clustering of Proteins Modified with Well-Localized S-GlcNAc 
To understand possible functions of protein S-GlcNAcylation, we clustered 
glycoproteins with well-localized S-GlcNAcylation sites using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, v6.8).59 Based on cellular compartment, the 
most highly enriched categories are cell-cell adherens junction, nuclear part, organelle lumen, 
and intracellular membrane-bounded organelle (Fig. 4.9A). 40 identified glycoproteins are 
located in the cell-cell adherens junction with an extremely low P value of 6.46E-23. Almost 
half of the proteins (137) are nuclear proteins with a P value of 3.65E-22. There are 27 proteins 
belonging to the chromosomal part, and 9 proteins are from the SWI/SNF (SWItch/Sucrose 
Non-Fermentable) superfamily-type complex, listed in Table 5.1. SWI/SNF is a nucleosome 
remodeling complex that exists in both eukaryotes and prokaryotes. However, the exact action 
mode of this complex remains to be further explored. Protein S-GlcNAcylation may contribute 
to its function. Based on the clustering results, two major functions are related to these 
glycoproteins modified with S-GlcNAc: the regulation of cell-cell interactions and gene 
expression, which likely are the major functions of protein S-GlcNAcylation. From DAVID, 
among 298 glycoproteins, most of them (260) are also phosphoproteins, and 164 glycoproteins 
can be acetylated. This modification may cross-talk with acetylation and phosphorylation to 





Figure 5.8 Comparison of (A) well-localized S-GlcNAcylation sites; (B) Four motifs were 
identified among the well-localized S-GlcNAcylation sites. 
The clustering results based on molecular function are displayed in Fig. 4.9B. Nearly 
half of the glycoproteins (131) are nucleic acid binding proteins with a P value of 2.51E-15. 
Furthermore, 16 proteins have transcription cofactor activities, and 8 proteins are bound to 
histones. 39 proteins belong to the category of binding proteins involved in cell adhesion with 
a P value of 4.78E-22. These results further consolidate the possible functions related to this 
















Table 5.1 The identification of S-GlcNAcylation sites in glycopeptides from the SWI/SNF 
superfamily-type complex. 
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Q12830 BPTF 
C#APAPPPPPPPPTSG
PIGGLR 0.36 2.25 20 85.3 




DPIVGEPGYC#PVR 0.96 4.06 367 80.9 
Bromodomain-containing protein 7, 
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target chromatin remodeling factors, 
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Figure 5.9 Clustering of glycoproteins with well-localized S-GlcNAcylation sites based on 
cellular compartment (A) and molecular function (B). The right y axis is –Log(P) and the left 



















































In this work, global and site-specific analysis of protein GlcNAcylation reveals 
unexpected S-GlcNAcylation on cysteine residues extensively existing in human cells. This 
result was further confirmed by different independent experiments. Motif analysis showed that 
the modified cysteine sites surrounded with an acidic amino acid residue (D or E) are highly 
enriched, which strongly suggests that a particular type of enzyme is responsible for this 
modification and has a preference for the sites surrounded by acidic amino acids. Protein 
clustering results demonstrated that glycoproteins with well-localized S-GlcNAcylation sites 
are involved in the regulation of cell-cell interactions and gene expression. For the first time, 
we discovered extensive protein S-GlcNAcylation existing in human cells through global and 
site-specific analysis of protein GlcNAcylation. Further work remains to be performed for a 
better understanding of protein S-GlcNAcylation, including the identification of possible 














5.2 Exploring Protein S-GlcNAcylation with Different Sugar Analog Labelling and in 
Various Types of Human Cells 
 
5.2.1 Introduction  
Protein glycosylation is highly diverse because of the heterogeneity of glycans and 
multiple side chains of amino acid residues being glycosylated.6, 60, 61 It regulates many cellular 
events and is essential for mammalian cell survival.5, 62-64 Aberrant protein glycosylation events 
are hallmarks of human diseases, such as cancer and infectious diseases.65-69 Among several 
types of protein glycosylation, the dynamic posttranslational attachment of β-N-
acetylglucosamine (GlcNAc) to the side chains of serine and threonine via O-linkage is termed 
O-GlcNAcylation,70 which modifies numerous cytoplasmic and nuclear proteins and regulates 
their activity, stability, and localization.71-73 Protein O-GlcNAcylation was discovered by 
Torres and Hart over three decades ago,8 and since then many O-GlcNAc-centered studies have 
been conducted.37, 38, 74-79  
Compared to O-GlcNAcylation, the attachment of GlcNAc onto the side chain of 
cysteine, i.e. S-GlcNAcylation, is nearly unexplored with few publications in the literature. In 
2011, S-GlcNAc was found to attach to Cys43 of Glycocin F, a bacteriocin from Lactobacillus 
plantarum through S-linkage.12 Last year, Maynard et al. reported S-GlcNAcylation events in 
mice samples through performing mass spectrometric analysis using electron transfer 
dissociation (ETD).13 Recently synthetic S-GlcNAc was reported to be an enzymatically stable 
and structurally reasonable surrogate for O-GlcNAc at the peptide and protein levels.80  
Recent advancements in mass-spectrometry (MS)-based proteomic techniques have 
provided a unique opportunity to globally and site-specifically investigate protein 
modifications.11, 17-21, 25, 81-87 Due to the low abundance of glycoproteins, it is imperative to 
separate and enrich the modified proteins or peptides prior to MS analysis.16, 27-32, 55, 88, 89 In 
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recent years, the combination of metabolic labeling and click chemistry has been proven to be 
very powerful to enrich modified proteins or peptides for global analysis of protein 
modifications with MS-based proteomics.39, 44, 54, 57, 90-93 In our previous work, by combining 
metabolic labelling, click chemistry and cleavable linkers with MS-based proteomics, we 
unexpectedly found that S-GlcNAcylation extensively existed in human cells.94 Several 
biologically independent experiments were performed to confirm that it was not produced by 
side reactions of the thiol groups during sample preparation, the cleavable linker utilized in the 
experiments, or false site assignments.94 Further investigations will aid in a better 
understanding of protein S-GlcNAcylation. 
In this work, we explored protein S-GlcNAcylation by evaluating the metabolic 
labelling with two different sugar analogs, namely GalNAz and GlcNAz, for global analysis of 
protein O- and S-GlcNAcylation. Furthermore, S-GlcNAcylation was systematically 
investigated in three types of human cells (MCF7, HEK 293T, and HeLa). The percentages of 
S-GlcNAcylation sites among the total well-localized sites are very similar across all these 
cells with over 70% of the well-localized sites being located on cysteine. We further performed 
motif and domain analysis for the well-localized S-GlcNAcylation sites. Together these data 
provide a systematic view of protein S-GlcNAcylation events in human cells. 
 
5.2.2 Experimental section 
5.2.2.1 Cell culturing and metabolic labelling 
MCF-7, HEK 293 T, and HeLa cells are from American type culture collection (ATCC) 
and were seeded in T-75 culturing flasks upon thawing. Cells were grown in a humidified 
incubator at 37 °C and 5.0% CO2 in Dulbecco's modified eagle's medium (DMEM) (Sigma-
Aldrich) containing 10% fetal bovine serum (FBS) (Thermo). When cells reached ~60% 
confluency, the media was switched to DMEM containing 10% dialyzed FBS with 100 µM 
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GalNAz or GlcNAz (Click Chemistry Tools) for metabolic labelling. Cells were labeled for 36 
h and then treated with 50 µM O-(2-acetamido-2-deoxy-D-glucopyranosylidenamino)N-
phenylcarbamate (PUGNAc) (Cayman Chemicals) for two hours before harvest.  
 
5.2.2.2 Sample preparation, LC-MS/MS analysis and data processing 
 See section 5.1.2. 
 
5.2.3 Results and discussion 
5.2.3.1 Experimental procedure of GlcNAcylation site identification  
Here we used the method integrating metabolic labelling, click chemistry and a 
cleavable linker to enrich GlcNAcylated peptides and generate a small tag on GlcNAcylation 
sites. Then the enriched glycopeptides were analyzed using MS-based proteomics, as shown in 
Figure 5.10. Cells were labeled with either GalNAz or GlcNAz, and then lysed. Labeled 
proteins in the cell lysate were reacted with bis-N-[1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)ethyl] (DDE)-biotin-alkyne through copper(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC) to incorporate a biotin tag for affinity enrichment.56 Proteins were 
digested, and the labeled peptides were enriched with NeutrAvidin beads. Non-specific binding 
peptides were removed with stringent washes and the GlcNAcylated peptides were released 
through cleaving the DDE group with hydrazine (N2H4). This resulted in a mass tag of 
299.1230 Da on the GlcNAcylation sites, which can be used for glycopeptide identification 
and glycosylation site localization. A total of four experiments were performed: GalNAz 
labelling of MCF7 cells (GAlNAz-MCF7), GlcNAz labelling of MCF7 cells (GlcNAz-MCF7), 





Figure 5.10 Experimental procedure for the chemoproteomic analysis of protein 
GlcNAcylation. 
 
We previously demonstrated that S-GlcNAcylation was not from side reactions during 
sample preparation, produced by the cleavable linker, or due to false assignment.94 Serine and 
threonine are among the most frequent amino acid residues in proteins, and the percentages of 
S and T residues in glycopeptides are even higher, rendering the site localization more difficult. 
Therefore, the ModScores of the GlcNAcylated sites identified in proteomics experiments are 
generally lower than those for N-glycosylation sites.  
 
Identification of S- and O-GlcNAcylated
Peptides with the Tag







Figure 5.11 The totall and well-localized S- and O-GlcNAcylation sites identified from the 
four experiments: (A) GalNAz-MCF7; (B) GlcNAz-MCF-7; (C) GlcNAz-HEK 293T; (D) 
GlcNAz-HeLa. 
 
The total and well-localized O- and S-GlcNAcylation site numbers in the four 
experiments are compared in Figure 5.11. Interestingly, the site localization confidence for S-
GlcNAcylation sites is generally higher partially due to the fact that there are a considerable 
amount of S-GlcNAc-containing peptides without any S or T residue in the sequence while 







































































5.2.3.2 Distinctive labelling performances of GalNAz and GlcNAz  
Firstly, we compared labelling MCF7 cells using two different sugar analogs (GalNAz 
and GlcNAz) for the global analysis of protein GlcNAcylation. In the literature, it was reported 
that although the sugar analog GlcNAz was structurally more similar to GlcNAc, GalNAz was 
able to label O-GlcNAcylated proteins in human cells more efficiently.95 In addition, UDP-
GalNAz and UDP-GlcNAc are interconvertible through their salvage pathways.95, 96 The 
current results further indicated that GalNAz outperformed GlcNAc for the identification of O-
GlcNAcylated proteins, while GlcNAz appeared to be more effective to label S-GlcNAcylated 
proteins (Figure 5.12A).  
In this work, in order to ensure the technical rigor and to avoid the site localization 
ambiguity caused by false site assignment, we only analyzed the well-localized sites with 
ModScore > 13. As shown in Figure 5.12A, many more sites were identified in the GlcNAz 
labelling experiment and the majority of them were S-GlcNAcylation sites, while GalNAz 
labelling generated more O-GlcNAcylation sites. In the GalNAz labelling experiment, 69.3% 
of the well-localized sites were O-GlcNAcylation sites while it was only 19.1% for GlcNAz 
labelling (Figure 5.12A). For S-GlcNAcylation site identification, the labelling with GlcNAz 
dramatically outperformed GalNAz with 313 well-localized S-GlcNAcylation sites from the 
GlcNAz labelling vs. 58 from the GalNAz labelling. Labelling using these two sugar analogs 
resulted in a relatively small overlap (Figure 5.12B), and the overlapped sites are mostly 






Figure 5.12 (A) Distributions of the well-localized sites on cysteine, serine, and 
threonine in the GalNAz and GlcNAz labelling experiments; (B) The site overlap 
between the two experiments; (C) The O- and S-GlcNAcylation site percentages among 
the overlapped sites.  
 
 Although the sites identified from the two experiments are quite different, the 
GlcNAcylated proteins identified from the two experiments have shown a better overlap with 
nearly half of the proteins identified in the GalNAz labelling experiment also detected in the 






























identified from each experiment based on cellular compartment (Figure 5.14) and molecular 
function (Figure 5.15) using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID, v6.8).59 The proteins identified from the two experiments were mostly 
intracellular and nuclear proteins with a much smaller portion of them involved in adherens 
junction, which could potentially locate on cell surface (Figure 5.14). Clustering based on 
molecular function showed that the glycoproteins from the two experiments participated in 
several types of binding activities, such as nucleic acid binding and cell adhesion molecule 
binding (Figure 5.15). The protein clustering results imply that although O- and S-GlcNAc 
locate on different sites from different proteins, many GlcNAcylated proteins have similar 





Figure 5.13 The overlap between the GlcNAcylated proteins identified in the GalNAz-MCF7 








Figure 5.14 Clustering of the GlcNAcylated proteins from (A) the GalNAz-MCF7 experiment 


















































Figure 5.15 Clustering of the GlcNAcylated proteins from (A) the GalNAz-MCF7 experiment 














































































5.2.3.3 Comparison of protein GlcNAcylation in three types of human cells 
After identifying GlcNAz as a more robust probe for protein S-GlcNAcylation 
identification, we then analyzed protein GlcNAcylation in different types of cells using this 
sugar analog to label cells. The cell lines have different origins with distinctive disease statuses. 
MCF7 is a breast cancer cell line, HEK 293T is an immortalized but not cancerous cell line 
originally derived from human embryonic kidney, and HeLa cells were from cervical cancer 
tissue.  
 
Figure 5.16 The (A) number and (B) percentage distributions of the O- and S-











































The comparison of the total and well-localized sites from the three experiments is 
shown in Figure 5.11, and the distributions of the well-localized sites on cysteine, serine, or 
threonine for three types of cells are displayed in Figure 5.16. The greatest number of S-
GlcNAcylation sites were identified from HEK 293T cells (Figure 5.16A). MCF7 has the 
highest percentage of S-GlcNAcylation sites while HeLa has the highest percentage of O-




Figure 5.17 (A) the site overlap of the three experiments, and (B) the O- and S-GlcNAcylation 
site percentages among the overlapped sites. 
 
Overall, the percentages of S-GlcNAcylation sites among the total well-localized sites 
were  similar across the three types of cell, and 80.9%, 75.5%, and 71.5% of GlcNAcylation 


















The overlap is less at the site level than the protein level (Figure 5.17A). Among the overlapped 
sites, 96.4% of them are located on cysteine (Figure 5.17B), featuring an even higher 
percentage of S-GlcNAcylation sites than it from the overlap between the GalNAz and GlcNAz 
labelling experiments. Although the percentages of S-GlcNAcylation sites change only slightly 
across these different cell lines, the site location was quite different. The possible reasons are 
that some sites may be cell-specific, and that similar to O-GlcNAcylayion, S-GlcNAcylation 
may also be dynamic. 
The comparison of the GlcNAcylated proteins identified in the three experiments is 
shown in Figure 5.18A. Compared to labelling MCF7 cells using two different sugar analogs, 
labelling different types of human cells using one sugar analog has resulted in a better overlap. 
We clustered the non-overlapping proteins in each type of cells separately using DAVID v6.8 
according to their tissue expressions through the UniGene category. As expected, the non-
overlapping proteins have shown tissue and disease-specificity as the exact tissue origin and 








Figure 5.18 (A) GlcNAcylated proteins identified from GlcNAz labelling in three types 
of human cells; (B) The non-overlapping proteins have shown cell type and disease 
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5.2.3.4 Analysis of the well-localized S-GlcNAcylation sites  
Taken together, we identified a total of 1132 well-localized GlcNAcylation sites 
from the four experiments, among which 724 are located on cysteine, 240 on serine, and 
168 on threonine (Figure 5.19). We clustered the O- and S-GlcNAcylated proteins based 
on their cellular compartment, molecular function, and biological process and found the 





Figure 5.19 The distribution of the well-localized O- and S-GlcNAcylation site identified in 
all experiments taken together.  
 
After optimizing the experimental conditions and using different types of cells 
and sugar analogs, we identified dramatically more well-localized sites on cysteine than 
those in our previous study (724 vs. 199).94 Based on many more well-localized S-
GlcNAcylation sites, motif analysis results should be more statistically meaningful.  
Several motifs with an acidic amino acid near the modification site were once again 
identified (Figure 5.20), demonstrating that our motif analysis results were highly 











acids away from the modified cysteine was found here. Identification of these motifs 




Figure 5.20 The motifs identified from the well-localized S-GlcNAcylation sites. 
 
  Moreover, in the literature, researchers found that the location of cysteine-related 
motifs, such as the CP motif for heme-responsive proteins97, 98 and CXXC for redox 
proteins99, 100 are usually important for their functions. We also studied the S-
GlcNAcylation site locations along the protein sequences, but no obvious trend was 
found (Figure 5.21). The sites seem to locate evenly along their protein sequences 
despite that there are slightly fewer sites located within 10-20% of the protein length 






Figure 5.21 The S-GlcNAcylation site location distribution along the protein sequence.  
 
5.2.3.5 Domain analysis of the well-localized S-GlcNAcylation sites 
We further performed domain analysis for the well-localized S-GlcNAcylation sites. 
Ninety-nine sites are located in a variety of functional domains. Figure 5.18C shows the 
domains with the most site hits. Four domains are involved in binding: RRM is a putative RNA-
binding domain that binds single strand RNAs,101 KH-1 is a nucleic acid binding domain,102 tr-
type G is a translational-type guanine nucleotide-binding domain,103 and EF-hand domain is 
responsible for calcium binding.104 Some sites were located in kinase activity-related domains, 
such as SH3, which is a tyrosine kinase activity-related domain.105 These results correspond 
well with the protein clustering results above and in our previous work, and hence demonstrate 
that S-GlcNAcylation may be majorly involved in gene expression (especially nucleotides-
related binding activities) and signal transduction (protein kinase activity), which are similar 
to O-GlcNAc. This increases the possibility that protein S-GlcNAcylation has similar functions 
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Table 5.2 Clustering of the S- and O-GlcNAcylated proteins according to cellular compartment, 







Cellular  Intracellular part 552 4.60E-44 276 
1.90E-
22 
Compartment Nuclear part 270 1.00E-41 147 
7.80E-
28 















involved in cell 
adhesion 
54 7.90E-23 34 
1.30E-
17 










 Cellular localization 149 2.70E-13 70 
1.20E-
05 






Protein glycosylation is essential for mammalian cell growth and proliferation, and it is 
highly diverse. Previously we made an unexpected finding of extensive protein S-GlcNAcylation 
existing in human cells. Compared to O-GlcNAcylation, this type of glycosylation remains largely 
unexplored. Here we investigated protein S-GlcNAcylation with the two different sugar analogs 
and in three types of human cells. The experimental results demonstrated the different percentages 
of O- and S-GlcNAcylation sites were identified with the GalNAz or GlcNAz labeling. The sugar 
analog GalNAz outperformed GlcNAz on the identification of protein O-GlcNAcylation, while 
the latter was proven to be much more effective for the global analysis of protein S-GlcNAcylation. 
In the comparison of protein GlcNAcylation in three types of human cells: MCF7, HEK 293T and 
HeLa, the greatest number of GlcNAcylation sites were identified in HEK 293T cells. The 
percentages of S-GlcNAcylation sites among the total well-localized sites are similar across the 
three types of human cells, and the majority of the well-localized glycosylation sites were located 
on the cysteine residues. The results of the S-GlcNAcylation site motif analysis are consistent with 
our previous finding of several motifs with an acidic amino acid around the site. Compared to other 
domains, the RNA-binding domains (RRM and KH-1) have the greatest number of sites located 
within, which is in a good agreement with the clustering results that proteins related to nucleic acid 
binding and chromatin binding were enriched. Taken together, this work demonstrated the 
dramatic difference of GlcNAcylated protein labelling with the two sugar analogs, and proteins 
are S-GlcNAcylated to a similar extent in the three different types of human cells tested. Further 
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6.1 Systematic Investigation of Cellular Response and Pleiotropic Effects in Atorvastatin-
treated Liver Cells by MS-based Proteomics 
 
6.1.1 Introduction 
Heart and cardiovascular diseases (CVDs) are the leading causes of morbidity and 
mortality in the United States and around the world.1, 2 With the increase in life expectancy, these 
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age-related diseases are becoming increasingly prevalent. Statins, as effective cholesterol-
lowering 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors, are 
recommended as treatment and preventative drugs by the American Heart Association (AHA).2, 3 
Currently statins are very popular drugs, with ~15 percent of adults in the United States taking 
statins. In November 2013, the AHA and American College of Cardiology released a new clinical 
practice guideline for the treatment of blood cholesterol in people at high risk for CVDs caused by 
atherosclerosis. The guideline identifies four major groups of patients for whom statins have the 
greatest chance of preventing stroke and heart attack.4 Under the new guideline, one third of all 
American adults would meet the threshold to consider taking cholesterol-lowering statin drugs.5  
The first statin, lovastatin, was approved by the Food and Drug Administration in 1987. In 
1996, Pfizer introduced atorvastatin (Lipitor) as a pharmaceutical for the reduction of cholesterol 
as a preventative measure for heart disease. Atorvastatin quickly became one of the best-selling 
pharmaceuticals in history, recording sales of $12.4 billion in 2008 alone.6 Atorvastatin, as well 
as other statins, were designed to inhibit the rate-limiting step of the cholesterol biosynthesis 
pathway, known as the mevalonate pathway. The enzyme responsible for catalyzing this rate-
limiting step is HMGCR.7 As more than two-thirds of the body’s total cholesterol is synthesized 
in cells,8 blocking this pathway to achieve a therapeutic decrease of cholesterol is immensely 
effective. 
HMGCR is an enzyme in the upstream portion of the mevalonate pathway. Besides 
cholesterol, the synthesis of many intermediate and end products in this pathway, including 
ubiquinone, dolichol and farnesyl-pyrophosphate (farnesy-PP), are significantly affected by the 
inhibition of this enzyme. Ubiquinone is a component of the electron transport chain and 
participates in aerobic cellular respiration, generating energy in the form of adenosine triphosphate 
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(ATP), which accounts for 95% of the total energy generated in the body.9, 10 Dolichol plays an 
essential role in protein N-glycosylation, and functions as a membrane anchor for the formation of 
a precursor oligosaccharide.11 Farnesyl-PP and geranylgeranyl pyrophosphate (geranylgeranyl-
PP) are also important compounds responsible for two other types of protein post-translational 
modifications, i.e. farnesylation and geranylgeranylation, which are involved in protein trafficking 
and localization, and subsequently regulate cell signaling via protein phosphorylation.12-14 Several 
end products in the mevalonate pathway play critical roles in cells. Therefore, many other 
cholesterol-independent effects, so-called pleiotropic effects, have been reported: improving 
endothelial function,15 attenuating vascular and myocardial remodeling, inhibiting vascular 
inflammation and oxidation,16, 17 and stabilizing atherosclerotic plaques.7, 18-22Statins have been 
shown to reduce the chance of cardiac rejection in cardiac transplants.23 They have also been 
reported to inhibit cellular proliferation and induce necrosis, thus allowing them to be potential 
anticancer agents.24-29 In addition, statins are associated with a significant reduction in the risk of 
hip fracture,30 and could be used as potential anti-Alzheimer’s 31-33 and antidiabetic drugs.34-36 
Several adverse effects of statins have also been reported, including rare acute kidney injury, 
memory loss and confusion.37 However, the molecular mechanisms of these pleiotropic effects of 
statins are largely unknown.  
With the development of mass spectrometry (MS) instrumentation, genomic science and 
computer technology, modern liquid chromatography (LC)-MS-based proteomics techniques 
provide a unique opportunity to globally analyze proteins and protein post-translational 
modifications in complex biological samples.38-45 These methods have great advantages for 
characterizing proteins and protein modifications; they are applicable to identify proteins, locate 
modification sites and quantify their abundance changes without requiring antibodies.46-54 Protein 
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changes in the secretome55 and lipid rafts56 in endothelial cells treated by statin were reported 
recently. Additionally, protein abundance changes in HL-60 (human acute promyelocytic 
leukemia) cells treated by lovastatin were investigated by MS-based quantitative proteomics 
techniques.57 It was found that the abundances of estrogen receptor α and steroid receptor RNA 
activator 1 in the estrogen receptor signaling pathway were decreased, and glutamate metabolism 
was altered in treated HL-60 cells.57 Intracellular signal transduction is mainly carried out by 
protein phosphorylation, but global analysis of protein phosphorylation in cells treated by statin 
has yet to be reported. Considering that the majority of cholesterol (~85%) in the human body is 
synthesized in the liver,58 investigating the liver cell response to atorvastatin is of great interest. 
Comprehensive and systematic investigation of proteins and protein phosphorylation in liver cells 
will provide a better understanding of liver cell responses to statin and the underlying molecular 
mechanisms of the corresponding pleiotropic effects. This information will be beneficial in 
expanding the use of statins to other noncardiac vascular diseases and minimizing potential side 
effects.   
In this work, we have globally and quantitatively studied protein and protein 
phosphorylation changes in cells treated by atorvastatin. Since the majority of cholesterol is 
produced in the liver, a liver carcinoma cell line (HepG2) was used in this study. After cells were 
treated by atorvastatin for 24 hours, proteins and phosphoproteins were globally identified and 
quantified by MS-based proteomics techniques. As expected, many lipid-related proteins were up-
regulated in cells treated by atorvastatin, including HMGCR, FDFT, SQLE and LDLR. 
Phosphopeptides on a group of G-protein modulators were up-regulated, which strongly suggests 
that cell signal rewiring was a result of statin treatment on lipidated proteins. Several basic motifs 
were enriched among down-regulated phosphorylation sites, which indicates that kinases with 
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preference for these motifs, such as PKA and PKC, have attenuated activities. The current work 
represents the first global analysis of proteins and phosphoproteins in liver cells treated by 
atorvastatin, which can provide a better understanding of the mode of action of statins and the 
molecular mechanisms of their pleiotropic effects. 
 
6.1.2 Materials and methods 
6.1.2.1 Cell culture, SILAC labeling and atorvastatin treatment 
HepG2 (C3A) cells (from American type culture collection (ATCC)) were grown in 
Dulbecco's modified eagle's medium (DMEM) (Sigma-Aldrich) containing 1000 mg/L glucose 
and 10% fetal bovine serum (FBS) (Thermo). “Heavy” and “light” SILAC (stable isotope labeling 
by amino acids in cell culture) (Sigma-Aldrich) media were freshly prepared by adding 0.146 g/L 
13C615N2 L-lysine (Lys-8) (Cambridge Isotopes) or the corresponding non-labeled lysine, 12C614N2 
L-lysine (Lys-0) and supplemented with 10% dialyzed FBS (Corning). Cells were cultured for 
about seven generations under 37 ºC, 5% CO2 and humidified atmosphere before treatment. 40 
mM atorvastatin (Cayman Chemical) stock solution was prepared by dissolving in DMSO (Sigma-
Aldrich). About 9 × 107 heavy HepG2 cells were treated with 15 µM atorvastatin in serum-free 
heavy medium for 24 h. A similar number of light cells were treated by DMSO in serum-free light 
medium as a control.  
 
6.1.2.2. Cell lysis, protein extraction and digestion 
Heavy and light SILAC-labeled HepG2 cells were harvested by scraping in phosphate 
buffered saline (PBS), and equally combined based on the protein ratio from a trial run. The cell 
mixtures were pelleted by centrifugation at 500 g for 3 min, washed with cold PBS and lysed 
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through end-over-end rotation at 4 ºC for 45 minutes in lysis buffer (50 mM  HEPES pH=7.6, 150 
mM NaCl, 50 mM NaF, 50 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, 10 mM sodium pyrophosphate, 0.5% SDC, 10 units/mL benzonase 
and one protease inhibitor cocktail tablet (complete mini, EDTA-free, Roche) per 10 mL). Lysates 
were centrifuged, and the resulting supernatant was transferred to new tubes. Proteins were 
subjected to disulfide reduction with 5 mM DTT (56 ºC, 25 min) and alkylation with 14 mM 
iodoacetamide (RT, 20 min in the dark). Detergent was removed by methanol chloroform 
precipitation. The purified proteins were digested with 10 ng/µL Lys-C (Wako) in 50 mM HEPES 
pH 8.6, 1.6 M urea, 5% ACN at 31ºC for 16 h. 
 
6.1.2.3 Peptide separation for protein analysis 
Digestion mixtures were acidified by addition of trifluoroacetic acid (TFA) to a final 
concentration of 0.1%, clarified by centrifugation and desalted using tC18 SepPak cartridge 
(Waters). For protein expression analysis, the peptide mixture was separated by high pH reversed-
phase high-performance liquid chromatography (HPLC) into 21 fractions with a 40-min gradient 
of 5-55% ACN in 10 mM ammonium acetate (pH=10).  
 
6.1.2.4 Phosphopeptide enrichment 
Effective enrichment is critical to globally identify and quantify protein phosphorylation, 
and here two-step enrichment was employed. The first separation of phosphopeptides from non-
phosphopeptides was carried out using strong cation change (SCX) chromatography as 
described.59 At pH~3, phosphate groups carrying negative charges make phosphopeptides elute 
earlier than their counterparts. The sample was separated into 12 fractions. Phosphopeptides in 
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each fraction were further enriched by TiO2 particles (GL Science Inc., Japan). Enriched 
phosphopeptide samples were purified by tC18 SepPak cartridge prior to MS analysis. 
  
6.1.2.5 LC-MS/MS analyses  
Purified and dried peptide samples were dissolved in a solution of 5% ACN and 4% formic 
acid (FA), and 2 µL of the resulting solutions were loaded onto a microcapillary column packed 
with C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, Michrom Bioresources) by a 
Dionex WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid Separation Pulled 
Loop Wellplate Sampler). Peptides were separated by reversed-phase chromatography using an 
UltiMate 3000 binary pump with a 90 min gradient of 4-30% ACN (in 0.125% FA).  For 
phosphorylation samples, a 110 min gradient was used. Peptides were detected with a data-
dependent Top20 method60 in a hybrid dual-cell quadrupole linear ion trap – Orbitrap mass 
spectrometer (LTQ Orbitrap Elite, ThermoFisher, with Xcalibur 3.0.63 software). For each cycle, 
one full MS scan (resolution: 60,000) in the Orbitrap at 106 AGC target was followed by up to 20 
MS/MS in the LTQ for the most intense ions. The selected ions were excluded from further analysis 
for 90 seconds. Ions with singly or unassigned charge were not sequenced. Maximum ion 
accumulation times were 1000 ms for each full MS scan and 50 ms for MS/MS scans. 
 
6.1.2.6 Database searches and data filtering 
Raw data files from the mass spectrometer were converted into mzXML format. Individual 
precursors selected for MS2 sequencing were checked for incorrect monoisotopic peak 
assignments while refining precursor ion mass measurements.50 All MS2 spectra were then 
searched using the SEQUEST algorithm (version 28),61 and spectra were matched against a 
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database encompassing sequences of all proteins in the UniProt Human (Homo sapiens) database 
(downloaded in February 2014) containing common contaminants such as keratins.  Each protein 
sequence was listed in both forward and reversed orders to control the false discovery rate (FDR) 
of peptide and protein identification.  Data from protein expression experiments were searched 
using the following parameters: 20 ppm precursor mass tolerance; 1.0 Da product ion mass 
tolerance; fully digested with Lys-C; up to three missed cleavages; variable modifications: 
oxidation of methionine (+15.9949); fixed modifications: carbamidomethylation of cysteine 
(+57.0214).  Phosphopeptide samples were searched using the same parameters, with the addition 
of a variable modification of serine, threonine, and tyrosine (+79.9663).  
The target-decoy method was employed to estimate and control FDRs at the peptide and 
protein levels.62, 63 Data for either protein or protein phosphorylation analysis were processed 
separately. Linear discriminant analysis (LDA) was used to distinguish correct and incorrect 
peptide identifications using numerous parameters such as Xcorr, ΔCn, precursor mass error, and 
charge state.50 Separate linear discriminant models were trained for each LC-MS analysis using 
forward and reversed peptide sequences to provide positive and negative training data. This 
approach is similar to other methods in the literature which employed different features or 
alternative classifiers.64-66 After scoring, only peptides with at least seven amino acid residues in 
length were kept, and peptide spectral matches were filtered to a 1% FDR based on the number of 
decoy sequences in the remaining data set. Since phosphorylated and non-phosphorylated peptides 
have different score distributions, the dataset was restricted to phosphopeptides when determining 
FDRs for phosphopeptide identification.67 
When large proteomics datasets are assembled, the protein-level FDR is often dramatically 
accumulated with the increased sample numbers, despite keeping the peptide-level FDR at a 
 
252 
constant 1% for each run. Therefore, we applied an additional protein-level filter to each dataset 
to reduce the protein-level FDRs (<1%) for proteins and phosphoproteins.  Consequently the FDRs 
at the peptide level were markedly reduced. 
  
6.1.2.7 Phosphorylation site localization and peptide quantification 
To assign phosphorylation site localizations and measure the assignment confidence, we 
applied a probabilistic algorithm67 that considers all phospho-forms of a peptide and uses the 
presence or absence of experimental fragment ions unique to each form to calculate an ambiguity 
score (Ascore). The Ascore indicates the likelihood that the best site match is correct when 
compared with the next best match. We considered sites with Ascore ≥13 (P≤ 0.05) to be 
confidently localized. For peptide quantification, we required an S/N value >3 for both heavy and 
light species. If the S/N value of one member of a pair was less than 3, the partner was required to 
be greater than 5.  
 
6.1.2.8 Motif analysis 
In the motif analysis, only quantified sites were used, i.e. singly phosphorylated peptides 
with well-localized phosphorylation sites (Ascore≥13) were considered. For up- and down-
regulated phosphorylation sites, sequences were centered on each phosphorylation site and 
extended to 13 aa (6 residues on each side of the site) and analyzed with the Motif-X algorithm.68 






6.1.3 Results and discussion 
6.1.3.1 Protein identification and quantification 
HepG2 cells were treated by atorvastatin for 24 hours before harvest and subsequent 
protein and protein phosphorylation analysis, as shown in Figure 6.1. For protein identification 
and quantification, proteins were digested by Lys-C, purified and then fractionated into 21 samples 
by HPLC. Each fraction was then measured by LC-MS/MS. Overall, 157,118 total peptides 
corresponding to 78,316 unique peptides were identified, and 6,316 proteins (based on gene 
symbols) were identified with 0.99% FDR at the protein level and 0.12% at the peptide level.   
Examples of both a mass spectrum (MS) and tandem mass spectrum (MS2) are displayed 
in Figure 6.2. The MS shows a pair of the peptide isotope profiles; the heavy peptide is from cells 
treated by atorvastatin, which has stronger intensity, while the light peptide is from untreated cells.  
The peptide DQEVLLQTFLDDASPGDK# (# refers to the heavy lysine) was confidently 
identified in the MS2 with an XCorr of 6.6 and a mass accuracy of -0.05 ppm (Figure 6.2b). This 
peptide is from the protein APOB (apolipoprotein B), which is a very large protein that is a major 





Figure 6.1 Experimental procedure of the global analysis of proteins and protein phosphorylation. 
 
We identified 270 total and 194 unique peptides from this protein. The elution profiles of 
the light and heavy versions of the peptide are shown in Figure 6.2c. The ratio of the areas under 
the curves provides highly accurate protein abundance changes. From over 100 quantified unique 
peptides, we obtained an overall abundance change of 2.02 between treated and untreated cells.  
Based on the criteria described in the methods section, we were able to quantify 6,181 
proteins (listed in a table online at doi.org/10.1021/pr501277g), with their abundance distribution 
displayed in Figure 6.3a. At least two peptides were quantified in 5,907 proteins. A total of 104 
proteins were down-regulated while 81 proteins were up-regulated by over 2-fold in cells treated 
by atorvastatin. As expected, few proteins were regulated because atorvastatin is mild enough that 
it can be taken for many years without significant side effects, and cells were only treated for one 




Figure 6.2 Examples of (a) a mass spectrum, (b) a tandem mass spectrum and (c) the elution 
profiles of heavy (atorvastatin-treated) and light (untreated) versions of the peptide 












































6.1.3.2 Up-regulated proteins related to lipid metabolic process 
Upon inhibition of HMGCR by atorvastatin, a considerable number of proteins related to the lipid 
metabolic process were up-regulated. About 21% of up-regulated proteins (17 out of 81), listed in 
Table 6.1, are related to the lipid metabolic process, which is highly enriched with a P value of 8.7 
x 10-8 (Figure 6.3b) based on the analysis using the Database for Annotation, Visualization and 




Figure 6.3 (a) Protein abundance changes for cells treated by atorvastatin vs. untreated, and (b) 




For example, ACSS2, acetyl-coenzyme A synthetase, which is located in the cytoplasm 
and activates acetate for lipid synthesis or energy generation, was up-regulated by 2.6-fold. 
CYP19A1, aromatase, which is crucial for cholesterol homeostasis, was up-regulated by 2.2-fold. 
It catalyzes a rate-limiting step in cholesterol catabolism and bile acid biosynthesis by introducing 
a hydrophilic moiety at position 7 of cholesterol (http://www.uniprot.org/uniprot/P22680). CNBP, 
a cellular nucleic acid-binding protein involved in sterol-mediated repression, was also quantified 
to be up-regulated by 2.7-fold in treated cells.  
 
Table 6.1 Up-regulated proteins related to lipid metabolic processes. 





P33121 ACSL1 39 2.3 Long chain fatty acid CoA ligase 1 
Q08AH3 ACSM2A 3 3.1 Acyl-coenzyme A synthetase ACSM2A, mitochondrial 
Q68CK6 ACSM2B 3 3.1 Acyl-coenzyme A synthetase ACSM2B, mitochondrial 
Q9NR19 ACSS2 22 2.6 Acetyl-coenzyme A synthetase, cytoplasmic 
P06727 APOA4 24 4.9 Apolipoprotein A-IV 
P04114 APOB 239 2.0 Apolipoprotein B-100 
P62633 CNBP 20 2.0 Cellular nucleic acid-binding protein 
P11511 CYP19A1 8 2.2 Aromatase 
Q9H5J4 ELOVL6 1 4.3 Elongation of very long chain fatty acids protein 6 
O95864 FADS2 3 3.0 Fatty acid desaturase 2 
P37268 FDFT1 69 2.8 Squalene synthase 
P04035 HMGCR 21 15.3 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
Q14693 LPIN1 2 2.1 Phosphatidate phosphatase LPIN1 
Q8NBP7 PCSK9 9 3.8 Proprotein convertase subtilisin/kexin type 9 
Q5T2R2 PDSS1 3 2.4 Decaprenyl-diphosphate synthase subunit 1 
O00767 SCD 13 2.4 Acyl-CoA desaturase 




6.1.3.3 Abundance changes of proteins in the mevalonate pathway 
Atorvastatin inhibited HMGCR which prevented the synthesis of cholesterol and other 
lipids in the mevalonate pathway. HMGCR was highly up-regulated by 15.3-fold, which is 
consistent with the up-regulation of HMGCR mRNA in a previous study.70 We identified 26 total 
peptides, and 18 unique peptides from this protein. After filtering based on the criterion of S/N>3, 
the final abundance change was calculated from 12 unique quantified peptides. In the mevalonate 
pathway, the abundance of the upstream protein HMGCS1, HMG-CoA synthase, was elevated by 
1.8-fold. The abundances of both ACAT1, acetyl-CoA acetyltransferase in mitochondria, and 
ACAT2, acetyl-CoA acetyltransferase in cytoplasm, were also increased by 1.4- and 1.5-fold, 
respectively. Downstream proteins, including MVK, PMVK, MVD, FDPS and GGPS1, were not 
significantly regulated, as shown in Figure 6.4. The essential intermediate in this pathway, 
farnesyl-PP, can be converted into different types of lipids including squalene, ubiquinones, sterols, 
heme A, dolichols, and geranylgeranyl-PP. Interestingly, FDFT1, which catalyzes farnesyl-PP to 
squalene, was up-regulated by 2.8-fold, and another downstream enzyme, SQLE, squalene 
monooxygenase, was also up-regulated by 4.4-fold.  
Low-density lipoprotein receptor (LDLR), which binds LDL, is the major cholesterol-
carrying plasma lipoprotein, and is transported into cells by endocytosis. It has been reported that 
statin can up-regulate the hepatic LDLR, resulting in lower serum LDL levels.71 It was also 
documented that an increase at the LDLR mRNA level occurred in human circulating mononuclear 
cells as a response to atorvastatin.72 In the current work, LDLR was quantified to be up-regulated 
by 2.0-fold in cells treated by atorvastatin, which is correlated with increased cholesterol intake 








Figure 6.4 Abundance changes of proteins in the mevalonate pathway and some proteins related 
to cholesterol transportation (all abundance changes refer to intracellular proteins). 
 
 


































































APOA4 is another critical protein in the secretion and catabolism of chylomicrons and 
VLDL. It is required for efficient activation of lipoprotein lipase by ApoC-II and is a potent 
activator of LCAT. Furthermore, the anti-oxidant and anti-antherogenic properties of APOA473, 74 
may contribute to the pleiotropic effects of statins. This protein is highly up-regulated by 4.9-fold. 
Proteome analysis can provide a global view of protein abundance changes in atorvastatin-treated 
cells. Most proteins in this pathway are not significantly regulated, while several very important 
proteins, including HMGCR, FDFT1, SQLE, LDLR and APOA4, are up-regulated. 
 
6.1.3.4 Clustering of down-regulated proteins 
Among 104 down-regulated proteins, 30 proteins (29%) with gene expression function are 
enriched with a P value of 1.1 x 10-3. Some proteins related to nucleobase and nucleic acid 
metabolic process, cytoskeleton organization, macromolecular biosynthetic process, and cell cycle 
process are also down-regulated. In addition, proteins that have roles in cellular response to stress 
and DNA damage are also enriched among down-regulated proteins.  
For down-regulated proteins, 44 are located in the nucleus, which is the most highly 
enriched location based on cellular compartment clustering, with a P value of 2.8 x 10-5. In addition, 
32 proteins are related to nucleic acid binding with a P value of 5.7 x 10-4. Three proteins 
corresponding to chronic myeloid leukemia were down-regulated: E2F3, MDM2, and NFKBIA. 
A group of eight proteins associated with programmed cell death, CFLAR, TOP1, SEMA6A, 
CASP4, MAP1S, NFKBIA, ACIN1, and CCAR1, were also found to be down-regulated, and they 
are marked in green in Figure 6.3a. For instance, CCAR1, cell division cycle and apoptosis 
regulator protein 1, may play an important role in transcriptional regulation and apoptosis signaling. 
Here we quantified 15 unique peptides from this protein, with its abundance down-regulated by 
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2.8-fold in cells treated by atorvastatin. CASP4 (Caspase-4) is involved in the activation cascade 
of caspases responsible for apoptosis execution, and was also decreased by 2.1-fold.    
 
6.1.3.5 Global analysis of protein phosphorylation  
For protein phosphorylation, effective enrichment is vital to achieve large-scale 
identification and quantification by MS. A two-step enrichment method was used for protein 
phosphorylation analysis. SCX can be used to separate phosphopeptides from non-phophopeptides 
based on charge. At pH~3, the phosphate group is negatively charged, which makes 
phosphopeptides carry a lower overall positive charge. Therefore they elute from the SCX column 
before non-phosphopeptides. Following SCX fractionation, each of the twelve fractions was 
further enriched by TiO2. In this experiment, we identified 27,369 total phosphopeptides with a 
false positive rate of less than 0.1% at the phosphopeptide level, and 15,513 unique 
phosphopeptides were identified from 2,302 proteins.  
The overlap between identified proteins and phosphoproteins is shown in Figure 6.5a. 
Although the amount of starting material for protein analysis was over 50 times less than that for 
protein phosphorylation analysis, over 82% overlap between the datasets clearly demonstrated that 
the protein coverage was very high in the protein analysis. In total, 6,730 proteins were identified 
in HepG2 cells. 
 Overall, 9,791 unique phosphopeptides in 2,238 proteins were quantified (listed in a table 
online at doi.org/10.1021/pr501277g), among which 759 unique phosphopeptides from 354 
proteins were down-regulated by at least twofold while 431 phosphopeptides in 266 proteins were 
up-regulated. Compared to protein abundance changes, phosphopeptide abundance changes were 
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more dynamic, which is consistent with the fact that proteins have much longer half-lives than 




Figure 6.5 (a) Comparison of proteins (6,316) identified in the protein experiment and 
phosphoproteins (2,302) in the phosphorylation experiment, and (b) the abundance distribution of 
quantified phosphopeptides. 
 
6.1.3.6 Motif analysis of regulated phosphorylation sites 
Due to the specific structures of kinase catalytic domains, every type of kinase has a 
preferential motif surrounding the phosphorylation sites of substrates. Motif analysis of regulated 
phosphorylation sites may provide valuable information regarding the effect of atorvastatin on the 










only singly phosphorylated peptides with well-localized phosphorylation sites (Ascore > 13) were 
considered.  Based on the dataset of over 9,000 quantified unique phosphopeptides, 3,409 
phosphopeptides met these requirements, among which 218 were down-regulated and 106 were 
up-regulated. The motif analysis results showed that the [S/T]P motif was found among both up- 
and down-regulated phosphorylation sites, which is the typical motif of cyclin-dependent kinases 
(CDKs) and mitogen-activated protein kinases (MAPKs). The up- and down-regulated sites with 
the [S/T]P motif could be from the direct and indirect effects of atorvastatin. Besides [S/T]P, no 
other motif was identified among up-regulated phosphorylation sites. 
 In contrast, several other types of motifs were found exclusively among down-regulated 
phosphorylation sites, including SPK, SD, E….S, K.T, K..S and K….S (“.” represents any amino 
acid residue), as shown in Figure 6.6. Basophilic enzymes such as PKA and PKC can recognize 
basic side chains preceding the target serine or threonine residues. Three identified motifs have a 
K before down-regulated phosphorylation sites. For example, K..S is the preferred motif of PKC.75 
PKC family members play significant roles in a variety of intracellular signal transduction 
processes, and are involved in receptor desensitization, modulating membrane structure events, 
regulating transcription, mediating immune responses, and regulating cell growth. These functions 
are achieved by PKC-mediated phosphorylation of their protein substrates. PKC, activated by 
tumor promoter phorbol ester, may phosphorylate potent activators of transcription, and thus lead 
to increased expression of oncogenes, promoting cancer progression.76 Here, phosphorylation sites 
with the preferred basic motif K..S were enriched among down-regulated sites in cells treated by 







Figure 6.6 The results of motif analysis among down-regulated phosphorylation sites. 
 
6.1.3.7 Pathway analysis based on regulated protein phosphorylation 
Phosphoproteins containing up- or down-regulated phosphopeptides were clustered using 
DAVID.69 Proteins related to gene expression, cell cycle and macromolecular metabolic process 
are highly enriched among up- and down-regulated phosphoproteins.  For example, 99 out of 354 
down-regulated phosphoproteins were related to gene expression with a P value of 1.9 x 10-8, while 
68 of 266 up-regulated phosphoproteins were found to belong to this category (P=3.6 x 10-4).  
Regulation of gene expression by protein phosphorylation is very complex in cells treated by statin. 
Up-regulated phosphoproteins: Similar to the protein abundance changes, after statin 
treatment, phosphopeptides from several proteins with functions relating to metabolism of lipids 
and lipoproteins were up-regulated, including HMGCR, HMGCS1, HMGCL, FDFT1, FASN, 
HADHA and LDLR. Protein activities are often regulated by their phosphorylation and the up-
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regulation of protein phosphorylation very likely corresponds to the increased activities of these 
proteins.  
While statins inhibit HMGCR to lower cholesterol, the synthesis of other lipids through 
the mevalonate pathway is also inhibited, including farnesy-PP and geranylgeranyl-PP. Therefore, 
protein lipidation will be dramatically impacted. Lipidation of proteins plays critical roles in 
protein localization and signal transduction, for example the lipidated proteins Ras, Rho and Rap.13 
In this experiment, twelve G-protein modulators that contained up-regulated phosphopeptides 
were quantified, listed in Table 6.2. For example, ARHGAP11A, Rho GTPase-activating protein 
11A, is involved in the regulation of small GTPase mediated signal transduction. Four unique 
phosphopeptides were quantified, but only the peptide AGCFS@PK (@ refers to the 
phosphorylation site) with a site at S422 was highly up-regulated by 6.6-fold. This site contains 
the SP motif. The doubly phosphorylated peptide with sites at S718 and S719 has a ratio of 1.5, 
and the other two phosphopeptides with sites at S484 or S868 have ratios of 1.0 and 1.3, 
respectively. Without protein lipidation, Ras, Rho and Rap cannot be localized to the plasma 
membrane and correspondingly cannot transduce signals effectively, which may be the 
explanation of why many G-protein modulators have up-regulated phosphorylation. In addition, 
some phosphopeptides from these G-protein modulators were down-regulated (listed in a table 
online at doi.org/10.1021/pr501277g) as a result of atorvastatin treatment. It is well-known that 
signal transduction by protein phosphorylation is extremely intricate in cells. The current 






Table 6.2 Up-regulated phosphopeptides from G-protein modulators.  





EEQ 0.8 2.98 361 78.2 9.5 















EEK# 0.8 2.60 466 17.3 2.0 
Q9UBC2 EPS15L1 
DSLRSTPS@HGSVSSL





Epidermal growth factor 
receptor substrate 15-like 
1 
P85299 PRR5 FMSSPSLS@DLGK# 1.7 1.67 16 6.6 7.1 
Subunit of mTORC2, 
which regulates cell 
growth and survival. 
Q9NYI0 PSD3 
SHS@SPSLNPDT@SPI





PH and SEC7 domain-
containing protein 3 
Q96QF0 RAB3IP 
STSSAMSGS@HQDLS
VIQPIVK 0.5 2.77 296 0.0 2.2 
Rab-3A-interacting 
protein 












DDSSK -0.1 4.89 775 0.0 3.3 
TBC1 domain family 
member 5, a GTPase-










Triple functional domain 
protein, promotes the 
exchange of GDP by GTP, 




PK 0.4 4.91 1749 2.6 43.3 
 
The activities of kinases are often regulated by their phosphorylation, and many 
phosphopeptides from several kinases were up-regulated, including EPHA2, PTK2, CAMK1, 
CDK1, CAMK2D, MAP3K4, PAK2, PKN1, RPS6KC1, STK33 and TLK1, TGFBR2 and TPR. 
MAP3K4, mitogen-activated protein kinase kinase kinase 4, is a component of a protein kinase 
signal transduction cascade and activates the CSBP2, P38 and JNK MAPK pathways. Three out 
of four quantified phosphopeptides were up-regulated by 2.0-2.5-fold, respectively. The three up-
regulated peptides have the same sequence, but different phosphorylation sites. This could be due 
to incorrect site assignments because of insufficient fragment information in the MS2 spectra. 
TLK1, a serine/threonine-protein kinase tousled-like 1, is rapidly and transiently inhibited by 
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phosphorylation following the generation of DNA double-stranded breaks during S-phase.77, 78 In 
our experiment, two triply phosphorylated peptides were up-regulated, which suggested that the 
activity of TLK1 was attenuated in cells treated by atorvastatin. However, several quantified 
phosphopeptides from TLK2 were not regulated. TGFBR2 is a transmembrane serine/threonine 
kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-
promiscuous receptor for the TGF-beta cytokines TGFB1 (transforming growth factor beta-1), 
TGFB2 and TGFB3. It transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to 
the cytoplasm and is thus regulating a plethora of physiological and pathological processes 
including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell 
proliferation and differentiation, wound healing, extracellular matrix production, 
immunosuppression and carcinogenesis (http://www.uniprot.org/uniprot/P37173). The C-terminal 
peptides (located in the cytoplasm) with the phosphorylation sites at S562 and T566 were up-
regulated by 2.8-fold. More detailed information about quantified phosphopeptides in kinases is 
included in listed in a table online at doi.org/10.1021/pr501277g. 
Down-regulated phosphoproteins: In this experiment, more phosphopeptides were down-
regulated than up-regulated. In addition to many phosphoproteins related to gene expression and 
the cell cycle, other interesting pathways, including the splicesome, tight junction, apoptosis, and 
CARM1 (coactivator-associated arginine methyltransferase 1) and regulation of estrogen receptor 
pathways, contain down-regulated phosphoproteins.        
Tight junctions, also known as occluding junctions, are the closely associated areas of two 
cells whose membranes join together forming a virtually impermeable barrier to fluid. In the tight 
junction pathway, phosphopeptides from seven proteins were found to be down-regulated, 
including EPB41L2, INADL, CTTN, PARD3, OCLN, CGN and MLLT4. Down-regulation of 
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these phosphoproteins in the tight junctions may interfere with cell-cell interactions, which may 
be related to the pleiotropic effects of statins.  
Four proteins (SRA1, BRCA1, MED1 and POLR2A) that have roles in the CARM1 and 
regulation of estrogen receptor pathway were found to contain down-regulated phosphopeptides 
in cells treated by the statin. SRA1, steroid receptor RNA activator 1, enhances cellular 
proliferation and differentiation, and promotes apoptosis in vivo and may play a role in 
tumorigenesis.79 It is highly expressed in the liver and skeletal muscle and is up-regulated in human 
tumors of the breast, ovary, and uterus. At the protein level, SRA1 is slightly down-regulated with 
a ratio of 0.77, which is similar to literature reports.57 In the phosphorylation experiment, one 
peptide RVAAPQDGS@PRVPAS@ETSPGPPPMGPPPPSSK was down-regulated by 2.5-fold, 
but the other singly phosphorylated peptide at the C-terminus of the protein was not regulated.  
MED1 is a component of the Mediator complex, and a coactivator involved in the regulated 
transcription of nearly all RNA polymerase II-dependent genes. In cells treated by atorvastatin, the 
abundance of MED1 was decreased by a ratio of 0.62, which is in a very good agreement with the 
~ 30% decrease previously reported in HL-60 cells treated by lovastatin.57 Based on the 
quantification of protein phosphorylation, 21 out of 24 unique quantified phosphopeptides were 
down-regulated in MED1. Our phosphorylation results clearly demonstrate that atorvastatin has 
an impact on the CARM1 and regulation of estrogen receptor pathway, which may contribute to 
its anti-cancer activity. 
 
6.1.4 Conclusions 
Statins are the most common and effective drugs for lowering cholesterol in patients.  The 
have pleiotropic effects possibly due to off-target effects and/or secondary effects from lipid 
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synthesis inhibition in the mevalonate pathway. Here we systemically investigated the protein and 
protein phosphorylation abundance changes in HepG2 cells treated by atorvastatin. Over 6,000 
proteins were quantified, but only a very small portion of them were regulated, i.e. 104 down-
regulated and 81 up-regulated.  As expected, many lipid-related proteins were up-regulated, 
including HMGCR, FDFT, SQLE and LDLR, while proteins related to gene expression, cellular 
response to stress and apoptosis were down-regulated. We quantified almost 10,000 unique 
phosphopeptides, which were more dynamic than proteins. The protein phosphorylation results 
demonstrate that many proteins with gene expression and cell cycle function have regulated 
phosphorylation, including both up- and down-regulated phosphorylation. Several basic motifs 
found among down-regulated sites indicated that kinases with preferences for these motifs have 
attenuated activities, including PKA and PKC. In addition to phosphoproteins related to lipid 
metabolism, phosphopeptides on a group of G-protein modulators were up-regulated, which may 
be due to cell signal transduction changes resulted from the effect of protein lipidation by the statin. 
Phosphopeptides from several proteins related to the tight junction, apoptosis, and CARM1 and 
regulation of estrogen receptor pathways were down-regulated. MS-based proteomics techniques 
provide an ideal way to gain insight into the protein and modified protein changes in cells treated 
by statin. A more comprehensive understanding of the cellular response to statins and the 
underlying molecular mechanisms of their pleiotropic effects will be beneficial in applying them 







6.2 Mass Spectrometric Analysis of the Human N-glycoproteome in Statin-Treated Liver 
Cells with Two Lectin-Independent Chemical Enrichment Methods 
 
6.2.1 Introduction 
Protein glycosylation is critical in determining protein folding, trafficking, stability and 
activity 80, 81. Among multiple types of protein glycosylation, N- and O-linked glycosylation are 
the two major types 82, 83. N-linked glycosylation occurs on the side chain of the asparagine residue 
and often has an N-X-S/T/C (X stands for any amino acid residues other than proline) 84, 85, while 
O-linked glycosylation is on the side chains of serine and threonine residues 86-88. N-glycosylation 
typically begins with the synthesis of the dolichol-linked precursor oligosaccharide 
(GlcNAc2Man9Glc3), followed by en bloc transfer of the precursor oligosaccharide to newly 
synthesized peptides in the endoplasmic reticulum (ER) 89, 90. Due to its importance in biological 
systems 91-93, N-glycosylation has also brought extensive attention for its role in human disease, 
such as Alzheimer’s disease (AD), cancer, and infectious diseases 92, 94, 95. 
             With the development of mass spectrometry (MS) instrumentation and computation 
techniques, current MS-based proteomics is very powerful in analyzing protein modifications, 
including glycosylation, in complex biological samples 96-107. Due to the low abundance of many 
glycoproteins, sub-stoichiometry of protein glycosylation, and the complexity of biological 
samples, it is imperative to enrich glycoproteins prior to MS analysis 106, 108, 109. Conventional 
lectin-based enrichment methods have been extensively used 110, 111. However, due to the binding 
specificity of lectin, no single or several types of lectin can cover all glycoproteins that have highly 
diverse glycans in human cells.  
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In recent years, several very elegant methods have been developed and tremendously 
advanced the glycoproteomics field 85, 106, 107, 112-114. In this work, we systematically compared two 
lectin-independent chemical methods to enrich and analyze glycoproteins in human cells: one 
based on boronic acid and cis-diol interactions 108, 115 and the other benefited from metabolic 
labeling and click reaction 116-118. For the first method, we utilized the universal and reversible 
interactions between boronic acid and sugar molecules. Boronic acid and cis-diols can form 
reversible covalent bonds in basic solutions, and conversely, the bonds are prone to cleavage under 
acidic conditions. The reversible nature of this bond ensures that glycopeptides can be effectively 
released after capturing. The second method takes advantage of the endogenous glycoprotein 
synthesis machinery to incorporate a chemical handle into glycans for further click chemistry and 
biotin avidin-based glycopeptide enrichment. An unnatural sugar analog containing an azide group 
was employed to feed cells in order to generate the chemical handle mentioned above. Comparing 
to BA, we reasoned that MC has the advantage of better reflecting the dynamic changes in cells 
since only the newly-synthesized glycoproteins are labeled by the sugar analog, while BA may be 
more universal for glycoprotein enrichment.   
In this work, we designed an experiment to comprehensively compare the identification 
and quantification of glycoproteins with these two methods. We analyzed the glycoproteome 
changes in statin-treated liver cells using these two methods. Statins are a group of cholesterol-
lowering drugs that target 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), which 
is the rate-limiting enzyme of the mevalonate pathway. Upon inhibition of HMGCR, the synthesis 
of many intermediate and end products in this pathway was affected, which induced many well-
known pleiotropic effects of statins. Dolichol is one of the end products and is involved in protein 
N-glycosylation, functioning as the membrane anchor for precursor oligosaccharides formation. 
 
272 
Therefore, we expected that protein N-glycosylation was attenuated in statin-treated cells. Using 
liver cells (HepG2) as a biological model, we systematically evaluated the performance of these 
two methods and explained the underlying mechanisms for the differences observed. The current 
work may provide useful information for future selection of enrichment methods to study the cell 
glycoproteome under different circumstances. 
 
6.2.2 Experimental section 
6.2.2.1 Cell Culture and metabolic labeling 
HepG2 (C3A) cells (from American type culture collection (ATCC)) were grown in 
“heavy” and “light” SILAC (stable isotope labeling with amino acids in cell culture) Dulbecco's 
modified eagle's medium (DMEM) (Sigma-Aldrich) for five generations before treatment with a 
statin. The medium also contained 1000 mg/L glucose and 10% dialyzed fetal bovine serum 
(diFBS) (Corning).  “Heavy” and “light” SILAC media were freshly prepared by adding 0.146 g/L 
13C615N2 L-lysine (Lys-8) and 0.84 g/L 13C6 L-arginine (Arg-6) (Cambridge Isotope Lab) or the 
corresponding non-labeled L-lysine (Lys-0) and L-arginine (Arg-0). When cells reached about 
70% confluency, we switched to SILAC media without diFBS and added 15 µM atorvastatin to 
the heavy group. Meanwhile, dimethyl sulfoxide (DMSO) was used to treat the light group as a 
vehicle control. For the MC experiments, 100 µM tetra-acetylated N-azidoacetylgalactosamine 
(Ac4GalNAz) (Click Chemistry Tools) was added into both heavy and light cells at the statin or 
mock treatment time. Cells were then maintained in a humidified incubator at 37 °C and 5.0% CO2 





6.2.2.2 Cell lysis, click reaction, and protein digestion 
Cells were washed twice with phosphate buffered saline (PBS), harvested by scraping in 
PBS, and pelleted by centrifugation at 500 g for 3 min. Two trial runs using about 2% of total cells 
were conducted to calibrate the heavy and light cell ratios in the BA and MC experiments. For the 
real experiments, heavy and light cells were mixed based on the protein ratio of 1:1 according to 
the results from the trial runs. The cell pellets were lysed through end-over-end rotation at 4 ºC for 
45 minutes in a lysis buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
pH=7.6, 150 mM NaCl, 0.5% sodium deoxycholate (SDC), 25 units/mL benzonase and 1 tablet/ 
10 mL protease inhibitor (EDTA-free, Roche)). Lysates were centrifuged, and the resulting 
supernatant was transferred to new tubes. For the MC experiment, the supernatant was reacted 
with 100 µM dibenzocyclooctyne (DBCO)-sulfo-biotin to have the metabolically labeled 
glycoproteins tagged with biotin through the specific click reaction between the azido group and 
DBCO 119-121. Proteins were subjected to disulfide reduction with 5 mM 1,4-dithiothreitol (DTT) 
(56 ºC, 25 min) and alkylation with 14 mM iodoacetamide (RT, 20 min in the dark). Detergent 
was removed by the methanol-chloroform protein precipitation method. The purified proteins were 
digested with 10 ng/µL Lys-C (Wako) in 50 mM HEPES pH 8.2, 1.6 M urea, 5% ACN at 31 ºC 
for 16 h, and 10 ng/uL trypsin (Promega) at 37 ºC for 4 h. 
 
6.2.2.3 Glycopeptide separation, enrichment and deglycosylation 
Digestion mixtures were acidified by addition of trifluoroacetic acid (TFA) to a final 
concentration of 0.1%, clarified by centrifugation, desalted using tC18 SepPak cartridge (Waters), 
and lyophilized. For the BA experiment, purified peptides were dried and enriched with boronic 
acid-conjugated magnetic beads (Figure 6.7a). Briefly, beads were washed three times with 100 
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mM ammonium acetate. Peptides were dissolved in the same buffer and mixed with the beads. The 
mixture was incubated in a shaking incubator at room temperature for an hour, and the beads were 
washed with the buffer mentioned above to remove non-glycopeptides. Finally, the beads were 
eluted with ACN:H2O:TFA = 49:50:1 with shaking. The elution was lyophilized and purified with 
tC18 SepPak cartridge, dried overnight, and treated with four units of peptide-N-glycosidase F 
(PNGase F, Sigma-Aldrich) in 80 µL buffer containing 50 mM NH4HCO3 in heavy oxygen water 
(H218O) at 37 °C for 3 h. The reaction was quenched by addition of 1% TFA to pH~2, desalted, 
and dried. The glycopeptides were fractionated by high pH reversed-phase high-performance 
liquid chromatography (HPLC) into 10 fractions with a 40-min gradient of 5-55% ACN in 10 mM 
ammonium acetate (pH=10). The fractions were dried and further purified with the stage-tip 
method. 
For the MC experiment, purified and dried peptides were enriched with NeutrAvidin beads 
(Thermo) at 37 °C for 30 min (Fig. 5.7b). The samples were transferred to spin columns and 
washed according to manufacturer’s protocol. Peptides were eluted from the beads by 3-min 
incubations with 300 µL of 8 M guanidine-HCL (pH=1.5) at 56 °C three times. Eluates were 
combined, desalted using tC18 SepPak cartridge, and lyophilized overnight. Dried peptides were 
deglycosylated as described in the BA experiment and quenched using the same method. 
Subsequently, we also attempted to fractionate the glycopeptide sample using HPLC, but the 
results were not ideal because the enriched sample amount in the MC experiment was much lower 
than the sample amount in the BA experiment since only the newly-synthesized and metabolically 
labeled glycopeptides were enriched. Finally, we fractionated the deglycosylated peptides during 
the stage-tip step, and the sample was separated into 3 fractions using the elution buffer with 20%, 










6.2.2.4 LC-MS/MS analyses  
Purified and dried peptide samples were dissolved in 10 µL solution of 5% ACN and 4% 
formic acid (FA) each, and 4 µL of the resulting solutions were loaded onto a microcapillary 
column packed with C18 beads (Magic C18AQ, 3 µm, 200 Å, 100 µm x 16 cm, Michrom 
Bioresources) by Dionex WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid 
Separation Pulled Loop Wellplate Sampler). Peptides were separated by reversed-phase 
chromatography using UltiMate 3000 binary pump with a 110 min gradient with increasing 
concentration of ACN (in 0.125% FA). Peptides were detected with a data-dependent Top20 
method 42, 60 in a hybrid dual-cell quadrupole linear ion trap - Orbitrap mass spectrometer (LTQ 
Orbitrap Elite, ThermoFisher, with Xcalibur 3.0.63 software). For each cycle, one full MS scan 
(resolution: 60,000) in the Orbitrap at 106 AGC target was followed by up to 20 MS/MS in the 
LTQ for the most intense ions. The selected ions were excluded from further analysis for 90 
seconds. Ions with singly or unassigned charge were not sequenced. Maximum ion accumulation 
times were 1000 ms for each full MS scan and 50 ms for MS/MS scans. 
 
6.2.2.5 Database searches and data filtering 
Raw data files from the mass spectrometer were converted into mzXML format, and 
precursor ion mass measurements were refined by checking the monoisotopic peak assignments 
50. All spectra were searched using the SEQUEST algorithm (version 28) 61 and matched against 
a database encompassing sequences of all proteins in the UniProt Human (Homo sapiens) database 
containing common contaminants. Each protein sequence was listed in both forward and reverse 
orders to control the false discovery rate (FDR) of glycopeptide identifications. We performed the 
database search using the following parameters: 10 ppm precursor mass tolerance; 1.0 Da product 
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ion mass tolerance; fully digested with trypsin; up to two missed cleavages; variable modifications: 
oxidation of methionine (+15.9949), O18 tag of asparagine (+2.9883), heavy lysine (+8.0142), and 
heavy arginine (+6.0201); fixed modifications: carbamidomethylation of cysteine (+57.0214).  
The target-decoy method was employed to estimate and control FDRs at the glycopeptide 
levels 62, 63. Through linear discriminant analysis (LDA), which is similar to other methods reported 
in the literature 64-66, several parameters (such as XCorr, ΔCn, precursor mass error, and charge 
state) were used to distinguish correct and incorrect peptide identifications 50. After scoring, 
peptides shorter than six amino acid residues were removed, and the dataset was restricted to 
glycopeptides when determining FDRs. Glycopeptide FDRs were filtered to <1 % based on the 
number of decoy sequences in the final data set.  
 
6.2.2.6 Glycopeptide quantification and glycosylation site localization  
For peptide quantification, we required an S/N value larger than 3 for both heavy and light 
species. If the S/N value of one member of a heavy and light pair was less than 3, the partner was 
required to be greater than 5. A probabilistic algorithm was used to localize N-glycosylation sites 
and to estimate the assignment confidence 67, 122. A ModScore was calculated for each 
glycosylation site, and sites with a ModScore >13 (P<0.05) were considered to be confidently 
localized.  
 
6.2.3 Results and discussion 
6.2.3.1 Examples of glycopeptide identification 
The enriched glycopeptides were treated with PNGase F in heavy oxygen water to remove 
N-glycans and to generate a common tag. When this enzymatic reaction occurs in heavy oxygen 
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water, the converted Asp from the glycosylation site contains heavy oxygen, which creates a mass 
shift of +2.9883 Da for MS analysis. In this case, heavy oxygen on Asp enabled us to distinguish 
authentic N-glycosylation sites from those caused by spontaneous asparagine deamidation, which 
may happen in vivo and during sample preparation. It could also occur during PNGase F treatment, 
which may result in false positive identifications of protein N-glycosylation sites. To minimize 
false positive identifications, we ran the reaction for 3 h, during which the effect of deamidation 
was nearly negligible 118. 
Two examples of N-glycopeptide identifications are shown in Figure 6.8. Formerly 
glycosylated peptide YHYN*GTLLDGTLFDSSYSR@ (*-N-glycosylation site, @-heavy 
arginine) was confidently identified with XCorr of 5.9 from the BA experiment (Figure 6.8a). This 
peptide is from protein FKBP9, one of the peptidyl-prolyl cis-trans isomerases (PPIases) that 
accelerates the folding of proteins during protein synthesis. The other deglycosylated peptide 
SSCGKEN*TSDPSLVIAFGR shown in Figure 6.8b is from protein LAMP1- lysosome-
associated membrane glycoprotein 1, which has the major function of presenting carbohydrate 
ligands to selectins. This peptide was identified in the MC experiment with an even higher XCorr 
of 6.2 and mass accuracy of -0.23 PPM. The site N84 is confidently identified to be glycosylated 
with ModScore=1,000, and the score of 1,000 means that only one possible glycosylation site 






Figure 6.8 Tandem mass spectra of (a) the glycopeptide YHYN*GTLLDGTLFDSSYSR@ (*-N-
glycosylation site, @-heavy arginine) from protein FKBP9 identified in the BA experiment, and 





















































































































 In this work, a total of 2,641 unique formerly glycosylated peptides were identified with 
the boronic acid-based enrichment method and 1,493 with the method combining metabolic 
labeling with click chemistry. These results indicated that the boronic acid enrichment method is 
more universal. 
  
6.2.3.2 N-glycosylation sites identified with the two lectin-independent enrichment methods 
 Boronic acids and sugars can form reversible covalent bonds. Based on this universal 
reaction, our lab has employed this chemical enrichment method to analyze the yeast 
glycoproteome 108. The results demonstrated that this method can be used to effectively enrich 
glycopeptides from digested whole cell lysates. The potential pitfall of this reaction is that the 
interactions are relatively weak, which could affect the enrichment of glycopeptides from low-
abundance glycoproteins. 
Metabolic labeling can be employed to label proteins and/or modified proteins, and the 
labeled proteins and modified proteins may bind to fluorophore for visualization or be selectively 
enriched for further analysis 116, 123. In this study, we incorporated an azide-containing sugar analog 
(Ac4GalNAz) into glycans in glycoproteins, and this azide group was used as a chemical handle 
to tag a biotin molecule onto the metabolically labeled glycans through click chemistry 124, 125. 
Tagging glycoproteins with biotin allowed further glycopeptide enrichment through the strong 
interaction between biotin on labeled peptides and NeutrAvidin beads after cell lysis and digestion. 
The detailed experimental procedure is shown in Figure 6.7b. Stringent wash was employed to 
remove non-glycopeptides. Compared to BA, MC has more steps, and the enrichment is largely 
dependent on metabolic labeling and click reaction efficiency. Since only sugar analog-labeled 
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peptides were enriched with the MC method, it can largely minimize sample complexity, which is 





Figure 6.9 Comparison of glycosylation sites (a) and glycoproteins (b) identified using the two 
enrichment methods. 
 
For glycosylation site identification, in addition to running the PNGase F treatment for 
three hours and filtering glycopeptides with <1% FDR, we also applied another criterion: all 



















acid other than proline). We confidently identified 1,045 N-glycosylation sites on 432 proteins 
with the boronic acid-based enrichment method, and the sites are listed in a table online at 
doi.org/10.1016/j.ijms.2017.05.010. Using the enrichment method combined with metabolic 
labeling and click chemistry, 685 N-glycosylation sites were identified on 351 proteins (listed in a 
table online at doi.org/10.1016/j.ijms.2017.05.010). 418 common sites were identified in both 
experiments (Figure 6.9a). Many proteins contain one glycosylation site while some proteins are 
highly glycosylated. For instance, LRP1, prolow-density lipoprotein receptor-related protein 1 is 
a large protein with molecular weight 504,606 Da and 4,454 amino acid residues. We identified 
very similar number of glycosylation sites on this protein through the two experiments: 21 sites in 
BA and 20 in MC. As expected, the overlap at the protein level was higher, and 259 common 
glycoproteins were identified from the two experiments (Figure 6.9b).  
 
6.2.3.3 Protein clustering based on molecular function 
 We clustered the glycoproteins identified exclusively in either BA or MC experiment 
according to the molecular function analysis using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) 69 (Figure 6.10). Interestingly, we found that the most enriched 
categories for glycoproteins identified in the BA experiment are intracellular enzyme activity-
related, such as hydrolase and transferase activities. However, among glycoproteins identified in 
the MC experiment, the top enriched categories are binding, receptor, and molecular transducer 
activities. These activities are known to occur prominently on the cell surface. The differences 
may be attributed to the following reasons. The boronic acid-based enrichment method is universal, 
which may unbiasedly enrich cell surface and intracellular glycoproteins. However, the enrichment 
method based on metabolic labeling and click chemistry is very dependent on the metabolic 
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labeling efficiency, and the latter relies on the endogenous glycan synthesis machinery. In this 
work, we used Ac4GalNAz to feed the cells and labeled the glycans containing GalNAc or GlcNAc. 
Normally, cell surface glycoproteins have mature glycan structures in order to be transported to 
the plasma membrane and/or be secreted, thus these glycans are more likely to have GalNAc 




Figure 6.10 Clustering of the glycoproteins identified only in the (a) BA or (b) MC experiment 
based on molecular function. 
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Although all N-Glycans have GlcNAc, GalNAz must convert into GlcNAz before labeling. 
Therefore, the labeling of GlcNAz may not be as efficient as GalNAz over a relatively short 
labeling period. For intracellular glycoproteins, especially those still in the ER and Golgi, because 
their glycan structures are likely immature, the chance of being labeled would be lower than those 
on the cell surface. Overall, BA is a more global and universal method, while MC has better 
performance on the identification of glycoproteins located on the cell surface. 
 
 
6.2.3.4 Quantification of cell glycoproteome changes in statin-treated cells  
Statins are a family of popular drugs for lowering cholesterol, but they may affect protein 
N-glycosylation because the inhibition of HMGCR by statins also prevents the synthesis of other 
products in the mevalonate pathway, including ubiquinone, dolichol, and farnesyl-pyrophosphate 
(farnesyl-PP) 7. Dolichol is essential to protein N-glycosylation in the form of dolichyl phosphate 
(Dol-P), which serves as the carrier in pyrophosphate-linked oligosaccharide assembly as well as 
acting as the acceptor in the synthesis of the sugar donors Dol-P-Man and Dol-P-Glc from GDP-
Man and UDP-Glc, respectively. Thus, protein N-glycosylation is expected to be impacted while 
the dolichol synthesis is hindered by the statin treatment. Perturbation of protein N-glycosylation 
by statins may contribute to the well-known “pleiotropic effects” of statins 7, 126. Systematic and 
quantitative investigation of protein N-glycosylation changes by statins will provide insight into 
the molecular mechanisms of the pleiotropic effects and allow patients to benefit further from the 
drug. 
 Statin is a relatively mild drug, and patients typically take it for months or years 3. Here, 
we used it to treat cells only for one day, and the drug indirectly affected N-glycosylation; in 
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addition, dolichol in cells was not depleted. Therefore, we did not expect that N-glycosylation 
would be dramatically influenced over a short period of the treatment. 
 An example of the full MS and elution profiles of the heavy and light versions of 
glycopeptide WSFSN*GTSWR are shown in Figure 6.11a and 5.11b. Based on the areas under 
the curves from both elution profiles, we were able to accurately quantify the ratio of the 
glycopeptide as 2.17. This peptide is from protein NEU1 (sialidase-1), which catalyzes the removal 
of sialic acid moieties from glycoproteins and glycolipids. The protein abundance was up-
regulated by 2.07 fold under the drug treatment.  
We quantified a total of 1,247 unique glycopeptides from BA and 682 glycopeptides from 
MC with an overlap of 376 peptides (Figure 6.11c). As anticipated, majority of the quantified 
peptides were not regulated when two-fold change was used as a threshold. With the BA method, 
59 glycopeptides were down-regulated while 93 were up-regulated before normalization. With the 
MC method, 24 glycopeptides were down-regulated while 62 were up-regulated. 
 
6.2.3.5 Glycosylation site quantification and normalization by their corresponding parent protein 
abundance changes 
For the N-glycosylation site quantification, besides the identification criteria discussed 
above, all glycopeptides must be singly glycosylated with the site ModScore > 13. With the site 
localization confidence, the quantitation can be site-specific. Although 1,045 glycosylation sites 
were identified from BA, only 719 sites (listed in a table online at 
doi.org/10.1016/j.ijms.2017.05.010) were quantified; while in MC, the combination of MC and 
SILAC led to the confident quantitation of 584 glycosylated sites (listed in a table online at 
doi.org/10.1016/j.ijms.2017.05.010) out of 685 unique glycosylation sites identified. 330 sites 
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were quantified in both experiments (Figure 6.11d). Relatively low overlap was expected because 
the principles of two enrichment methods are different. The powerful MS-based proteomics can 




Figure 6.11 (a) An example of the full MS of the heavy (WSFSN*GTSWR@) and light 
(WSFSN*GTSWR) glycopeptides with the same sequence; (b) the elution profiles of the two 
glycopeptides; (c) comparison of unique glycopeptides quantified in the two experiments; (d) 



























































When performing quantitative study of protein modifications, we need to pay attention to 
the abundance changes of their parent proteins. For instance, if a protein is dramatically up-
regulated in treated cells while the stoichiometry of the modification sites from this protein are 
largely unaffected or even down-regulated, we could still profile these sites to be up-regulated 
because site down-regulation cannot cancel out the effect of protein up-regulation. As shown in 
Figure 6.12a, for example, if we assume that two out of three copies of a certain protein are N-
glycosylated, then it will result in 66.7% glycosylation rate. After the drug treatment, although 
four copies of this protein are glycosylated, the glycosylation percentage is significantly lowered. 
This is due to protein expression up-regulation in the treated cells. Therefore, we normalized the 
raw site ratios by the corresponding parent protein ratios we obtained previously 117 to provide 
more quantitative information. This normalization strategy was previously applied for 
phosphorylation analysis in the literature 52.   
 The site ratio distributions in the BA and MC experiments before and after normalization 
are shown in Figure 6.12b and c. The whole series were shifted towards the down-regulation side 
after normalization. We listed a few quantified sites as examples in Table 6.3; two-fold was set as 
the threshold for defining a site to be regulated. All the listed sites have raw ratios larger than 2. 
However, their protein ratios are also larger than 2, which demonstrated that these proteins were 
up-regulated in the statin-treated cells. For instance, the first site in the list is from protein 
HMGCR, the rate-liming enzyme in the mevalonate pathway and the direct target of statins. Since 
the function of this protein was inhibited by the statin, this protein expression was up-regulated 
dramatically in the statin-treated cells, and the protein ratio for HMGCR increased by 15.4 fold. 
Without normalization by the protein ratio, N-glycosylation site 281 on HMGCR was up-regulated 
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by 25.9 fold, while the normalized ratio was 1.7. After normalization, six out of seven N-
glycosylation sites were determined to be not regulated. 
 Among 640 normalized sites from the BA experiment (listed in a table online at 
doi.org/10.1016/j.ijms.2017.05.010), 22 were up-regulated, and 35 were down-regulated. In 
contrast, 30 sites were up-regulated, and 50 were down-regulated among 518 normalized sites 
from the MC experiment. Although we quantified fewer sites from the MC experiment, more sites 
were down-regulated. This phenomenon is in very good agreement with the expectation that the 
results from the MC experiment may be more dynamic because it only enriches the newly-
synthesized glycoproteins during the statin treatment. 
 
Table 6.3 Some example N-glycosylation sites quantified in the BA experiment.  
Gene 









HMGCR -0.43 4.24 WIADPSPQN*STADTSK# 281 1000 25.89 15.35 1.69 
KLB -0.28 2.17 FALDWASVLPTGN*LSAVNR@ 611 31.94 14.24 2.02 7.05 
SLCO4C1 -1.06 1.93 VYYN*CSCIER 544 1000 5.39 4.18 1.29 
KLB -1.18 2.32 MGQN*VSLNLR 391 59.30 2.88 2.02 1.43 




179 1000 2.75 3.05 0.90 
NEU1 
0.06 1.43 VN*LTLR@ 343 1000 2.47 2.07 1.19 
0.30 1.77 WSFSN*GTSWRK 352 1000 2.17 2.07 1.05 






Figure 6.12 (a) An illustration of glycosylation site and glycoprotein abundance changes; 
glycosylation site regulation distributions before and after normalization using corresponding 















































6.2.4. Conclusions  
Protein glycosylation alteration is often a hallmark of human disease. In-depth analysis of 
glycoprotein changes may aid in a better understanding of glycoprotein functions and lead to the 
discovery of disease biomarkers and drug targets. Modern MS-based proteomics is very powerful 
in globally analyzing protein modifications, but it is pivotal to enrich modified proteins in complex 
biological samples prior to MS analysis. Lectin-based enrichment methods have been used 
extensively to enrich glycopeptides. However, the binding specificity of lectin prevents high 
coverage of glycopeptides. Here, we evaluated two lectin-independent chemical enrichment 
methods (namely, BA and MC) for global analysis of protein N-glycosylation. BA is based on the 
reversible interactions between boronic acids and hydroxyl groups on glycans; MC utilizes the 
endogenous glycan synthesis pathways in human cells to incorporate a sugar analog with a 
chemically functional, but biologically inert group, into the glycan structure, followed by 
biorthogonal reactions and affinity enrichment. BA is more universal and helped identify a greater 
number of glycosylation sites, whereas MC has better performance on cell surface glycoprotein 
identification. Furthermore, the quantitative results from the MC experiment were more dynamic 
because it enriched the newly synthesized glycoproteins under the drug treatment. For the 
quantification of protein modification, normalization using the parent protein ratios can provide 
more quantitative information regarding the protein expression and modification changes. Because 
of the high abundance of proteins and sugars in human cells, the interactions between proteins and 
sugars are ubiquitous. Global analysis of protein glycosylation will dramatically facilitate 
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A1. Simultaneous Time-Dependent Surface Enhanced Raman Spectroscopy, Metabolomics 
and Proteomics Reveal Cancer Cell Death Mechanisms Associated with Au-Nanorod Photo-
Thermal Therapy 
Reproduced with permission from American Chemical Society  
Ali, M. R. K., Wu, Y., Han, T. G., Zang, X. L., Xiao, H. P., Tang, Y., Wu, R. H., Fernandez, F. 
M., El-Sayed, M. A. Simultaneous time-dependent surface enhanced raman spectroscopy, 
metabolomics and proteomics reveal cancer cell death mechanisms associated with Au-nanorod 
photo-thermal therapy, Journal of the American Chemical Society, 2016, 138, 15434-15442. 
Copyright 2016 American Chemical Society. 
In cancer plasmonic photothermal therapy (PPTT), plasmonic nanoparticles are used to 
convert light into localized heat, leading to cancer cell death. Among plasmonic nanoparticles, 
gold nanorods (AuNRs) with specific dimensions enabling them to absorb near-infrared laser light 
have been widely used. The detailed mechanism of PPTT therapy, however, still remains poorly 
understood. Typically, surface-enhanced Raman spectroscopy (SERS) has been used to detect 
time-dependent changes in the intensity of the vibration frequencies of molecules that appear or 
disappear during different cellular processes. A complete proven assignment of the molecular 
identity of these vibrations and their biological importance has not yet been accomplished. Mass 
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spectrometry (MS) is a powerful technique that is able to accurately identify molecules in chemical 
mixtures by observing their m/z values and fragmentation patterns. Here, we complemented the 
study of changes in SERS spectra with MS-based metabolomics and proteomics to identify the 
chemical species responsible for the observed changes in SERS band intensities during PPTT. We 
observed an increase in intensity of the bands at around 1000, 1207, and 1580 cm–1, which were 
assigned in the literature to phenylalanine, albeit with dispute. Our metabolomics results showed 
increased levels of phenylalanine, its derivatives, and phenylalanine-containing peptides, 
providing evidence for more confidence in the SERS peak assignments. To better understand the 
mechanism of phenylalanine increase upon PPTT, we combined metabolomics and proteomics 
results through network analysis, which proved that phenylalanine metabolism was perturbed. 
Furthermore, several apoptosis pathways were activated via key proteins (e.g., HADHA and 
ACAT1), consistent with the proposed role of altered phenylalanine metabolism in inducing 
apoptosis. Our study shows that the integration of the SERS with MS-based metabolomics and 
proteomics can assist the assignment of signals in SERS spectra and further characterize the related 
molecular mechanisms of the cellular processes involved in PPTT. 
 
A2. Evaluation and Optimization of Reduction and Alkylation methods to Maximize Peptide 
Identification with MS-based Proteomics 
Reproduced with permission from The Royal Society of Chemistry  
Suttapitugsakul, S., Xiao, H. P., Smeekens, J. M., Wu, R. H. Evaluation and optimization of 
reduction and alkylation methods to maximize peptide identification with MS-based proteomics, 
Molecular BioSystems, 2017, 13, 2574-2582. Copyright 2017 The Royal Society of Chemistry. 
Mass spectrometry (MS) has become an increasingly important technique to analyze 
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proteins. In popular bottom-up MS-based proteomics, reduction and alkylation are routine steps to 
facilitate peptide identification. However, incomplete reactions and side reactions may occur, 
which compromise the experimental results. In this work, we systematically evaluated the 
reduction step with commonly used reagents, i.e., dithiothreitol, 2-mercaptoethanol, tris(2-
carboxyethyl)phosphine, or tris(3-hydroxypropyl)phosphine, and alkylation with iodoacetamide, 
acrylamide, N-ethylmaleimide, or 4-vinylpyridine. By using digested peptides from a yeast whole-
cell lysate, the number of proteins and peptides identified were very similar using four different 
reducing reagents. The results from four alkylating reagents, however, were dramatically different 
with iodoacetamide giving the highest number of peptides with alkylated cysteine and the lowest 
number of peptides with incomplete cysteine alkylation and side reactions. Alkylation conditions 
with iodoacetamide were further optimized. To identify more peptides with cysteine, thiopropyl-
sepharose 6B resins were used to enrich them, and the optimal conditions were employed for the 
reduction and alkylation. The enrichment resulted in over three times more cysteine-containing 
peptides than without enrichment. Systematic evaluation of the reduction and alkylation with 
different reagents can aid in a better design of bottom-up proteomic experiments. 
 
A3. Global Analysis of Secreted Proteins and Glycoproteins in Saccharomyces Cerevisiae 
Reproduced with permission from American Chemical Society  
Smeekens, J. M., Xiao, H. P., Wu, R. H. Global analysis of secreted proteins and glycoproteins in 
Saccharomyces cerevisiae, Journal of Proteome Research, 2017, 16, 1039-1049. Copyright 2017 
American Chemical Society. 
 Protein secretion is essential for numerous cellular activities, and secreted proteins in 
bodily fluids are a promising and noninvasive source of biomarkers for disease detection. 
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Systematic analysis of secreted proteins and glycoproteins will provide insight into protein 
function and cellular activities. Yeast (Saccharomyces cerevisiae) is an excellent model system for 
eukaryotic cells, but global analysis of secreted proteins and glycoproteins in yeast is challenging 
due to the low abundances of secreted proteins and contamination from high-abundance 
intracellular proteins. Here, by using mild separation of secreted proteins from cells, we 
comprehensively identified and quantified secreted proteins and glycoproteins through inhibition 
of glycosylation and mass spectrometry-based proteomics. In biological triplicate experiments, 
245 secreted proteins were identified, and comparison with previous experimental and 
computational results demonstrated that many identified proteins were located in the extracellular 
space. Most quantified secreted proteins were down-regulated from cells treated with an N-
glycosylation inhibitor (tunicamycin). The quantitative results strongly suggest that the secretion 
of these down-regulated proteins was regulated by glycosylation, while the secretion of proteins 
with minimal abundance changes was contrarily irrelevant to protein glycosylation, likely being 
secreted through nonclassical pathways. Glycoproteins in the yeast secretome were globally 
analyzed for the first time. A total of 27 proteins were quantified in at least two protein and 
glycosylation triplicate experiments, and all except one were down-regulated under N-
glycosylation inhibition, which is solid experimental evidence to further demonstrate that the 
secretion of these proteins is regulated by their glycosylation. These results provide valuable 
insight into protein secretion, which will further advance protein secretion and disease studies. 
 
A4. Evidence for the Importance of Post-Transcriptional Regulatory Changes in Ovarian 
Cancer Metastasis and the Contribution of miRNAs  
Reproduced with permission from Macmillan Publishers Limited, part of Springer Nature.  
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Zhang, M. N., Matyunina, L. V., Walker, L. D., Chen, W. X., Xiao, H. P., Benigno, B. B., Wu, R. 
H., McDonald, J. F. Evidence for the importance of post-transcriptional regulatory changes in 
ovarian cancer metastasis and the contribution of miRNAs, Scientific Reports, 2017, 7:8171. 
Copyright 2017 Macmillan Publishers Limited, part of Springer Nature. 
 High-throughput technologies have identified significant changes in patterns of mRNA 
expression over cancer development but the functional significance of these changes often rests 
upon the assumption that observed changes in levels of mRNA accurately reflect changes in levels 
of their encoded proteins. We systematically compared the expression of 4436 genes on the RNA 
and protein levels between discrete tumor samples collected from the ovary and from the omentum 
of the same OC patient. The overall correlation between global changes in levels of mRNA and 
their encoding proteins is low (r = 0.38). The majority of differences are on the protein level with 
no corresponding change on the mRNA level. Indirect and direct evidence indicates that a 
significant fraction of the differences may be mediated by microRNAs. 
 
A5. Specific Identification of Glycoproteins Bearing the Tn antigen in human cells 
Reproduced with permission from Wiley-VCH Verlag GmbH &Co. 
Zheng, J. N., Xiao, H. P., Wu, R. H. Specific identification of glycoproteins bearing the Tn antigen 
in human cells, Angewandte Chemie International Edition, 2017, 56, 7107-7111. Copyright 2017 
Wiley-VCH Verlag GmbH &Co. 
 Glycoproteins contain a wealth of valuable information regarding the development and 
disease status of cells. In cancer cells, some glycans (such as the Tn antigen) are highly up-
regulated, but this remains largely unknown for glycoproteins with a particular glycan. Herein, an 
innovative method combining enzymatic and chemical reactions was first designed to enrich 
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glycoproteins with the Tn antigen. Using synthetic glycopeptides with O-GalNAc (the Tn antigen) 
or O-GlcNAc, we demonstrated that the method is selective for glycopeptides with O-GalNAc and 
can distinguish between these two modifications. The diagnostic ions from the tagged O-GalNAc 
further confirmed the effectiveness of the method and confidence in the identification of 
glycopeptides with the Tn antigen by mass spectrometry. Using this method, we identified 96 
glycoproteins with the Tn antigen in Jurkat cells. The method can be extensively applied in 
biological and biomedical research. 
 
A6. Gold Nanorod-Assisted Plasmonic Photothermal Therapy of Cancer: Efficacy, Toxicity 
and Mechanistic Studies in vivo 
Reproduced with permission from National Academy of Sciences (U.S.). 
Ali, M. R. K., Rahman, M. A., Wu, Y., Han, T. G., Peng, X. H., Mackay, M. A., Wang, D. S., 
Shin, H. J., Chen, Z., Xiao, H. P., Wu, R. H., Tang, Y., Shin, D. M., El-Sayed, M. A. Gold nanorod-
assisted plasmonic photothermal therapy of cancer: efficacy, toxicity and mechanistic studies in 
vivo, Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 
E3110-E3118. Copyright National Academy of Sciences (U.S.). 
 Gold nanorods (AuNRs)-assisted plasmonic photothermal therapy (AuNRs-PPTT) is a 
promising strategy for combating cancer in which AuNRs absorb near-infrared light and convert 
it into heat, causing cell death mainly by apoptosis and/or necrosis. Developing a valid PPTT that 
induces cancer cell apoptosis and avoids necrosis in vivo and exploring its molecular mechanism 
of action is of great importance. Furthermore, assessment of the long-term fate of the AuNRs after 
treatment is critical for clinical use. We first optimized the size, surface modification [rifampicin 
(RF) conjugation], and concentration (2.5 nM) of AuNRs and the PPTT laser power (2 W/cm2) to 
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achieve maximal induction of apoptosis. Second, we studied the potential mechanism of action of 
AuNRs-PPTT using quantitative proteomic analysis in mouse tumor tissues. Several death 
pathways were identified, mainly involving apoptosis and cell death by releasing neutrophil 
extracellular traps (NETs) (NETosis), which were more obvious upon PPTT using RF-conjugated 
AuNRs (AuNRs@RF) than with polyethylene glycol thiol-conjugated AuNRs. Cytochrome c and 
p53-related apoptosis mechanisms were identified as contributing to the enhanced effect of PPTT 
with AuNRs@RF. Furthermore, Pin1 and IL18-related signaling contributed to the observed 
perturbation of the NETosis pathway by PPTT with AuNRs@RF. Third, we report a 15-month 
toxicity study that showed no long-term toxicity of AuNRs in vivo. Together, these data 
demonstrate that our AuNRs-PPTT platform is effective and safe for cancer therapy in mouse 
models. These findings provide a strong framework for the translation of PPTT to the clinic. 
 
A7. Targeting Cancer Cell Integrins Using Gold Nanorods in Photothermal Therapy Inhibits 
Migration through Affecting Cytoskeletal Proteins 
Reproduced with permission from National Academy of Sciences (U.S.). 
Ali, M. R. K., Wu, Y., Tang, Y., Xiao, H. P., Chen, K. C., Han, T. G., Fang, N., Wu, R. H.,  El-
Sayed, M. A. Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits 
migration through affecting cytoskeletal proteins. Proceedings of the National Academy of 
Sciences of the United States of America, 2017, 114, E5655-E5663. Copyright National Academy 
of Sciences (U.S.). 
 Metastasis is responsible for most cancer-related deaths, but the current clinical treatments 
are not effective. Recently, gold nanoparticles (AuNPs) were discovered to inhibit cancer cell 
migration and prevent metastasis. Rationally designed AuNPs could greatly benefit their 
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antimigration property, but the molecular mechanisms need to be explored. Cytoskeletons are cell 
structural proteins that closely relate to migration, and surface receptor integrins play critical roles 
in controlling the organization of cytoskeletons. Herein, we developed a strategy to inhibit cancer 
cell migration by targeting integrins, using Arg–Gly–Asp (RGD) peptide-functionalized gold 
nanorods. To enhance the effect, AuNRs were further activated with 808-nm near-infrared (NIR) 
light to generate heat for photothermal therapy (PPTT), where the temperature was adjusted not to 
affect the cell viability/proliferation. Our results demonstrate changes in cell morphology, 
observed as cytoskeleton protrusions-i.e., lamellipodia and filopodia-were reduced after treatment. 
The Western blot analysis indicates the downstream effectors of integrin were attracted toward the 
antimigration direction. Proteomics results indicated broad perturbations in four signaling 
pathways, Rho GTPases, actin, microtubule, and kinases-related pathways, which are the 
downstream regulators of integrins. Due to the dominant role of integrins in controlling 
cytoskeleton, focal adhesion, actomyosin contraction, and actin and microtubule assembly have 
been disrupted by targeting integrins. PPTT further enhanced the remodeling of cytoskeletal 
proteins and decreased migration. In summary, the ability of targeting AuNRs to cancer cell 
integrins and the introduction of PPTT stimulated broad regulation on the cytoskeleton, which 
provides the evidence for a potential medical application for controlling cancer metastasis. 
 
A8. Exosomes Isolated from Bone Marrow-Derived MSCs Support the ex vivo Survival of 
Human Peripheral Blood-Derived Plasma Cells 
Reproduced under the terms of the Creative Commons Attribution-NonCommercial License. 
Lewis, C. H., Nguyen, D., Garimalla, S., Xiao, H. P., Gibson, G., Wu, R. H., Galipeau, J., Lee, F. 
E. Exosomes isolated from bone marrow-derived MSCs support the ex vivo survival of human 
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peripheral blood-derived plasma cells. Journal of Extracellular Vesicles, accepted. Copyright 
retained by the authors. 
 Conditioned medium (CM) was from marrow-derived mesenchymal stromal cells (MSCs) 
was previously demonstrated to be able to maintains blood ASCs cell function for up to 30 days 
in vitro. We here purified MSC-derived exosomes from CM, and tested whether these vesicles 
could recapitulate the homeostatic interactions of the marrow niche. We treated MSC CM with a 
liposome-disrupting agent, abolishing plasma cell antibody-secretion by 75%. We further 
interrogated exosome production from replicating and irradiated, growth-arrested MSCs to better 
mirror the physiology of endogenous mobilized or quiescent marrow MSCs. We isolated 
Exosomes and the accompanying Exosome-Depleted CM (Exo-Depl CM), and assessed their 
ability to sustain antibody-secreting cells (ASCs) from healthy adult humans in vitro. Purified 
exosomes from both irradiated (Irrad) and Non-Irrad MSCs were comparable in their ability to 
support ASC functionality.  However, Exo-Depl CM derived from Non-Irrad-MSCs was 50% less 
effective than corresponding fractions from Irrad-MSCs.  Taken together, these findings indicate 
that MSC exosomes are an effective support system for the ex vivo culture of ASCs, and that 
growth arrested MSCs also produce additional products which act additively on ASCs. To identify 
which factors account for such differential support, we used proteomics and pathway analysis, 
identifying proteins involved in the survival of B-lineage cells and stroma cells, that were enriched 
in exosomes, including the ectoenzyme bone marrow stromal cell antigen-1 (CD157). Our data 
support the hypothesis that the in vitro support of ASC by MSC can be recapitulated with purified 
exosomes, suggesting a niche support mechanism which can operate independently of cell contact 
and MSC cell cycle status. These findings have great import for the exosome field and elucidation 
of factors that modulate B-cell biology. 
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A9. A Boronic Acid-Based Enrichment for Site-Specific Identification of the N-
glycoproteome Using MS-Based Proteomics 
Reproduced with permission from Springer International Publishing AG. 
Xiao H. P., Tang G.X., Chen W. X., Wu R. H. A Boronic Acid-Based Enrichment for Site-Specific 
Identification of the N-glycoproteome Using MS-Based Proteomics. In: Grant J., Li H. (eds) 
Analysis of Post-Translational Modifications and Proteolysis in Neuroscience. Neuromethods, 
2015, vol 114. Humana Press, New York, NY. Copyright 2017 Springer International Publishing 
AG. 
 Modification of proteins by N-linked glycans plays a critically important role in biological 
systems, including determining protein folding and trafficking as well as regulating many 
biological processes. Aberrant glycosylation is well known to be related to disease, including 
cancer and neurodegenerative diseases. Current mass spectrometry (MS)-based proteomics 
provides the possibility for site-specific identification of the N-glycoproteome; however, this is 
extraordinarily challenging because of the low abundance of many N-glycoproteins and the 
heterogeneity of glycans. Effective enrichment is essential to comprehensively analyze N-
glycoproteins in complex biological samples. The covalent interaction between boronic acid and 
cis-diols allows us to selectively capture glycopeptides and glycoproteins, whereas the reversible 
nature of the bond enables them to be released after non-glycopeptides are removed. By virtue of 
the universal boronic acid-diol recognition, large-scale mapping of N-glycoproteins can be 
achieved by combining boronic acid-based enrichment, PNGase F treatment in the presence of 
heavy oxygen (18O) water, and MS analysis. This method can be extensively applied for the 
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